EULAR 2017 Congress Madrid - Preliminary Scientific Programme - PLEASE OBSERVE THE EMBARGO

Please note that this is a Preliminary Version of the Scientific Programme for the EULAR Congress 2017 in Madrid. The programme is subject to change at any time.
THE EULAR ABSTRACT EMBARGO IS IN PLACE UNTIL 14 JUNE 2017 00:01 CET. See the EULAR Congress Website
Details on Oral Abstract Presentations and Poster Tours will be published approximately one month prior to the congress. Until then, you will see the lecture slot, but without presenter name and without abstract title.
To select single time slots, please use the drop down selection option (Standard: Overview all days and sessions).
To print, please use the 'File - Print' option of your browser. Best results are achieved using landscape and scaling down to 75 percent in the printer preferences.

 


Wednesday 14.06.2017 13:00 - 14:30


 
Basic and Translational Science Session - South Auditorium
  
Joint EULAR - APLAR session: Novel animal models – where no researcher has gone before...
   ChairBurmester Gerd Rüdiger (Germany)  
   ChairYamamoto Kazuhiko (Japan)  
   SpeakerPap Thomas (Germany)SP0001Relevance of animal models in osteoarthritis
   SpeakerYu Xinhua (Germany)SP0002Novel animal models in SSc
   SpeakerIwakura Yoichiro (Japan)SP0003Novel animal model in arthritis
   SpeakerYamamoto Kazuhiko (Japan)SP0004From the animal model to the patient. Similarities and differences

Wednesday 14.06.2017 13:30 - 14:30


 
Health Professionals Session - N101 / N102
  
Health Professionals Welcome Session
   ChairOpava Christina H. (Sweden)  
   ChairGobbo Montoya Milena (Spain)  
   SpeakerVliet Vlieland Thea (Netherlands)SP0005Looking back at 70 years of Eular and 30 years of HP involvement: a rehabilitation perspective
   SpeakerHill Jackie (United Kingdom)SP0006Looking back at 70 years of Eular and 30 years of HP involvement: a nursing perspective
   SpeakerBijlsma Johannes W.J. (Netherlands)SP000770 years past and a view of the future
   Speakerde Thurah Annette (Denmark)SP0008The future for HPs in Rheumatology

Wednesday 14.06.2017 15:00 - 16:30


 
WIN & HOT Session - Hall 6
  
WIN & HOT Session
   ChairCollantes Esteves Eduardo (Spain)  
   ChairSousa Elsa (Portugal)  
   SpeakerMachado Pedro (United Kingdom) WIN Session: Axial and peripheral spondyloarthritis
   SpeakerLories Rik (Belgium)SP0009WIN Session: Psoriatic Arthritis

 
Clinical Science Session - Hall 8
  
Moving towards new criteria in SLE, Sjögren‘s and APS
   ChairCervera Ricardo (Spain)  
   ChairBootsma Hendrika (Netherlands)  
   SpeakerAringer Martin (Germany)SP0010Classification of SLE – challenges and potential solutions
   SpeakerBowman Simon (United Kingdom)SP0011Sjögren's criteria revisited!
   SpeakerMeroni Pier Luigi (Italy)SP0012Advanced APS criteria 2016/2017
   AbstractMorand Eric (Australia)OP0001THE LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) DEFINITION DISCRIMINATES RESPONDERS IN A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TRIAL: POST-HOC ANALYSIS OF THE PHASE IIB MUSE TRIAL OF ANIFROLUMAB
   AbstractJohnson Sindhu (Canada)OP0002MULTICRITERIA DECISION ANALYSIS FOR DEVELOPING NEW CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS

 
Challenges in Clinical Practice Session - Hall 7A
  
The differential diagnosis of diffuse skin sclerosis and of Raynaud's phenomenon and a practical approach to assessment
   ChairHerrick Ariane L. (United Kingdom)  
   ChairGabrielli Armando (Italy)  
   PresenterSuarez Annabel (United Kingdom)SP0013Case 1 presentation: Widespread cutaneous thickening – Could this be early diffuse cutaneous systemic sclerosis?
   DiscussantPauling John (United Kingdom)SP0014Case 1 discussion: The differential diagnosis of diffuse sclerosing skin disease and a practical approach to assessment
   PresenterHughes Michael (United Kingdom)SP0015Case 2 presentation: New onset Raynaud’s phenomenon – Could this be early limited cutaneous systemic sclerosis?
   DiscussantHerrick Ariane L. (United Kingdom)SP0016Case 2 discussion: The differential diagnosis of Raynaud’s phenomenon and practical approach to assessment with a focus on imaging

 
From Bench to Bedside - Hall 7B
  
Controlling the balance between cancer and autoimmunity
   ChairCalabrese Leonard (United States)  
   ChairMariette Xavier (France)  
   SpeakerRosen Anthony (United States)SP0017The same mechanism at the origin of cancer and autoimmunity
   SpeakerMarabelle Aurélien (France)SP0018Check points inhibitors - from discovery to clinical applications
   SpeakerSchaeverbeke Thierry (France) Rheumatic immune related adverse events with cancer immunotherapy
   AbstractCalabrese Cassandra (United States)OP0003RHEUMATIC IMMUNE RELATED ADVERSE EVENTS OF CHECKPOINT THERAPY FOR CANCER: CASE SERIES OF AN EMERGING NOSOLOGIC ENTITY
   AbstractBelkhir Rakiba (France)OP0004RHEUMATOID ARTHRITIS OCCURING AFTER IMMUNE CHECKPOINT INHIBITORS

 
Clinical Science Session - N103 / N104
  
Fibromyalgia: a disease of the peripheral or central nervous system
   ChairMcMahon Stephen (United Kingdom)  
   ChairAtzeni Fabiola (Italy)  
   SpeakerTreede Rolf-Detlef (Germany)SP0019Signs, symptoms and co-morbidities of fibromyalgia
   SpeakerSommer Claudia (Germany)SP0020Peripheral pathologies in fibromyalgia
   SpeakerKosek Eva (Sweden)SP0021Central pathologies in fibromyalgia
   AbstractProvan Sella (Norway)OP0005FIBROMYALGIA IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A 10-YEAR PERSPECTIVE
   AbstractAtzeni Fabiola (Italy)OP0006INFLUENCE OF AUTONOMIC NERVOUS SYSTEM DYSFUNCTION IN THE GENESIS OF SLEEP DISORDERS IN FIBROMYALGIA PATIENTS

 
Basic and Translational Science Session - South Auditorium
  
Chondrocyte Channels (Role in Mechanotransduction) or “Channeling the chondrocyte”
   ChairMalfait Anne-Marie (United States)  
   ChairAppleton Tom (Canada)  
   SpeakerBeier Frank (Canada) Pannexins in Cartilage
   SpeakerMobasheri Ali (United Kingdom) The chondrocyte channelome
   SpeakerMoilanen Eeva (Finland)SP0022TRPA1 in osteoarthritis
   AbstractLatourte Augustin (France)OP0007CCR2 INHIBITION ABROGATES IL-6–INDUCED ACTIVATION OF MATRIX METALLOPROTEINASES IN CARTILAGE
   AbstractLópez de Figueroa Paloma (Spain)OP0008DEFICIENT AUTOPHAGY INDUCES CHONDROCYTE DYSFUNCTION THROUGH LAMIN A/C ACCUMULATION IN AGING AND OSTEOARTHRITIS

 
Health Professionals Session - N101 / N102
  
Wearable technologies in 21st century healthcare
   ChairSwinnen Thijs (Belgium)  
   ChairPrimdahl Jette (Denmark)  
   SpeakerClarke-Cornwell Alex (United Kingdom)SP0023Review of wearable technologies – the state of the art
   SpeakerMcCarthy Marie (Ireland)SP0024Wearable technologies in research and clinical trials
   SpeakerCulén Alma Leora (Norway) Ethics and politics of the use and the design of technology in health care
   SpeakerSilva Mitchell (Belgium) Patients perspective on wearables
   AbstractBayraktar Deniz (Turkey)OP0009-HPRTHE EFFECT OF AN 8-WEEK WATER EXERCISE PROGRAM ON ANAEROBIC EXERCISE CAPACITY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

 
Clinical Science Session - N105 / N106
  
Assessment and management of osteoporosis
   ChairTam Lai-Shan (China, People's Republic of)  
   ChairLems Willem F. (Netherlands)  
   SpeakerÅkesson Kristina (Sweden)SP0025The use of biomarkers for osteoporosis in clinics
   SpeakerChapurlat Roland D. (France)SP0026Novel imaging techniques for assessing osteoporotic fracture risk
   SpeakerGeusens Piet (Netherlands)SP0027Emerging therapies for osteoporosis
   AbstractLems Willem (Netherlands)OP0010EFFECT OF DENOSUMAB COMPARED WITH RISEDRONATE IN GLUCOCORTICOID-TREATED INDIVIDUALS: RESULTS FROM THE 12-MONTH PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY

 
The Young Rheumatologist - N111 / N112
  
Systematic literature review: the link from science to clinical practice
   ChairRivellese Felice (Italy)  
   ChairGossec Laure (France)  
   SpeakerRamiro Sofia (Netherlands)SP0028Systematic literature review: where to start
   SpeakerLandewé Robert B.M. (Netherlands)SP0029Linking science to clinical practice: from the systematic literature review to the formulation of recommendations
   SpeakerVisser Karen (Netherlands)SP0030Beyond the recommendations: examples of systematic literature review in daily clinical practice
   AbstractHILLIQUIN Stéphane (France)OP0011DOES A VERY EARLY THERAPEUTIC INTERVENTION IN VERY EARLY ARTHRITIS / PRE-RHEUMATOID ARTHRITIS PATIENTS PREVENT THE ONSET OF RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND METANALYSIS.

 
Joint Session Clinical / HPR / PARE Session - N115 / N116
  
EULAR Campaign: Don't Delay, Connect Today
   ChairBurmester Gerd Rüdiger (Germany)  
   ChairBosworth Ailsa (United Kingdom)  
   SpeakerSchwarting Andreas (Germany) Ways to improve early diagnosis despite limited rheumatologists resources
   SpeakerMallen Christian D. (United Kingdom)SP0031How could GPs enhance the early diagnosis of rheumatic diseases
   SpeakerKirwan Paul (Ireland)SP0032The contribution of physiotherapists to early detection of inflammatory arthritis
   SpeakerChurch John (Ireland)SP0033The EULAR campaign and how organisations can get involved
   AbstractBennett Louise (United Kingdom)OP0012-PARERHEUMATOSPHERE: REACH NEW HEIGHTS IN DIAGNOSIS AND TREATMENT OF ARTHRITIS BY ENGAGING, EMPOWERING AND INSPIRING.

 
EULAR Projects in Paediatric Rheumatology - N117 / N118
  
Standing Committee Session on Paediatric Rheumatology
   ChairAvcin Tadej (Slovenia)  
   ChairWouters Carine (Belgium)  
   SpeakerBeresford Michael (United Kingdom)SP0034SHARE recommendations on systemic vasculitides
   SpeakerZulian Francesco (Italy)SP0035SHARE recommendations on juvenile scleroderma
   Speakervan Royen Annet (Netherlands)SP0036SHARE recommendations on juvenile dermatomyositis
   AbstractHetlevik Siri (Norway)OP0013PULMONARY MANIFESTATIONS IN JUVENILE ONSET MIXED CONNECTIVE TISSUE DISEASE AFTER LONG-TERM DISEASE DURATION – A NORWEGIAN CASE-CONTROL STUDY
   AbstractMarteau Pauline (France)OP0014CONVENTIONAL RADIOGRAPHY IN JUVENILE IDIOPATHIC ARTHRITIS: JOINED RECOMMENDATIONS FROM THE FRENCH SOCIETIES FOR RHEUMATOLOGY, RADIOLOGY AND PEDIATRIC RHEUMATOLOGY

 
Practical Skills Session - N107 / N108
  
Crystals I
   ChairPascual Eliseo (Spain)  
   ChairTausche Anne Kathrin (Germany)  
   TutorNorkuviene Eleonora (Lithuania)  
   TutorSivera Francisca (Spain)  
   TutorPimentao José (Portugal)  
   TutorOliviero Francesca (Italy)  

 
Practical Skills Session - N109 / N110
  
Ultrasound Basic I
   ChairBruyn George A. W. (Netherlands)  
   ChairKortekaas Marion (Netherlands)  
   SpeakerFilippou Georgios (Italy)SP0037How to assess US elementary lessons in CPPD + demo
   SpeakerMandl Peter (Austria)SP0038How to assess cartilage in RA and pitfalls + demo
   SpeakerIagnocco Annamaria (Italy)SP0039How to evaluate the subtalar joint + demo
   SpeakerMöller Ingrid (Spain)SP0040How to scan the hip - new approaches + demo
   TutorMidtboell Oernbjerg Lykke (Denmark)  

Wednesday 14.06.2017 17:00 - 18:30


 
Abstract Session - Hall 8
  
Abstract Session: Still breaking news on TNF inhibitors in rheumatoid arthritis
   ChairCombe Bernard (France)  
   ChairNam Jackie (United Kingdom)  
   AbstractCaporali R (-)OP0015INDUCTION OF REMISSION AND MAINTENANCE IN EARLY, AGGRESSIVE RHEUMATOID ARTHRITIS USING ADALIMUMAB IN COMBINATION WITH METHOTREXATE WITH OR WITHOUT SHORT-TERM HIGH-DOSE GLUCOCORTICOIDS: RESULTS OF A PHASE IV MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY (CLINTRIAL.GOV: NCT00480272)
   AbstractTuresson Carl (Sweden)OP0016COMPARATIVE EFFECTIVENESS AT 1 YEAR OF DIFFERENT ANTI-TNF DRUGS AS FIRST BIOLOGIC DMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS – RESULTS FROM THE NATIONWIDE SWEDISH REGISTER
   AbstractMariette Xavier (France)OP0017LACK OF PLACENTAL TRANSFER OF CERTOLIZUMAB PEGOL DURING PREGNANCY: RESULTS FROM CRIB, A PROSPECTIVE, POSTMARKETING, MULTICENTER, PHARMACOKINETIC STUDY
   AbstractPham Thao (France)OP0018TOOL AND THRESHOLD PREDICTING A SUCCESSFUL BIOLOGICAL DMARDS TAPERING IN PATIENTS WITH RA REMISSION DETERMINATION
   AbstractPope Janet (Canada)OP0019DMARD WITHDRAWAL IN RA PATIENTS ACHIEVING THERAPEUTIC RESPONSE WITH CERTOLIZUMAB PEGOL COMBINED WITH DMARDS: INTERIM RESULTS FROM A CANADIAN OBSERVATIONAL RANDOMIZED STUDY
   AbstractShimizu Tomohiro (United States)OP0020ASSESSMENT OF 3-MONTH CHANGES IN BONE MICROSTRUCTURE UNDER ANTI-TNFΑ THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS USING HR-PQCT
   AbstractAlten R (United Kingdom)OP0021EFFICACY AND SAFETY RESULTS OF A PHASE III STUDY COMPARING FKB327, AN ADALIMUMAB BIOSIMILAR, WITH HUMIRA®, THE ADALIMUMAB REFERENCE PRODUCT, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
   AbstractReed George (United States)OP0022TNFI AND TOFACITINIB MONOTHERAPY AND COMPARATIVE EFFECTIVENESS IN CLINICAL PRACTICE: RESULTS FROM CORRONA REGISTRY

 
Abstract Session - Hall 7A
  
Abstract Session: Progress in managment of SpA
   ChairBaraliakos Xenophon (Germany)  
   Chairde Hooge Manouk (Belgium)  
   Abstractvan der Heijde Desiree (Netherlands)OP0023FOUR-YEAR IMAGING OUTCOMES IN AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL, INCLUDING PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
   AbstractEklund Kari (Finland)OP0024DRUG TROUGH LEVELS AND ANTIDRUG ANTIBODIES IN NONSELECTED ANKYLOSING SPONDYLITIS PATIENTS USING SELF-INJECTED ANTITNF DRUGS
   AbstractRuwaard Jill (Netherlands)OP0025ANTIDRUG ANTIBODIES DETECTION IS STRONGLY INFLUENCED BY THE TYPE OF ASSAY USED.
   AbstractCarron Philippe (Belgium)OP0026HIGH DRUG-FREE REMISSION IN EARLY PERIPHERAL SPONDYLOARTHRITIS AFTER INDUCTION THERAPY WITH GOLIMUMAB.
   AbstractDevauchelle Agathe (France)OP0029EVALUATION OF THE EFFICIENCY OF SACROILIAC JOINTS CORTICOID INJECTIONS UNDER SCAN CONTROL AND ITS RELATIONSHIP WITH THE PRESENCE OR ABSENCE OF SACROILIITIS LESIONS SEEN ON MRI OF PATIENTS WITH SPONDYLOARTHRITIS
   AbstractXu Dan (China)OP0028LOW DOSE IL-2 THERAPY CAN RECOVERY TH17/TREG CELL BALANCE IN PATIENTS WITH ANKYLOSING SPONDYLITIS
   AbstractNikiphorou Elena (United Kingdom)OP0030INEQUITY IN BIOLOGIC DMARD PRESCRIPTION FOR SPA ACROSS THE GLOBE. RESULTS FROM THE ASAS COMOSPA STUDY.

 
Abstract Session - Hall 7B
  
Abstract Session: Early diagnosis of systemic sclerosis and myositis: Biomarkers and diagnostic tool
   ChairDenton Christopher (United Kingdom)  
   ChairSmith Vanessa (Belgium)  
   AbstractMoroncini Gianluca (Italy)OP0031DEVELOPMENT OF A NOVEL EPITOPE-BASED DIAGNOSTIC ASSAY FOR SYSTEMIC SCLEROSIS
   AbstractFernandes Susana (Portugal)OP0032IS IMMUNOHISTOCHEMISTRY USEFUL TO PREDICT RESPONSE TO TREATMENT IN NECROTIZING MYOPATHIES?
   AbstractDiederichsen Louise (Denmark)OP0033SPECT- AND PET/CT IMAGING IN NEWLY ONSET IDIOPATHIC INFLAMMATORY MYOPATHY
   AbstractMihai Carina (Romania)OP0034FACTORS ASSOCIATED WITH DISEASE PROGRESSION IN EARLY-DIAGNOSED PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: LONGITUDINAL DATA FROM THE DETECT COHORT
   AbstractSmith Vanessa (Belgium)OP0035PRELIMINARY ANALYSIS OF NAILFOLD CAPILLAROSCOPY IN THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS (VEDOSS): THE CAPI-VEDOSS EXPERIENCE
   AbstractKubo Satoshi (Japan)OP0036SEROLOGICAL BIOMARKERS OF ECM TURNOVER ARE ASSOCIATED WITH SKIN FIBROSIS AND LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS
   AbstractRuaro Barbara (Italy)OP0037EVALUATION OF SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS PATIENTS BY USING TWO ULTRASOUND TRANSDUCERS WITH DIFFERENT FREQUENCY
   AbstractPinal-Fernandez Iago (United States)OP0038MYOSITIS AUTOANTIBODIES OUTPERFORM CLINICAL SUBGROUP CLASSIFICATION IN PREDICTING MUSCLE WEAKNESS IN MYOSITIS PATIENTS

 
Abstract Session - N103 / N104
  
Abstract Session: SLE, Sjögren's APS - clinical aspects
   ChairSvenungsson Elisabet (Sweden)  
   ChairBertsias Georges (Greece)  
   AbstractBultink Irene (Netherlands)OP0039A POPULATION-BASED STUDY ON MORTALITY AND THE INFLUENCE OF MEDICATION USE IN 4356 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND 21845 MATCHED CONTROLS FROM THE UNITED KINGDOM
   AbstractDevauchelle-Pensec Valérie (France)OP0040INTEGRATION OF SALIVARY-GLAND ULTRASONOGRAPHY IN CLASSIFICATION CRITERIA FOR PRIMARY SJÖGREN’S SYNDROME: AN INTERNATIONAL VIGNETTE-BASED STUDY.
   AbstractMoghaddam Bahar (Canada)OP0041ALL-CAUSE, CARDIOVASCULAR AND MALIGNANCY RELATED MORTALITY IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A POPULATION-BASED STUDY
   AbstractGalindo-Izquierdo Maria (Spain)OP0042BACTEREMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS FROM RELESSER REGISTRY: RISK FACTORS, CLINICAL AND MICROBIOLOGICAL CHARACTERISTICS AND OUTCOMES
   AbstractLiu Xiaoqing (China)OP0043THE NUMBER OF CIRCULATING REGULATORY T CELLS IS REDUCED AND LOW-DOSE IL-2 SELECTIVELY STIMULATES ITS PROLIFERATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractAlunno Alessia (Italy)OP0044ANTIBODIES ANTI-SACCHAROMYCES CEREVISIAE IN PRIMARY SJÖGREN’S SYNDROME: PREVALENCE, CLINICAL ASSOCIATIONS AND POSSIBLE CROSS-REACTIVITY WITH DISEASE SPECIFIC AUTOANTIGENS
   AbstractGiannakou Ioanna (Sweden)OP0045PREDICTORS OF PERSISTENT DISEASE ACTIVITY AND PERSISTENT LONG QUIESCENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS – RESULTS FROM THE HOPKINS LUPUS COHORT
   AbstractLazzaroni Maria Grazia (Italy)OP0046RISK FACTORS FOR ADVERSE PREGNANCY OUTCOME IN ANTIPHOSPHOLIPID ANTIBODIES CARRIERS: RESULTS FROM A MULTICENTER ITALIAN COHORT OVER 20 YEARS OF EXPERIENCE

 
Abstract Session - South Auditorium
  
Abstract Session: Osteoporosis treatment gap, new options and new strategies
   ChairChapurlat Roland D. (France)  
   ChairLems Willem F. (Netherlands)  
   AbstractSehgal Maanek (United States)OP0047OSTEOPOROTIC HIP FRACTURE PREVENTION: ARE WE IN A CRISIS ?
   AbstractGeusens Piet (Netherlands)OP0048ROMOSOZUMAB RAPIDLY REDUCES CLINICAL VERTEBRAL FRACTURE INCIDENCE: RESULTS FROM THE FRAME STUDY
   AbstractMakhzoum Anas (Canada)OP0049SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS EVALUATING BISPHOSPHONATES FOR THE PREVENTION AND TREATMENT OF GLUCOCORTICOID- INDUCED OSTEOPOROSIS
   AbstractSpångéus Anna (Sweden)OP0050THE TREATMENT GAP AFTER FRACTURE IN OSTEOPOROSIS PATIENTS IN SWEDEN
   AbstractDanila Maria (United States)OP0051THE ACTIVATING PATIENTS AT RISK FOR OSTEOPOROSIS STUDY: A RANDOMIZED TRIAL WITHIN THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN COHORT
   AbstractHaschka Judith (Austria)OP0052CORTICAL BONE LOSS IS AN EARLY FEATURE OF AXIAL SPONDYLOARTHRITIS
   AbstractRuzickova Olga (Czech Republic)OP0053BONE LOSS AND CARDIOVASCULAR RISK IN PATIENTS WITH EROSIVE AND NON-EROSIVE HAND OSTEOARTHRITIS
   AbstractSahuguet Julie (France)OP0054INCIDENCE OF VERTEBRAL FRACTURES IN EARLY SPONDYLOARTHRITIS : 5-YEAR PROSPECTIVE DATA OF THE DESIR COHORT

 
Health Professionals Session - N101 / N102
  
Rehabilitation and modern drug treatment – needs and challenges
   ChairKennedy Norelee (Ireland)  
   ChairSmucrova Hana (Czech Republic)  
   SpeakerBjörk Mathilda (Sweden)SP0041Current needs for rehabilitation
   SpeakerCatrina Florin (Romania)SP0042The art of juggling - a patient’s perspective
   SpeakerBrodin Nina (Sweden) Physical activity: subjective and objective outcome
   SpeakerPrior Yeliz (United Kingdom)SP0043Work retention rehabilitation in practice
   AbstractEsbensen Bente (Denmark)OP0055-HPRPREFERENCES FOR SELF-MANAGEMENT AND SUPPORT SERVICES IN PATIENTS WITH INFLAMMATORY ARTHRITIS: A DANISH NATIONWIDE CROSS-SECTIONAL STUDY

 
Abstract Session - N105 / N106
  
Abstract Session: Basic and clinical science in paediatric rheumatology
   ChairBeresford Michael (United Kingdom)  
   ChairKoné-Paut Isabelle (France)  
   AbstractFisher Corinne (United Kingdom)OP0056IL-23P19 IS UP-REGULATED IN MONOCYTE-DERIVED MACROPHAGES FROM HLA B27 POSITIVE PATIENTS WITH ENTHESITIS RELATED ARTHRITIS
   AbstractHorneff Gerd (Germany)OP0057FLUORESCENCE OPTICAL IMAGING IN JUVENILE IDIOPATHIC POLYARTICULAR DISEASE BEFORE AND DURING ANTIRHEUMATIC TREATMENT
   AbstractRuperto N (Italy)OP0058IMPROVEMENT IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC OR NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATED WITH SC ABATACEPT
   AbstractDomínguez Casas LC (Spain)OP0059GOLIMUMAB VERSUS TOCILIZUMAB FOR SEVERE AND REFRACTORY JUVENILE IDIOPATHIC ARTHRITIS-UVEITIS. MULTICENTER STUDY OF 33 PATIENTS
   AbstractListing Miriam (Germany)OP0060HEALTH BEHAVIOR IN ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS- RESULTS OF THE INCEPTION COHORT OF NEWLY DIAGNOSED PATIENTS (ICON)
   AbstractBlay Gabriela (Brazil)OP0061DIFFUSE ALVEOLAR HEMORRHAGE: A MULTICENTER STUDY IN 847 CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
   AbstractFogel Olivier (France)OP0062ASSESSMENT OF BIOTHERAPIES’ EFFICACY IN BLAU SYNDROME: DATA FROM AN INTERNATIONAL RETROSPECTIVE COHORT OF 23 CASES
   AbstractDe Benedetti Fabrizio (Italy)OP0063CANAKINUMAB TREATMENT IN PATIENTS WITH COLCHICINE-RESISTANT FMF (CRFMF), HIDS/MKD AND TRAPS: EFFICACY IN THE 16 WEEKS RANDOMISED CONTROLLED PHASE AND MAINTENANCE OF DISEASE CONTROL AND SAFETY AT WEEK 40

 
Abstract Session - N111 / N112
  
Abstract Session: Impact of rheumatic diseases
   ChairBoonen Annelies (Netherlands)  
   ChairVisser Karen (Netherlands)  
   AbstractBeauvais Catherine (France)OP0064CLEFS DE DOS: A UNIQUE PARE-LED VIDEO PROGRAM TO IMPROVE COPING SKILLS OF PEOPLE LIVING WITH AXIAL SPONDYLOARTHRITIS
   AbstractGoulenok Tiphaine (France)OP0065NURSE-LED VACCINATION PROGRAM DRAMATICALLY IMPROVES PNEUMOCOCCAL VACCINATION COVERAGE AMONG PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: A PROSPECTIVE PILOT STUDY
   AbstractGuillen-Astete Carlos (Spain)OP0066THE PROBLEM BASED LEARNING APPLIED TO TEACHING RHEUMATOLOGICAL TOPICS AMONG NON RHEUMATOLOGY RESIDENTS
   Abstractvan Dijk Bastiaan (Netherlands)OP0067DEVELOPMENT AND VALIDATION OF A MODEL TO FACILITATE RECOGNITION OF ARTHRITIS BY GENERAL PRACTITIONERS
   AbstractYazdany Jinoos (United States)OP0068PRACTICES PARTICIPATING IN THE ACR’S RHEUMATOLOGY INFORMATICS SYSTEM FOR EFFECTIVENESS (RISE) NATIONAL REGISTRY SHOW IMPROVEMENTS IN QUALITY OF CARE
   AbstractLee Jeong Seok (Korea, Republic Of)OP0069THE BURDEN OF ANKYLOSING SPONDYLITIS: A POPULATION BASED STUDY
   AbstractRodrigues Manica Santiago (Portugal)OP0070THE ROLE OF INDIVIDUAL AND COUNTRY-LEVEL SOCIO-ECONOMIC FACTORS IN WORK PARTICIPATION IN PATIENTS WITH SPONDYLOARTHRITIS ACROSS 22 COUNTRIES WORLDWIDE: RESULTS FROM THE COMOSPA STUDY
   AbstractNorli Ellen Sauar (Norway)OP0071SICK LEAVE AFTER SIX MONTHS IN 664 PATIENTS WITH RECENT-ONSET INFLAMMATORY ARTHRITIS

 
PARE Session - N115 / N116
  
Co-morbidities: Having one RMD is enough – we don’t need anything else
   ChairAndersen Jeanette (United Kingdom)  
   ChairMazuras Kristijonas (Lithuania)  
   SpeakerRusthoven Cindy (Netherlands) The patient experience on comorbidities
   SpeakerGossec Laure (France)SP0044Screening for comorbidities in daily practice: who and how?
   SpeakerBosworth Ailsa (United Kingdom)SP0045Do patient organisations have a role to play in preventing co-morbidities?
   SpeakerGarcia-Diaz Silvia (Spain)SP0046Prevention and the protective role of exercise and lifestyle interventions on comorbidities
   AbstractProulx Laurie (Canada)OP0072-PAREPREGNANCY AND PARENTING WITH ARTHRITIS – DEVELOPING AN EDUCATIONAL RESOURCE FOR PATIENT BY PATIENTS

 
Abstract Session - N117 / N118
  
Abstract Session: Risk factors for developing diseases or comorbidities
   ChairSymmons Deborah (United Kingdom)  
   ChairCourvoisier Delphine (Switzerland)  
   Abstractvan der Helm-van Mil Annette H.M. (Netherlands)OP0073PERFORMANCE OF THE EULAR DEFINITION OF ARTHRALGIA SUSPICIOUS FOR PROGRESSION TO RHEUMATOID ARTHRITIS – A LONGITUDINAL STUDY
   AbstractChen Hsin-Hua (Taiwan, Province of China)OP0074ASSOCIATION BETWEEN A HISTORY OF MYCOBACTERIAL INFECTION AND THE RISK OF SJÖGREN’S SYNDROME: A NATIONWIDE, POPULATION-BASED CASE-CONTROL STUDY
   AbstractLu Huifang (United States)OP0075OSTEOPOROTIC FRACTURE RISK ASSESSMENT USING FRAX FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
   AbstractAletaha Daniel (Austria)OP0076RISK OF DEVELOPING ADDITIONAL IMMUNE MEDIATED MANIFESTATIONS FOR PATIENTS WITH SYSTEMIC ARTHRITIDES
   AbstractPark Jun Won (Korea, Republic Of)OP0077PRIMARY PROPHYLAXIS FOR PNEUMOCYSTIS PNEUMONIA IN PATIENTS WITH RHEUMATIC DISEASE AND TREATED WITH PROLONGED, HIGH-DOSE STEROID: A RETROSPECTIVE COHORT STUDY WITH 12-YEAR OBSERVATION
   AbstractTiosano Shmuel (Israel)OP0078THE LONG TERM PROGNOSTIC SIGNIFICANCE OF PULMONARY HYPERTENSION IN SARCOIDOSIS - A BIG DATA ANALYSIS
   AbstractLinauskas Asta (Denmark)OP0079BODY FAT PERCENTAGE AND WAIST CIRCUMFERENCE WERE ASSOCIATED WITH THE DEVELOPMENT OF RHEUMATOID ARTHRITIS – A DANISH FOLLOW-UP STUDY
   AbstractKuo Chang-Fu (Taiwan, Province of China)OP0080RISK OF AUTISM SPECTRUM DISORDER IN CHILDREN BORN TO MOTHERS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS IN TAIWAN

 
Abstract Session - N107 / N108
  
Abstract Session: Scleroderma, myositis and related syndromes, etiology, pathogenesis
   ChairMüller-Ladner Ulf (Germany)  
   ChairSiegert Elise (Germany)  
   AbstractAvouac Jérôme (France)OP0081PAN-PPAR AGONIST IVA337 IS EFFECTIVE IN THE PREVENTION OF EXPERIMENTAL LUNG FIBROSIS AND PULMONARY HYPERTENSION
   AbstractCorallo Claudio (Italy)OP0082FIBROSIS AND MICROANGIOPATHY ARE THE MAIN HISTOPATHOLOGICAL HALLMARKS OF SCLERODERMA-RELATED MYOPATHY
   AbstractSchniering Janine (Switzerland)OP0083MOLECULAR TARGETED IMAGING BIOMARKERS FOR PERSONALIZED MEDICINE STRATEGIES IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
   AbstractStellato Mara (Switzerland)OP0084RESCUE FROM THE FAILING HEART IN SYSTEMIC SCLEROSIS, A NOVEL INSIGHT: TARGETING TGF-/FRA2-DEPENDENT AUTOPHAGY
   AbstractVolkmann Elizabeth (United States)OP0085LONGITUDINAL ANALYSIS OF THE GASTROINTESTINAL MICROBIOTA IN SYSTEMIC SCLEROSIS
   AbstractPachera Elena (Switzerland)OP0086LONG NONCODING RNA H19X AS A NEW THERAPEUTIC TARGET FOR FIBROSIS
   AbstractHirabayashi Megumi (Japan)OP0087PLATELET-SPECIFIC FLI1-KNOCKOUT MICE SHOW ACCELERATED WOUND CLOSURE ASSOCIATED WITH INCREASED MYOFIBROBLAST FORMATION IN THE INFLAMMATORY PHASE.
   AbstractRudnik Michal (Switzerland)OP0088THE ROLE AND FUNCTION OF MONOCYTE-DERIVED FIBROBLAST-LIKE CELLS IN MULTI-ORGAN FIBROSIS IN SYSTEMIC SCLEROSIS

 
Abstract Session - N109 / N110
  
Abstract Session: Novel insights in inflammatory mediators
   ChairMcInnes Iain (United Kingdom)  
   ChairRodriguez -Carrio Javier (Spain)  
   AbstractKim Sunhwa (United States)OP0089COMBINATION THERAPY OF SELECTIVE MMP9 AND TNF INHIBITORS ARE EFFICACIOUS IN THE MOUSE CIA MODEL OF RHEUMATOID ARTHRITIS
   AbstractMarchetti Carlo (United States)OP0090THE HUMAN SAFE NLRP3 INFLAMMASOME INHIBITOR OLT1177 SUPPRESSES JOINT INFLAMMATION IN MURINE MODELS OF EXPERIMENTAL ARTHRITIS
   AbstractPopp David (Germany)OP0091S100A8 TRIGGERS A NOVEL IMMUNE-REGULATORY MECHANISM IN DEVELOPING DENDRITIC CELLS
   AbstractCavalli Giulio (Italy)OP0092INTERLEUKIN 37 REVERSES THE METABOLIC COST OF INFLAMMATION, INCREASES OXIDATIVE RESPIRATION AND IMPROVES EXERCISE TOLERANCE
   AbstractLe Goff Benoît (France)OP0093IL-38 OVEREXPRESSION INDUCES ANTI-INFLAMMATORY EFFECTS IN MICE ARTHRITIS MODELS AND IN HUMAN MACROPHAGES IN VITRO
   AbstractMulhearn Ben (United Kingdom)OP0094DEVELOPMENT OF A 37-CHANNEL MASS CYTOMETRY (CYTOF) PANEL TO PREDICT TREATMENT RESPONSE IN RHEUMATOID ARTHRITIS
   AbstractMd Yusof Md Yuzaiful (United Kingdom)OP0095PREDICTION OF CONNECTIVE TISSUE DISEASE IN AN AT-RISK COHORT USING A NOVEL INTERFERON STIMULATED GENE EXPRESSION SCORE
   AbstractMendoza Fabian (United States)OP0096INTERFERON SIGNATURE IN SYSTEMIC SCLEROSIS LUNG MICROVASCULAR ENDOTHELIAL CELLS.

Thursday 15.06.2017 08:15 - 09:45


 
Basic and Translational Science Session - South Auditorium
  
Cytokines and chemokines
   ChairRovere-Querini Patrizia (Italy)  
   ChairStraub Rainer H. (Germany)  
   SpeakerRönnblom Lars (Sweden)SP0047Type I interferon system in autoimmunity
   SpeakerTas Sander W. (Netherlands)SP0048Targeting of angiogenic molecules
   SpeakerPisetsky David S. (United States)SP0049DNA aggregates as alarmins
   AbstractBodewes Iris (Netherlands)OP0097SYSTEMIC IFN TYPE I AND TYPE II SIGNATURES IN PRIMARY SJÖGREN’S SYNDROME REVEAL DIFFERENCES IN DISEASE SEVERITY

Thursday 15.06.2017 10:15 - 11:45


 
WIN & HOT Session - Hall 6
  
WIN & HOT Session
   ChairBranco Jaime C. (Portugal)  
   ChairStudenic Paul (Austria)  
   SpeakerMartinoli Carlo (Italy) WIN Session: What is the use of imaging for regional pain syndromes
   SpeakerHasset Afton (United States) WIN Session: Fibromyalgia

 
Abstract Session - Hall 8
  
Abstract Session: Progress in biological treatment of RA
   ChairFleischmann Roy (United States)  
   ChairEmery Paul (United Kingdom)  
   AbstractDörner Thomas (Belgium)OP0098REMISSION AND MAINTENANCE OF EFFICACY IN A PHASE 2B STUDY OF VOBARILIZUMAB, AN ANTI-INTERLEUKIN 6 RECEPTOR NANOBODY, IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS DESPITE TREATMENT WITH METHOTREXATE
   AbstractGaleazzi Mauro (Switzerland)OP0099SAFETY, TOLERABILITY AND INITIAL SIGNS OF EFFICACY OF THE FULLY HUMAN IMMUNOCYTOKINE DEKAVIL (F8IL10): A NOVEL THERAPEUTIC APPROACH FOR RHEUMATOID ARTHRITIS
   AbstractWadström Hjalmar (Sweden)OP0100OVERALL CANCER RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS, TOCILIZUMAB, ABATACEPT, OR RITUXIMAB
   AbstractSimon TA (United States)OP0101RISK OF OPPORTUNISTIC INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING ABATACEPT: ANALYSIS OF ALL AVAILABLE CLINICAL TRIAL DATA
   AbstractStrand Vibeke (United States)OP0102PATIENT REPORTED BENEFITS OF SARILUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN ADULT PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
   AbstractDasgupta Bidisha (United States)OP0103THE EFFECT OF SIRUKUMAB PLUS METHOTREXATE ON CIRCULATING BIOMARKERS OF JOINT DESTRUCTION IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS PATIENTS FROM THE SIRROUND-D PHASE 3 STUDY
   AbstractURATA Yukitomo (Japan)OP0104TOCILIZUMAB: DOSE REDUCTION OR INTERVAL SPACING – WHICH PROVES A BETTER TAPERING STRATEGY FOR RHEUMATOID ARTHRITIS IN CLINICAL REMISSION?
   AbstractMohan Shalini (United States)OP0105LONG-TERM SAFETY OF TOCILIZUMAB FROM LARGE CLINICAL TRIAL AND POSTMARKETING POPULATIONS

 
Abstract Session - Hall 7A
  
Abstract Session: PsA: A fascinating disease
   ChairSiebert Stefan (United Kingdom)  
   ChairCarubbi Francesco (Italy)  
   AbstractKristensen Lars Erik (Denmark)OP0106THE IMPACT OF COMORBIDITIES ON EFFECT AND DISCONTINUATION OF TUMOUR NECROSIS FACTOR INHIBITOR THERAPY IN PSORIATIC ARTHRITIS: A POPULATION-BASED COHORT STUDY
   AbstractConaghan Philip (United Kingdom)OP0107PAIN STILL REMAINS A HIGH UNMET NEED AMONG PSORIATIC ARTHRITIS PATIENTS RECEIVING EXISTING BIOLOGIC TREATMENT: RESULTS FROM A MULTI NATIONAL REAL-WORLD SURVEY
   AbstractLandewé Robert (Netherlands)OP0108INHIBITION OF RADIOGRAPHIC PROGRESSION IN PSORIATIC ARTHRITIS BY ADALIMUMAB INDEPENDENT OF THE CONTROL OF CLINICAL DISEASE ACTIVITY
   AbstractMichelsen Brigitte (Norway)OP0109IS MENTAL HEALTH COMPARABALE IN RHEUMATOID AND PSORIATIC ARTHRITIS PATIENTS? A COMPARATIVE ANALYSIS OF REAL LIFE LONGITUDINAL DATA FROM THE NOR-DMARD STUDY
   AbstractJani Meghna (United Kingdom)OP0110ASSOCIATION OF PHARMACOLOGICAL BIOMARKERS WITH TREATMENT RESPONSE AND LONG-TERM DISABILITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM OUTPASS
   AbstractEder Lihi (Canada)OP0111THE ASSOCIATION BETWEEN SONOGRAPHIC ENTHESITIS AND RADIOGRAPHIC JOINT DAMAGE IN PSORIATIC ARTHRITIS
   AbstractJørgensen Tanja (Denmark)OP0112IN PSORIATIC ARTHRITIS FATIGUE IS DRIVEN BY INFLAMMATION, DISEASE DURATION, AND CHRONIC PAIN: AN OBSERVATIONAL DANBIO REGISTRY STUDY
   AbstractOrtolan Augusta (Italy)OP0113METABOLIC SYNDROME AND LIVER STIFFNESS IN PSORIATIC ARTHRITIS AND PSORIASIS PATIENTS: A CASE-CONTROL STUDY.

 
Abstract Session - Hall 7B
  
Abstract Session: More or less imaging in axial SpA?
   ChairSampaio-Barros Percival D. (Brazil)  
   ChairMarzo-Ortega Helena (United Kingdom)  
   Abstractde Koning Anoek (Netherlands)OP0114LOW DOSE COMPUTED TOMOGRAPHY DETECTS MORE PROGRESSION OF BONE FORMATION IN COMPARISON TO CONVENTIONAL RADIOGRAPHY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE SIAS COHORT
   Abstractdougados maxime (France)OP0115EVALUATION OF THE CHANGES IN STRUCTURAL DAMAGE IN AXIAL SPONDYLOARTHRITIS ON PLAIN PELVIC RADIOGRAPHS: THE 5 YEARS DATA OF THE DESIR COHORT.
   AbstractDougados Maxime (France)OP0116SWITCH FROM NON-RADIOGRAPHIC TO RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IS HIGHLY DEPENDENT OF BASELINE OBJECTIVE SIGNS OF INFLAMMATION: 5 YEAR DATA OF THE DESIR COHORT
   AbstractWeber Ulrich (Denmark)OP0117BONE MARROW OEDEMA IN SACROILIAC JOINTS OF YOUNG ATHLETES SHOWS MOST FREQUENTLY IN THE POSTERIOR INFERIOR ILIUM
   AbstractProtopopov Mikhail (Germany)OP0118IMPACT OF RADIOGRAPHIC DAMAGE IN THE SACROILIAC JOINTS ON FUNCTION AND SPINAL MOBILITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT
   AbstractMeghnathi Bhowmik (France)OP0119EVALUATION OF THE PREDICTIVE VALIDITY OF THE ASAS AXIAL SPONDYLOARTHRITIS CRITERIA IN THE DESIR COHORT
   AbstractAkar Servet (Turkey)OP0120THE ROLE OF SMOKING IN THE DEVELOPMENT AND PROGRESSION OF STRUCTURAL DAMAGE IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE PRELIMINARY RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS.
   AbstractMaksymowych Walter (Canada)OP0121VALIDATION OF MRI STRUCTURAL LESIONS USING COMPUTED TOMOGRAPHY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS

 
Abstract Session - N103 / N104
  
Abstract Session: Clinical and therapeutical news in systemic sclerosis
   ChairGabrielli Armando (Italy)  
   ChairRadstake Timothy R. (Netherlands)  
   AbstractJohnson Sindhu (Canada)OP0122VENOUS THROMBOEMBOLISM IN SYSTEMIC SCLEROSIS: PREVALENCE, RISK FACTORS AND IMPACT ON SURVIVAL
   AbstractHerrick Ariane (United Kingdom)OP0123PREDICTION OF PROGRESSIVE SKIN THICKENING IN EARLY DIFFUSE SYSTEMIC SCLEROSIS USING THREE-MONTHLY SKIN SCORES FROM THE EUROPEAN SCLERODERMA OBSERVATIONAL STUDY (ESOS)
   AbstractVolkmann Elizabeth (United States)OP0124TREATMENT WITH CYCLOPHOSPHAMIDE FOR SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE DOES NOT IMPROVE SURVIVAL AFTER 12 YEARS OF FOLLOW UP
   AbstractYang Xinlei (China)OP0125MORTALITY IN PATIENTS WITH DERMATOMYOSITIS/POLYMYOSITIS IN A CHINESE MEDICAL CENTRE
   AbstractSpiera Robert (United States)OP0126A PHASE 2 STUDY OF SAFETY AND EFFICACY OF ANABASUM (JBT-101) IN SYSTEMIC SCLEROSIS
   AbstractHashimoto Naoaki (Japan)OP0127TEN YEARS FOLLOW-UP OF GASTROINTESTINAL INVOLVEMENT BY THE SMALL INTESTINAL CLEARANCE IN PATIENTS WITH SYSTEMIC SCLEROSIS
   AbstractPoindron Vincent (France)OP0128DETECTION OF SUB-CLINICAL DIFFUSE MYOCARDIAL FIBROSIS BY NATIVE T1 MAPPING MAGNETIC RESONANCE IMAGING IN A PROSPECTIVE SYSTEMIC SCLEROSIS COHORT
   AbstractFretheim Håvard (Norway)OP0129MYCOPHENOLATE MOFETIL VERSUS CYCLOPHOSPHAMIDE IN SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE IN A REAL LIFE SCENARIO

 
Abstract Session - South Auditorium
  
Abstract Session: Vasculitis Clinical and Pathogenic Highlights
   ChairLuqmani Raashid (United Kingdom)  
   ChairMolloy Eamonn S. (Ireland)  
   AbstractWechsler Michael (United States)OP0130MEPOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A PHASE III RANDOMISED, PLACEBO-CONTROLLED TRIAL
   AbstractStone J (United States)OP0131OPTIMAL DOSE OF TOCILIZUMAB FOR THE TREATMENT OF GIANT CELL ARTERITIS: EFFICACY, SAFETY, AND EXPOSURE-EFFICACY ANALYSIS FROM GIACTA
   AbstractFu Xiaolan (China)OP0132LOW-DOSE INTERLEUKIN-2 SELECTIVELY RESTORE RULATORY T CELL NUMBERS IN PATIENTS WITH BD
   AbstractJese Rok (Slovenia)OP0133COLOUR DOPPLER ULTRASONOGRAPHY OF FACIAL AND OCCIPITAL ARTERIES IN PATIENTS WITH GIANT CELL ARTERITIS: THE FREQUENCY OF INVOLVEMENT AND THE ROLE OF THEIR ASSESSMENT IN DAILY PRACTICE: A PROSPECTIVE STUDY
   AbstractComarmond Cloé (France)OP0134LONG TERM OUTCOME AND PROGNOSIS FACTORS OF COMPLICATIONS IN TAKAYASU'S ARTERITIS: MULTICENTER STUDY OF 318 PATIENTS
   AbstractVegas Revenga Nuria (Spain)OP0135TOCILIZUMAB IN GIANT CELL ARTERITIS: GIACTA TRIAL VERSUS A SERIES OF PATIENTS FROM CLINICAL PRACTISE
   AbstractHocevar Alojzija (Slovenia)OP0136MICRORNA-223-3P EXPRESSION IN AFFECTED SKIN OF ADULT IGA VASCULITIS CORRELATES WITH THE SEVERITY OF SKIN INVOLVEMENT
   AbstractCornec Divi (United States)OP0137AUTO-REACTIVE B CELLS ESCAPE PERIPHERAL TOLERANCE CHECKPOINTS IN PATIENTS WITH PR3-ANCA ASSOCIATED VASCULITIS

 
Abstract Session - N101 / N102
  
HPR Abstract Session: Mind over matter - patients perspectives
   ChairPrior Yeliz (United Kingdom)  
   ChairDomjan Andrea (Hungary)  
   AbstractSelten Ellen (Netherlands)OP0138-HPRDO PATIENTS’ TREATMENT BELIEFS AFFECT TREATMENT CHOICES IN KNEE AND HIP OSTEOARTHRITIS?
   AbstractHewlett Sarah (United Kingdom)OP0139-HPRREDUCING ARTHRITIS FATIGUE - CLINICAL TEAMS (RAFT) USING COGNITIVE-BEHAVIOURAL APPROACHES: AN RCT
   AbstractNealon Lennox Noirin (Ireland)OP0140-HPRACCEPTANCE AND COMMITMENT THERAPY: A RETROSPECTIVE STUDY OF OUTCOMES FROM A HOSPITAL-BASED, GROUP, PAIN REHABILITATION PROGRAMME IN RHEUMATOLOGY SERVICES IN THE SOUTH EAST OF IRELAND
   AbstractPeter Wilfred (Netherlands)OP0141-HPRAN INNOVATE MEASUREMENT INSTRUMENT TO ASSESS ACTIVITY LIMITATIONS IN HIP AND KNEE OSTEOARTHRITIS: THE COMPUTERIZED ANIMATED ACTIVITY QUESTIONNAIRE (AAQ) AND ITS PSYCHOMETRIC PROPERTIES.
   AbstractGeenen Rinie (Netherlands)OP0142-HPRTHE POTENTIAL BUFFERING ROLE OF SELF-EFFICACY AND PAIN ACCEPTANCE AGAINST INVALIDATION IN RHEUMATIC DISEASES
   AbstractBjörk Mathilda (Sweden)OP0143-HPRDISABILITY IN THE FEET RELATED TO PARTICIPATION IN DAILY LIFE IN PATIENTS WITH EARLY RA – AN INTERVIEW STUDY IN THE SWEDISH TIRA PROJECT.
   AbstractHenriques Marta (Portugal)OP0144-HPR“IT CAN’T BE ZERO”: A QUALITATIVE STUDY OF PATIENTS’ PERSPECTIVE ON PATIENT GLOBAL ASSESSMENT IN RHEUMATOID ARTHRITIS
   AbstractMathijssen Elke (Netherlands)OP0145-HPRRHEUMATOID ARTHRITIS PATIENTS’ SUPPORT NEEDS REGARDING MEDICATION USE AND THEIR PERSPECTIVES ON THE APPLICABILITY OF EHEALTH INTERVENTIONS TO ADDRESS THOSE NEEDS: A FOCUS GROUP STUDY

 
Abstract Session - N105 / N106
  
Abstract Session: RA: really a systemic disease?
   ChairNurmohamed Michael (Netherlands)  
   ChairAtzeni Fabiola (Italy)  
   AbstractFilhol Elisabeth (France)OP0146DECREASE IN CARDIOVASCULAR EVENT EXCESS RISK IN RHEUMATOID ARTHRITIS SINCE 2000': A META- ANALYSIS OF CONTROLLED STUDIES.
   AbstractSkielta Mattias (Sweden)OP0147TRENDS IN MORTALITY, CO-MORBIDITY AND TREATMENT AFTER ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS 1998-2013
   AbstractSparks Jeffrey (United States)OP0148IMPACT OF A CARDIOVASCULAR EVENT ON DMARD TREATMENT AMONG PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OR PSORIASIS
   AbstractHolmqvist Marie (Sweden)OP0149MORTALITY IN NEW-ONSET RHEUMATOID ARTHRITIS - HAS MODERN RHEUMATOLOGY HAD AN IMPACT?
   AbstractJonge A.V. de Jonge (Netherlands)OP0150PARADOXICAL EFFECT OF BIOLOGICAL DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH OVERWEIGHT AND OBESITY: LESS OFTEN CLINICAL REMISSION, BUT ALSO LESS RADIOLOGICAL DAMAGE
   AbstractNeumann Thomas (Germany)OP0151DOCOSAHEXAENOIC ACID TREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY
   AbstractOnishi Akira (Japan)OP0152A LONGITUDINAL STUDY OF THE EFFECTS OF DISEASE ACTIVITY ON RENAL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS UTILIZING LINEAR MIXED EFFECT MODELS - ANSWER COHORT STUDY -
   AbstractSubesinghe Sujith (United Kingdom)OP0153RECURRENT INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS, RESULTS FROM THE BSRBR

 
Abstract Session - N111 / N112
  
Abstract Session: Advances in RA and SpA pathophysiology
   ChairCiccia Francesco (Italy)  
   ChairHasseli Rebecca (Germany)  
   AbstractOspelt Caroline (Switzerland)OP0154ALTERED LYMPH NODE STROMAL CELLS DURING THE EARLIEST PHASES OF RHEUMATOID ARTHRITIS
   AbstractShi Maohua (China)OP0155MDM2-MEDIATED SUMOYLATION OF P53 CONTRIBUTES TO THE MIGRATION AND INVASION OF FIBROBLAST-LIKE SYNOVIOCYTES FROM PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractBergström Beatrice (Sweden)OP0156METHOTREXATE INCREASES EXPRESSION OF THE CELL CYCLE REGULATORS LBH AND P21 AND REDUCES FIBROBLAST-LIKE SYNOVIOCYTE PROLIFERATION AFTER MITOGEN STIMULATION
   AbstractPajak Agnieszka (Switzerland)OP0157APOPTOSIS RESISTANCE OF SYNOVIAL FIBROBLASTS OF PATIENTS WITH RHEUMATOID ARTHRITIS IS REGULATED BY THE LONG NON-CODING RNA FAS-AS1
   AbstractArellano-Martinez Adolfo (Mexico)OP0158PREVALENCE OF IMMUNIZATION OF PATIENTS WITH AUTOIMMUNE DISEASE IN MEXICO
   AbstractVan Tok Melissa (Netherlands)OP0159THE INITIATION, BUT NOT THE PERSISTENCE, OF EXPERIMENTAL SPONDYLOARTHRITIS IN HLA-B27/HUΒ2M TRANSGENIC RATS IS CRUCIALLY DEPENDENT ON THE IL-23 AXIS
   AbstractJacques Peggy (Belgium)OP0160GUT-DERIVED TNF AS RISK FACTOR FOR THE DEVELOPMENT OF SACROILIAC INFLAMMATION
   AbstractRobin-Jagerschmidt Catherine (France)OP0161THE JAK1 SELECTIVE INHIBITOR FILGOTINIB REGULATES BOTH ENTHESIS AND COLON INFLAMMATION IN A MOUSE MODEL OF PSORIATIC ARTHRITIS

 
PARE Session - N115 / N116
  
Bringing rheumatology research to the next level: Addressing the main challenges of patient partnerships in research and health care service design
   ChairHoronjeff Jennifer (United States)  
   ChairClausen Jürgen (Germany)  
   SpeakerOrbai Ana-Maria (United States)SP0050Ensuring representativeness of the patients’ perspectives in the final results generated from clinical research – challenges from the perspective of researchers
   SpeakerMateus Elsa (Portugal)SP0051Becoming a patient research partner in the field of rheumatology. My expectations and the challenges of being educated and taken seriously
   SpeakerLempp Heidi (United Kingdom)SP0052Building patient partnerships in health care service design and delivery
   AbstractStones Simon (United Kingdom)OP0162-PAREAN EXPLORATION OF LIVED EXPERIENCES AMONGST ADULTS WITH RHEUMATOID ARTHRITIS USING AN ONLINE RESEARCH COMMUNITY PLATFORM: A PILOT STUDY.
   AbstractClausen Jürgen (Germany)OP0163-PAREINVIGORATING THE PRINCIPLE OF PARTICIPATORY RESEARCH IN GERMANY - SETUP OF A TRAINING COURSE FOR PATIENT REPRESENTATIVES

 
Abstract Session - N117 / N118
  
Abstract Session: Osteoarthritis: new horizons for treatment
   ChairZhang Weiya (United Kingdom)  
   Chairnot confimed yet  
   AbstractBowes Michael (United Kingdom)OP0164OPTIMIZING RECRUITMENT CRITERIA FOR AN OSTEOARTHRITIS STRUCTURE MODIFICATION TRIAL: DATA FROM THE OAI
   AbstractBay-Jensen Anne (Denmark)OP0165A NEOEPITOPE FRAGMENT OF C-REACTIVE PROTEIN IS PROGNOSTIC OF RADIOGRAPHIC KNEE OA
   AbstractYazici Y. (United States)OP0166RADIOGRAPHIC OUTCOMES FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, INJECTABLE, WNT PATHWAY INHIBITOR (SM04690) IN THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE: WEEK 26 INTERIM ANALYSIS
   AbstractStevens Randall (United States)OP0167EFFICACY AND SAFETY OF CNTX-4975 IN SUBJECTS WITH MODERATE TO SEVERE OSTEOARTHRITIS KNEE PAIN: 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
   AbstractKloppenburg Margreet (Netherlands)OP0168A PHASE 2A, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF ABT-981, AN ANTI-INTERLEUKIN-1ALPHA AND -1BETA DUAL VARIABLE DOMAIN IMMUNOGLOBULIN, TO TREAT EROSIVE HAND OSTEOARTHRITIS (EHOA)
   AbstractZhu Zhaohua (Australia)OP0169EARLY OSTEOPHYTES DETECTED BY MRI ARE ASSOCIATED WITH CHANGES IN KNEE PAIN AND STRUCTURES IN OLDER ADULTS: A POPULATION-BASED COHORT STUDY
   AbstractVeenbrink Anne (Netherlands)OP0170LEPTIN AND ADIPONECTIN MEDIATE THE ASSOCIATION BETWEEN BODY MASS INDEX AND HAND AND KNEE OSTEOARTHRITIS
   AbstractWang Kang (Australia)OP0171SIGNAL INTENSITY ALTERATION WITHIN INFRAPATELLAR FAT PAD PREDICTS TOTAL KNEE ARTHROPLASTY WITHIN FOUR YEARS: DATA FROM THE OSTEOARTHRITIS INITIATIVE

 
Abstract Session - N107 / N108
  
Abstract Session: Cellular drivers of inflammation in rheumatic disease
   ChairElewaut Dirk (Belgium)  
   ChairFonseca Joao Eurico (Portugal)  
   AbstractBalzaretti Giulia (Netherlands)OP0172EXPANDED T-CELL CLONES PRESENT IN SYNOVIUM AT ONSET OF RHEUMATOID ARTHRITIS ARE ALREADY PRESENT IN THE SYNOVIUM IN THE SEROPOSITIVE “AT RISK” STAGE.
   AbstractKlarenbeek Paul (Netherlands)OP0173DOMINANT B-CELL RECEPTOR CLONES IN PERIPHERAL BLOOD PREDICT ONSET OF ARTHRITIS IN INDIVIDUALS AT RISK FOR RHEUMATOID ARTHRITIS
   AbstractSkriner Karl (Germany)OP0174NEW PROTEIN ARRAY TECHNOLOGY IDENTIFIES RITUXIMAB TREATED NON RESPONDER RHEUMATOID ARTHRITIS PATIENTS ARE GENERATING A NEW AUTOANTIBODY REPERTOIRE
   AbstractCorsiero Elisa (United Kingdom)OP0175CHARACTERIZATION OF NOVEL STROMAL-DERIVED AUTOANTIGENS RECOGNIZED BY RA SYNOVIAL MONOCLONAL ANTIBODIES.
   AbstractElewaut Dirk (Belgium)OP0176THE PARACASPASE MALT1 PLAYS A CENTRAL ROLE IN THE PATHOGENESIS OF RHEUMATOID ARTHRITIS
   AbstractScherer Hans (Netherlands)OP0177N-GLYCOSYLATION SITES IN THE VARIABLE DOMAIN OF B CELL RECEPTORS SPECIFIC FOR CITRULLINATED ANTIGENS
   AbstractCrowley Thomas (United Kingdom)OP0178FIBROBLAST PRIMING IS COMMON TO MANY SITES, AND PSORIATIC SKIN FIBROBLASTS MAY ACQUIRE INFLAMMATORY MEMORY
   AbstractBiavasco Riccardo (Italy)OP0179BRAFV600E PROMOTES MYELOID SKEWING IN MULTISYSTEMIC LANGERHANS CELL HISTIOCYTOSIS HUMANIZED MOUSE MODEL

 
Abstract Session - N109 / N110
  
Abstract Session: Joint health & joint damage: a tale of three tissues
   ChairBeier Frank (Canada)  
   ChairIoan-Facsinay Andreea (Netherlands)  
   AbstractAmantini David (France)OP0180PHARMACOLOGICAL CHARACTERIZATION OF THE ADAMTS-5 INHIBITOR GLPG1972: AN ORAL ANTI-CATABOLIC AGENT FOR THE TREATMENT OF OSTEOARTHRITIS
   AbstractFahmi Hassan (Canada)OP0181DELETION OF THE PROSTAGLANDIN D2 RECEPTOR DP1 EXACERBATES AGING-ASSOCIATED AND INSTABILITY-INDUCED OSTEOARTHRITIS
   AbstractMcGonagle Dennis (United Kingdom)OP0182CONVERGENCE OF JOINT REPAIR AND PAIN PATHWAYS VIA NERVE GROWTH FACTOR AND P75 EXPRESSING MESENCHYMAL STEM CELLS- A NOVEL EXPLANATION FOR OSTEOARTHRITIS PROGRESSION WITH ANTI-NGF IN OSTEOARTHRITIS
   AbstractAshraf Sadaf (United Kingdom)OP0183CORDYCEPIN, A NOVEL COMPOUND, REDUCES KNEE JOINT PATHOLOGY AND PAIN IN THE MONOSODIUM IODOACETATE (MIA) RAT MODEL OF OSTEOARTHRITIS
   AbstractNajm Aurelie (France)OP0184IMSYC IMMUNOLOGIC SYNOVITIS SCORE: A NEW HISTOLOGICAL SCORE FOR DISCRIMINATING INFLAMMATORY AND NON-INFLAMMATORY ARTHRITIS.
   AbstractCuervo Aguilera Andrea (Spain)OP0185IMMUNOHISTOLOGIC STUDY OF SYNOVITIS FROM PATIENTS WITH UNDIFFERENTIATED ARTHRITIS WHO EVOLVED TO RHEUMATOID ARTRHITIS OR PSORIATIC ARTHRITIS AFTER FOLLOW-UP.
   AbstractMediero Aranzazu (Spain)OP0186TENOFOVIR, A NUCLEOSIDE ANALOG REVERSE TRANSCRIPTASE INHIBITOR FOR TREATMENT OF HIV, PROMOTES OSTEOCLAST DIFFERENTIATION AND BONE LOST IN VIVO IN A MECHANISM DEPENDING ON ATP RELEASE AND ADENOSINE, AND DIPYRIDAMOLE MAY BE A USEFUL TREATMENT TO REVERT THE EFFECTS
   AbstractWiebe Edgar (Germany)OP0187TRANSGENIC DISRUPTION OF GLUCOCORTICOID-SIGNALING IN MATURE OSTEOBLASTS AND OSTEOCYTES ATTENUATES STRUCTURAL BONE DAMAGE IN A LONG-TERM MURINE K/BXN SERUM-INDUCED ARTHRITIS MODEL

Thursday 15.06.2017 11:45 - 13:30


 
Poster Tour - Poster Area
  
HPR Poster Tour: From top to toe; health professional practice
   ChairMoe Rikke Helene (Norway)  
   ChairDziedzic Krysia (United Kingdom)  
   AbstractTenten-Diepenmaat Marloes (Netherlands)THU0750-HPRTHE EFFECTIVENESS OF THERAPEUTIC FOOTWEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
   AbstractGijon-Nogueron Gabriel (Spain)THU0751-HPREFFECTIVENESS OF FOOT ORTHOSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS RELATED TO QUALITY OF LIFE AND PAIN. A SYSTEMATIC REVIEW AND META-ANALYSIS.
   AbstractSelten Ellen (Netherlands)THU0752-HPRDEVELOPMENT OF THE “TREATMENT BELIEFS IN KNEE AND HIP OSTEOARTHRITIS (TOA)” QUESTIONNAIRE
   AbstractHaroon Muhammad (Ireland)THU0753-HPRPREDICTING THE FUTURE DEVELOPMENT OF SPONDYLOARTHRITIS AMONG PATIENTS WITH IDIOPATHIC ACUTE ANTERIOR UVEITIS USING REAL-WORLD DATA
   AbstractJohannesson Sofia (Sweden)THU0754-HPRWORK STATUS IN WOMEN WITH FIBROMYALGIA- A 12-YEAR FOLLOW UP STUDY
   Abstractde Zwart Arjan (Netherlands)THU0755-HPRDIETARY PROTEIN INTAKE AND UPPER LEG MUSCLE STRENGTH IN PATIENTS WITH KNEE OSTEOARTHRITIS: DATA FROM THE OSTEOARTHRITIS INITIATIVE
   AbstractKinikli Gizem (Turkey)THU0756-HPRPREDICTORS OF FEAR OF MOVEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractVan der Elst Kristien (Belgium)THU0757-HPREUROPEAN QUALITATIVE RESEARCH PROJECT ON PATIENT-PREFERRED OUTCOMES IN EARLY RHEUMATOID ARTHRITIS (EQPERA): RATIONALE, DESIGN AND METHODS OF AN ONGOING MULTI-COUNTRY, MULTI-CENTER, MULTI-LANGUAGE, LONGITUDINAL QUALITATIVE STUDY
   AbstractNiedermann Karin (Switzerland)THU0758-HPRAPPLICATION OF THE EULAR RECOMMENDATIONS FOR PATIENT EDUCATION FOR PEOPLE WITH INFLAMMATORY ARTHRITIS IN SWITZERLAND
   AbstractKARAPINAR Merve (Turkey)THU0759-HPRDOES PHYSIOTHERAPY AND REHABILITATION PROGRAM IMPROVE MOBILITY AND DAILY LIVING ACTIVITIES IN ELDERLY INPATIENT WITH OSTEOPOROSIS ?
  
Poster Tour: A stroll among the crystals
   ChairSo Alexander (Switzerland)  
   ChairAndrés Mariano (Spain)  
   AbstractForien Marine (France)THU0401ULTRASOUND EVALUATION IN FOLLOW-UP OF URATE-LOWERING THERAPY IN GOUTY PATIENTS: THE USEFUL STUDY.
   AbstractPascart Tristan (France)THU0402ULTRASONOGRAPHY AND DUAL-ENERGY CT (DECT) DO NOT PROVIDE THE SAME QUANTIFICATION OF URATE DEPOSITION IN GOUT : RESULTS FROM A CROSS-SECTIONAL STUDY.
   AbstractKuo Chang-Fu (Taiwan, Province of China)THU0403URATE-LOWERING TREATMENT AND RISK OF INCIDENT UROLITHIASIS IN PEOPLE WITH GOUT: A NESTED CASE-CONTROL STUDY
   AbstractLandgren Anton (Sweden)THU0404SELF-REPORTED SEVERITY OF GOUT IN A PRIMARY CARE SETTING AND ASSOCIATED FACTORS – RESULTS FROM A GOUT SURVEY IN PRIMARY CARE
   AbstractRai Sharan (United States)THU0405KILLING TWO BIRDS WITH ONE STONE? THE DASH DIET AND THE RISK OF GOUT: 26-YEAR FOLLOW-UP OF A PROSPECTIVE COHORT
   AbstractPascual Eliseo (Spain)THU0406SERUM URIC ACID LOWERING TREATMENT APPEARS UNNECESSARY DURING HEMODIALYSIS.
   AbstractUhlig Till (Norway)THU0407HIGH GOUT CLASSIFICATION SCORE IS ASSOCIATED WITH ULTRASOUND FINDINGS IN PATIENTS WITH CRYSTAL-PROVEN GOUT
   AbstractSigurdardottir Valgerdur (Sweden)THU0408GOUT IS AN IMPORTANT PREDICTOR OF WORK DISABILITY IN BOTH MEN AND WOMEN
   AbstractSingh Gurkirpal (United States)THU0409NOT JUST A SWOLLEN BIG TOE: INCREASING ALL-CAUSE HOSPITALIZATIONS IN PATIENTS WITH GOUT IN THE UNITED STATES: 1993–2014
   AbstractSchlesinger Naomi (United States)THU0410GOUT AND THE RISK OF INCIDENT ERECTILE DYSFUNCTION: A BODY MASS INDEX-MATCHED POPULATION-BASED STUDY
  
Poster Tour: Clinicial features and treatment of orphan diseases
   ChairIonescu Ruxandra (Romania)  
   ChairBalanescu Andra (Romania)  
   AbstractLanzillotta Marco (Italy)THU0538EFFECTS OF GLUCOCORTICOIDS AND METHOTREXATE-BASED THERAPEUTIC REGIMENS ON B CELL SUBPOPULATIONS IN PATIENTS WITH IGG4-RELATED DISEASE
   AbstractPérez-Alvarez Roberto (Spain)THU0539SARCOIDOSIS IN SPAIN: CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS AT DIAGNOSIS IN 1082 PATIENTS
   AbstractFabiani Claudia (Italy)THU0540EFFICACY AND SAFETY OF ADALIMUMAB IN BEHÇET’S DISEASE RELATED UVEITIS: A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY
   AbstractColafrancesco Serena (Italy)THU0541ROLE OF IL-1 INHIBITION IN ADULT ONSET STILL’S DISEASE (AOSD): A RETROSPECTIVE, OBSERVATIONAL MULTICENTRIC STUDY FROM THE ITALIAN SOCIETY OF RHEUMATOLOGY STUDY GROUP ON AUTOINFLAMMATORY DISEASES
   AbstractUgurlu Serdal (Turkey)THU0542ANTI-INTERLEUKIN 1 THERAPY IN FMF AMYLOIDOSIS: A SINGLE CENTER EXPERIENCE (CASE SERIES)
   AbstractTang Chun (Hong Kong)THU0543A RETROSPECTIVE OVERVIEW OF THE TREATMENT MODALITY, OUTCOME AND RELAPSE RISK OF IGG4 RELATED DISEASE IN HONG KONG: A DATASET OF 108 PATIENTS FROM FOUR REGIONAL HOSPITALS
   AbstractCinar Muhammet (Turkey)THU0544THE IMPORTANCE OF R202Q POLYMORPHISM IN CLINICAL EXPRESSION OF FMF: A SINGLE CENTER CROSS-SECTIONAL STUDY
   AbstractGonzález García Andrés (Spain)THU0545COMPARISON OF THE CLINICAL AND LABORATORY FEATURES AT ONSET BETWEEN MULTICENTRIC CASTLEMAN'S DISEASE AND ADULT-ONSET STILL'S DISEASE
   AbstractLetarouilly Jean-Guillaume (France)THU0546IMPACT OF BONE LOCALISATION ON THE PROGNOSTIC OF LANGERHANS CELL HISTIOCYTOSIS: A MONOCENTRIC RETROSPECTIVE STUDY
   AbstractKozlova Anna (Russian Federation)THU0547CHARACTERIZATION OF A GROUP OF 12 PATIENTS WITH MEVALONATE KINASE DEFICIENCY: SYMPTOMS AND TREATMENT WITH IL-1 INHIBITORS
  
Poster Tour: Economical impact of biosimilars and dicussing risks with patients
   Chairvan der Heijde Désirée (Netherlands)  
   ChairPutrik Polina (Netherlands)  
   AbstractGlintborg Bente (Denmark)THU0648USE OF OUTPATIENT RHEUMATOLOGIC HEALTH CARE SERVICES BEFORE AND AFTER SWITCH FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB
   AbstractGrøn Kathrine (Denmark)THU0649MANDATORY CHOICE OF FIRST BDMARD IN DENMARK - AN OPPORTUNITY TO STUDY REAL-LIFE EFFECTIVENESS? RESULTS FROM THE DANBIO REGISTRY
   AbstractZavada Jakub (Czech Republic)THU0650THE EFFECT OF ANTI-TNF THERAPY ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS OVER ONE YEAR – REAL LIFE DATA FROM THE CZECH BIOLOGICS REGISTRY ATTRA
   AbstractGonzalez-Alvaro Isidoro (Spain)THU0651SHOULD WE REDUCE THE DOSE OF BIOLOGICAL THERAPY TO ALL PATIENTS WITH INFLAMMATORY ARTHRITIS ACHIEVING SUSTAINED THERAPEUTIC GOAL?
   AbstractDi Giuseppe Daniela (Sweden)THU0652ASSESSMENT OF BIOSIMILARS USING REAL WORLD DATA: THE COMPLEXITY OF CHOOSING A COMPARATOR AND UNDERSTANDING UPTAKE
   AbstractHarrison Mark (Canada)THU0653PREVENTING RHEUMATOID ARTHRITIS: A GENERAL POPULATION PILOT STUDY ON PERSPECTIVES OF THE RISK OF DEVELOPING THE DISEASE AND POTENTIAL PREVENTATIVE INTERVENTIONS
   AbstractCozmuta Raluca (United States)THU0654THE INFLUENCE OF RISK PRESENTATION FORMAT ON WILLINGNESS TO START A MEDICATION
   AbstractCozmuta Raluca (United States)THU0655DO VISUAL DECISION AIDS HELP PATIENTS CORRECTLY DIFFERENTIATE BETWEEN A 2% AND A 0.2% RISK?
   AbstractThakur Kunal (Switzerland)THU0656ETANERCEPT BIOSIMILAR USAGE AND ASSOCIATED COST SAVINGS IN GERMANY.
   AbstractThurah Annette (Denmark)THU0657A TELE-HEALTH FOLLOW-UP STRATEGY FOR TIGHT CONTROL OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS: RESULTS OF THE NON-INFERIORITY RANDOMISED CONTROLLED TRAIL (THE TERA STUDY)
  
Poster Tour: Genetic basis, epigenetics and genomics in disease
   ChairNeumann Elena (Germany)  
   ChairChang Hyun-Dong (Germany)  
   AbstractNair Nisha (United Kingdom)THU0001DIFFERENTIAL METHYLATION AS A POTENTIAL BIOMARKER OF METHOTREXATE RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractOliver James (United Kingdom)THU0002ETANERCEPT AND ADALIMUMAB EXHIBIT HETEROGENEOUS EARLY SIGNATURES OF RESPONSE IN RHEUMATOID ARTHRITIS THERAPY
   AbstractThalayasingam Nishanthi (United Kingdom)THU0003CD4+ AND B LYMPHOCYTE EXPRESSION QUANTITATIVE TRAITS AT RHEUMATOID ARTHRITIS RISK LOCI IN UNTREATED EARLY ARTHRITIS: IMPLICATIONS FOR CAUSAL GENE IDENTIFICATION?
   AbstractBowes John (United Kingdom)THU0004CROSS PHENOTYPE ASSOCIATION MAPPING OF THE MHC IDENTIFIES GENETIC VARIANTS THAT DIFFERENTIATE PSORIATIC ARTHRITIS FROM PSORIASIS
   AbstractLondono John (Colombia)THU0005ERAP POLYMORPHISMS AND ITS ASSOCIATION WITH HLA-B15 AND HLA-B27 POSITIVE SPONDYLARTHRITIS PATIENTS
   AbstractTerao Chikashi (Japan)THU0006TRANS-ETHNIC META-ANALYSIS OF GENOME-WIDE ASSOCIATION STUDIES IDENTIFIES GSDMA AND PRDM1 AS SUSCEPTIBILITY GENES TO SYSTEMIC SCLEROSIS.
   AbstractMccaffrey Timothy (United States)THU0007DEEP SEQUENCING TRANSCRIPTOME ANALYSIS OF THE EFFECT OF TRAUMEEL VERSUS DICLOFENAC THERAPEUTIC ACTION IN WOUND HEALING
   AbstractKurreeman Fina (Netherlands)THU0008MAST CELLS SHOW A REPROGRAMMED TRANSCRIPTIONAL SIGNATURE FOLLOWING REPEATED IGG STIMULATIONS.
   AbstractFernández-Moreno Mercedes (Spain)THU0009IN VITRO STUDIES USING CYBRIDS, SHOW THAT MTDNA FROM HEALTHY AND OA PATIENTS HAVE DIFFERENT MITOCHONDRIAL ACTIVITY
   AbstractHuang Yukai (China)THU0010ALTERED MIRNAS PROFILES IN PLASMA-DERIVED EXOSOME OF PATIENTS WITH ANKYLOSING SPONDYLITIS BY SMALL RNA-SEQ ANALYSIS
  
Poster Tour: Inflammatory mediators in Rheumatic disease
   ChairHerrmann Martin (Germany)  
   ChairKoenders Marije (Netherlands)  
   AbstractDavies Ruth (United Kingdom)THU0025IL-6 TRANS-SIGNALING CAUSES ACCELERATED ATHEROSCLEROSIS IN DISEASE PRONE ANIMALS
   AbstractNevin Katherine (United Kingdom)THU0026OSM IS MORE EFFECTIVE THAN IL-6 AT INDUCING ENDOMT OF HUMAN DERMAL MICROVASCULAR CELLS
   AbstractLennerová Tereza (Czech Republic)THU0027CLUSTERIN IS ELEVATED IN SERUM AND MUSCLE TISSUE IN IDIOPATHIC INFLAMMATORY MYOPATHIES AND IS ASSOCIATED WITH DISEASE ACTIVITY
   AbstractVlachogiannis Nikolaos (Greece)THU0028TYPE I INTERFERON SIGNATURE IN THE PERIPHERAL BLOOD AND CXCL4 PLASMA LEVELS IN PATIENTS WITH SYSTEMIC SCLEROSIS
   AbstractScanu Anna (Italy)THU0029BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN DOWNREGULATES THE INFLAMMATORY RESPONSE TO PATHOGENIC CRYSTALS IN VITRO AND IN VIVO
   AbstractYokoyama Yuichi (Japan)THU0030IL-2IC SUPPRESSES CIA IN MICE BY THE TH1/TH17 IMMUNE RESPONSES DUE TO ENHANCEMENT OF BOTH TREG NUMBERS AND TREG FUNCTIONS.
   AbstractHoshino-Negishi Kana (Japan)THU0031THERAPEUTIC TREATMENT OF ANTI-FRACTALKINE MONOCLONAL ANTIBODY INHIBITS JOINT DESTRUCTION IN COLLAGEN-INDUCED ARTHRITIS MODEL
   AbstractGeven Edwin (Netherlands)THU0032THE ROLE OF S100A9 IN PAIN RESPONSE DURING EXPERIMENTALLY INDUCED ACUTE SYNOVITIS.
   Abstractvan Dalen Stephanie (Netherlands)THU0033LOCAL INJECTION OF ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS IN EXPERIMENTAL INFLAMMATORY OA RESULTS IN INTERLEUKIN-1Β-MEDIATED ATTRACTION OF PMNS AND REDUCED S100A8/A9 RELEASE
   AbstractRenaudin Félix (France)THU0034THE INFLAMMATORY POTENTIAL OF CALCIUM PYROPHOSPHATE CRYSTALS DEPENDS ON THEIR CAPACITY TO INDUCE NF-ΚB AND MAPK PATHWAYS.
  
Poster Tour: MTX, GCs and JAK inhibitors in RA
   ChairTakeuchi Tsutomu (Japan)  
   ChairDe Cock Diederik (United Kingdom)  
   AbstractHope Holly (United Kingdom)THU0168PATIENTS’ POSITIVE BELIEFS AND CERTAINTY PREDICT METHOTREXATE ADHERENCE IN A RHEUMATOID ARTHRITIS COHORT: THE RAMS STUDY
   AbstractBeauvais Catherine (France)THU0169ONE-THIRD OF PATIENTS WITH RHEUMATOID ARTHRITIS ELIGIBLE FOR A FIRST BIOLOGIC ARE NOT ADHERENT TO METHOTREXATE: RESULTS OF FORGET, A CROSS-SECTIONAL SURVEY OF 244 PATIENTS.
   AbstractTsutsumino Michi (Japan)THU0170OUTCOMES OF THE RAPID DOSE ESCALATION OF METHOTREXATE IN JAPANESE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS; RESULTS FROM A RANDOMIZED CONTROLLED TRIAL
   AbstractAvdeeva Anastasia (Russian Federation)THU0171INCREASED FUNCTIONAL ACTIVITY OF FOXP3+REGULATORY T CELLS IN THE PERIPHERAL BLOOD OF DMARDS-NAÏVE METHOTREXATE-TREATED PATIENTS WITH EARLY RA USING
   AbstractSantos-Moreno Pedro (Colombia)THU0172IMPROVEMENT OF DISEASE ACTIVITY IN A 5-YEAR COHORT OF RHEUMATOID ARTHRITIS PATIENTS TREATED UNDER TREAT TO TARGET RECOMMENDATIONS AND A MULTISPECIALITY CARE MODEL RECEIVING CONVENTIONAL DMARD THERAPY
   AbstractAlten Rieke (Germany)THU0173LONG TERM SAFETY AND EFFICACY OF FILGOTINIB IN A PHASE 2B OPEN LABEL EXTENSION STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS UP TO 144 WEEKS
   AbstractFinckh Axel (Switzerland)THU0174DRUG RETENTION OF TOFACITINIB VERSUS BIOLOGIC ANTIRHEUMATIC AGENTS IN RHEUMATOID ARTHRITIS: OBSERVATIONAL DATA FROM THE SWISS SCQM REGISTRY
   AbstractConaghan Philip G (United Kingdom)THU0175INFLAMMATION DETECTED WITH MODERN SENSITIVE MRI ANALYSIS DEMONSTRATES THAT THERAPEUTIC RESPONSE AS EARLY AS ONE MONTH PREDICTS 12-MONTH RADIOGRAPHIC PROGRESSION: DATA FROM A STUDY USING TOFACITINIB AND METHOTREXATE IN METHOTREXATE-NAÏVE PATIENTS WITH EARLY RA
   AbstractLi Zhaohua (China)THU0176EFFICIENCY AND SAFETY OF RAPAMYCIN COMBINED WITH LOW-DOSE IL-2 TREATMENT COMPARED WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS
  
Poster Tour: Novelty in the clinical approach to SLE, Sjögren's and APS I
   ChairTincani Angela (Italy)  
   ChairLazzaroni Maria Grazia (Italy)  
   AbstractGergianaki Irini (Greece)THU0246THE IMPACT OF CLASSIFYING SLE PATIENTS WITH THE SLICC-2012 VERSUS THE ACR-1997 CLASSIFICATION CRITERIA ON EARLY DIAGNOSIS, SEVERITY, AND DAMAGE: DATA FROM THE COMMUNITY-BASED CRETAN LUPUS REGISTRY
   AbstractLondono Jimenez Alejandra (United States)THU0247THE PRESENCE OF ANTI-RO AND ANTI-LA ANTIBODIES IS ASSOCIATED WITH TUBULOINTERSTITIAL DAMAGE IN LUPUS NEPHRITIS
   AbstractTiosano Shmuel (Israel)THU0248THE ASSOCIATION BETWEEN SYSTEMIC LUPUS ERYTHEMATOSUS TO BIPOLAR DISORDER – A REAL-LIFE STUDY
   AbstractGuillen-Astete Carlos (Spain)THU0249SUBCLINICAL HAND ARTHROPATHY IN PATIENTS WITH SYSTEMIC LUPUS ERITHEMATOSUS
   AbstractZhan Zhongping (China)THU0250EFFECT OF FETAL UMBILICAL ARTERY DOPPLER ON PREDICTION OF ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractNakano Masahiro (Japan)THU0251DIFFERENT RESPONSES TO INDUCTION THERAPY IN TWO ONSET CATEGORIES OF LUPUS NEPHRITIS
   AbstractMelsens Karin (Belgium)THU0252NAILFOLD CAPILLAROSCOPY IN SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL
   AbstractLevy Roger (Brazil)THU0253TRIPLE POSITIVITY TO ANTIPHOSPHOLIPID ANTIBODIES IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: INCREASED RISK OF ARTERIAL THROMBOSES AND ABORTIONS
   AbstractGergianaki Irini (Greece)THU0254COMPARISON OF URBAN VERSUS RURAL ENVIRONMENT ASSOCIATED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RISK AND CLINICAL FEATURES
   AbstractPetri Michelle (United States)THU0255COMPARISON OF REMISSION AND LUPUS LOW ACTIVITY STATE AS PREDICTORS OF ORGAN DAMAGE
   AbstractTejera Segura Beatriz (Spain)THU0256DEVELOPMENT AND VALIDATION OF A SCORE TO PREDICT THE RISK OF SEVERE INFECTION IN SLE
   AbstractChoe Jung-Yoon (Korea, Republic Of)THU0257ENHANCED ACTIVATION OF NLRP3 INFLAMMASOMES IN PATIENTS WITH SJÖGREN'S SYNDROME
  
Poster Tour: Outcomes across all rheumatology
   ChairLandewé Robert B.M. (Netherlands)  
   ChairMahler Elien (Netherlands)  
   AbstractBartlett Susan (Canada)THU0695THE RA FLARE QUESTIONNAIRE (RA-FQ) IS RESPONSIVE TO CHANGE IN RA SYMPTOMS AND IMPACTS IN CLINICAL AND OBSERVATIONAL TRIALS
   AbstractCeccarelli Fulvia (Italy)THU0696ANTI-CARBAMYLATED PROTEINS ANTIBODIES IN SLE PATIENTS WITH JOINT INVOLVEMENT: A POSSIBLE NEW BIOMARKER FOR EROSIVE DAMAGE
   AbstractMaksymowych Walter (Canada)THU0697FEASIBILITY AND RELIABILITY OF THE SPARCC SACROILIAC JOINT STRUCTURAL SCORE FOR CHILDREN WITH SPONDYLOARTHRITIS
   AbstractDonaldson Mira (Canada)THU0698MEASUREMENT PROPERTIES OF PRESENTEEISM MEASURES WITH DUAL ANSWER KEYS IN INFLAMMATORY ARTHRITIS
   AbstractPan Feng (Australia)THU0699CHARACTERIZING AND VALIDATING THE PHENOTYPE OF KNEE PAIN: A LATENT CLASS ANALYSIS
   AbstractGoll Guro (Norway)THU0700IMMUNOGENICITY IN PATIENTS SWITCHING FROM STABLE ORIGINATOR INFLIXIMAB TREATMENT TO CT-P13: ANALYSES ACROSS SIX DISEASES FROM THE 52-WEEK RANDOMIZED NOR-SWITCH STUDY
   AbstractKerschbaumer Andreas (Austria)THU0701THE EFFECTS OF STRUCTURAL DAMAGE ON FUNCTIONAL DISABILITY IN PSORIATIC ARTHRITIS.
   AbstractBoeters Debbie (Netherlands)THU0702ARE MRI-DETECTED EROSIONS SPECIFIC FOR RA? A LARGE EXPLORATIVE CROSS-SECTIONAL STUDY
   AbstractMahmood Sehrash (Netherlands)THU0703SYSTEMATIC REVIEW OF RHEUMATOID ARTHRITIS CLINICAL STUDIES: SUBOPTIMAL STATISTICAL ANALYSIS OF RADIOLOGICAL DATA
   AbstractBoer Aleid (Netherlands)THU0704EVALUATION OF THE ACCURACY OF HAND AND FOOT MRI IN THE EARLY IDENTIFICATION OF RA: USING THE PREVALENCE OF LOW-GRADED INFLAMMATION IN THE SYMPTOM-FREE POPULATION AS REFERENCE REDUCES FALSE-POSITIVE MRI RESULTS
  
Poster Tour: Paediatric Rheumatology
   ChairAvcin Tadej (Slovenia)  
   ChairConsolaro Alessandro (Italy)  
   AbstractŚwidrowska-Jaros Joanna (Poland)THU0486ANGIOPOETIN-2 AS A NEW VALUABLE MARKER OF DISEASE ACTIVITY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS
   AbstractHorneff Gerd (Germany)THU0487REAL-LIFE TREATMENT WITH CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – FIRST EXPERIENCE FROM THE BIKER REGISTRY
   AbstractShoop-Worrall Stephanie (United Kingdom)THU0488THE IMPACT OF OLIGOARTICULAR AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS OVER THE FIRST FIVE YEARS FOLLOWING DIAGNOSIS
   AbstractDiaz-Cordoves Rego Gisela (Spain)THU0489ADIPOSITY AND INFLAMMATORY ACTIVITY IN JUVENILE IDIOPATHIC ARTHRITIS COULD THEY BE RELATED?
   AbstractCosta Reis Patricia (Portugal)THU0490MULTICENTRE STUDY OF LUPUS NEPHRITIS URINARY BIOMARKERS IN ADULT AND PAEDIATRIC PATIENTS
   AbstractGarrote Corral Sandra (Spain)THU0491COMPARISON OF CLINICAL AND SEROLOGICAL FEATURES OF JUVENILE AND ADULT-ONSET NEUROPSYCHIATRIC LUPUS IN SPANISH PATIENTS
   AbstractSato Stoshi (Japan)THU0492MACROPHAGE ACTIVATION SYNDROME AS THE INITIAL MANIFESTATION OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractSharma Avinash (India)THU0493STUDY OF LONG-TERM OUTCOME OF CHILDREN WITH JUVENILE DERMATOMYOSITIS FROM A SINGLE-CENTRE IN NORTH INDIA
   AbstractShi Lianjie (China)THU0494CLINICAL FEATURES OF CHILDREN WITH KAWASAKI DISEASE IN DIFFERENT AGE GROUPS IN SOUTHWEST CHINA
   AbstractBrogan Paul (United Kingdom)THU0495EFFECTIVENESS OF CHILDHOOD VACCINATIONS IN CAPS PATIENTS TREATED WITH CANAKINUMAB: RESULTS FROM AN OPEN-LABEL PHASE 3 EXTENSION STUDY
  
Poster Tour: Pathomechanism in SLE, SS, APS
   ChairDörner Thomas (Germany)  
   ChairAringer Martin (Germany)  
   AbstractSolé-Marcé Cristina (Spain)THU0216URINARY NEUROPILIN-1: A NEW BIOMARKER APPROACH IN THE PROGNOSIS OF LUPUS NEPHRITIS.
   AbstractUlff-Møller Constance (Denmark)THU0217DNA METHYLATION ANALYSIS IN MULTIPLE CELLULAR COMPARTMENTS DEMONSTRATES A UNIVERSAL DNA METHYLATION INTERFERON SIGNATURE IN MULTIPLE CELLULAR COMPARTMENTS AND PREDOMINANT B-CELL HYPERMETHYLATION IN TWINS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractPerez-Sanchez Carlos (Spain)THU0218CIRCULATING MICRORNAS AS BIOMARKERS FOR DIAGNOSIS AND TYPIFYING THE ATHEROTHROMBOTIC STATUS IN ANTIPHOSPHOLIPID SYNDROME
   AbstractGuleria Sandesh (India)THU0219AUTOANTIBODY PROFILE OF CHILDREN WITH JUVENILE DERMATOMYOSITIS FROM A TERTIARY CARE CENTRE IN NORTH INDIA
   AbstractPayne Andrew (United Kingdom)THU0220SELETALISIB, A NOVEL SELECTIVE PI3KΔ INHIBITOR WITH THERAPEUTIC POTENTIAL IN INFLAMMATION AND AUTOIMMUNITY
   AbstractKapsogeorgou Efstathia (Greece)THU0221DOWNREGULATED EXPRESSION OF MIR200B-5P IN MINOR SALIVARY GLANDS (MSG) OF PATIENTS WITH SJÖGREN’S SYNDROME (SS) ASSOCIATED LYMPHOMA
   AbstractClarke Stephen (United States)THU0222PROPHYLACTIC AND THERAPEUTIC ADMINISTRATION OF AN ANTI-CD40 ANTAGONIST ANTIBODY BLOCKS AND REVERSES PROTEINURIA AND NEPHRITIS IN NZB/W-F1 MICE.
   AbstractBlokland Sofie (Netherlands)THU0223ELEVATED MTORC1 SIGNATURE IN B CELLS FROM SJÖGREN’S SYNDROME PATIENTS CORRELATES WITH B CELL HYPERACTIVITY THAT IS ABROGATED BY MTOR INHIBITION: A NOVEL THERAPEUTIC STRATEGY TO HALT B CELL HYPERACTIVITY IN PSS?
   AbstractSacre Sandra (United Kingdom)THU0224ASSOCIATION OF IRAK-M WITH NEUROPSYCHIATRIC SYMPTOMS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS.
   AbstractFogel Olivier (France)THU0225ROLE OF THE IL-12/IL-35 BALANCE IN SJÖGREN’S SYNDROME
  
Poster Tour: Progress in managment of spondyloarthritis
   ChairElewaut Dirk (Belgium)  
   ChairBarcelos Anabela (Portugal)  
   AbstractKristianslund Eirik K (Norway)THU0345REAL-LIFE EFFECTIVENESS OF TNF INHIBITORS IN AXIAL SPONDYLARTHRITIS: ARE CHANGING NATIONAL POLICIES ON CHOICE OF TNF INHIBITOR REFLECTED IN RESPONSE TO TREATMENT?
   AbstractMoltó Anna (France)THU0346CONCOMITANT FIBROMYALGIA IN AXIAL SPONDYLOARTHRITIS HAS A NEGATIVE IMPACT ON TNF ALPHA BLOCKERS TREATMENT EFFECT IN REAL LIFE.
   AbstractMicheroli Raphael (Switzerland)THU0347IMPACT OF OBESITY ON THE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS IN AXIAL SPONDYLOARTHRITIS
   AbstractDeodhar Atul (United States)THU0348SAFETY AND EFFICACY OF INTRAVENOUS GOLIMUMAB IN ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS THROUGH WEEK 28
   AbstractMulleman Denis (France)THU0349METHOTREXATE REDUCES ADALIMUMAB IMMUNOGENICITY IN PATIENTS WITH SPONDYLOARTHRITIS: A RANDOMIZED CLINICAL TRIAL
   AbstractRivière Elodie (France)THU0350EFFECT OF NSAID CONSUMPTION ON CARDIOVASCULAR EVENTS IN SPONDYLOARTHRITIS
   AbstractLian Fan (China)THU0351ADALIMUMAB TAPERING WITH COMBINED METHOTREXATE CAN BE EFFECTIVE AS MAINTENANCE THERAPY IN SPA-RELATED UVEITIS
   AbstractMaksymowych Walter (Canada)THU0352TOFACITINIB TREATMENT IS ASSOCIATED WITH ATTAINMENT OF THE MINIMALLY IMPORTANT REDUCTION IN AXIAL MRI INFLAMMATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS
   AbstractMaksymowych Walter P (Canada)THU0353CHANGE IN MRI STRUCTURAL LESIONS IN THE SACROILIAC JOINT AFTER TWO YEARS OF ETANERCEPT THERAPY IN COMPARISON TO A CONTEMPORARY CONTROL COHORT IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
   AbstractGoll Guro (Norway)THU0354DISEASE WORSENING AND SAFETY IN PATIENTS SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN THE RANDOMIZED NOR-SWITCH-STUDY: EXPLORATIVE ANALYSIS IN SPA PATIENTS
  
Poster Tour: RA disease course and prognosis
   ChairPetersson Ingemar (Sweden)  
   ChairKristensen Lars Erik (Denmark)  
   AbstractTen Brinck Robin (Netherlands)THU0068THE RISK OF INDIVIDUAL AUTOANTIBODIES, AUTOANTIBODY COMBINATIONS AND AUTOANTIBODY LEVELS FOR ARTHRITIS DEVELOPMENT IN CLINICALLY SUSPECT ARTHRALGIA
   AbstractTorikai Eiji (Japan)THU0069HOW MANY RHEUMATOID ARTHRITIS PATIENTS IN REMISSION EXPERIENCE PAIN? WHAT TYPES AND WITH WHAT FREQUENCY WERE PAINKILLERS RECEIVED? IS REACHING REMISSION A REALISTIC GOAL?
   AbstractNorvang Vibeke (Norway)THU0070TREAT-TO-TARGET IN RA: WHAT LEVEL OF TREATMENT RESPONSE IS NECESSARY BY 3 MONTHS IN ORDER TO ACHIEVE THE TREATMENT TARGET BY 6 MONTHS? RESULTS FROM A REAL LIFE STUDY.
   AbstractSteunebrink Laura (Netherlands)THU0071RADIOGRAPHIC PROGRESSION IN EARLY RHEUMATOID ARTHRITIS PATIENTS FOLLOWING INITIAL COMBINATION VERSUS STEP-UP TREAT TO TARGET THERAPY IN DAILY CLINICAL PRACTICE: RESULTS FROM THE DREAM REGISTRY
   AbstractDreyer Lene (Denmark)THU0072RISK OF REVISION, PROSTHETIC JOINT INFECTION AND DEATH FOLLOWING TOTAL HIP OR KNEE ARTHROPLASTY IN PATIENTS WITH RHEUMATOID ARTHRITIS – A NATIONWIDE COHORT STUDY FROM DENMARK
   AbstractGoh Ee Teng (United Kingdom)THU0073FACTORS ASSOCIATED WITH TREATMENT ADHERENCE IN RHEUMATOID ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW
   AbstractAjeganova Sofia (Netherlands)THU0074BODY MASS INDEX IN EARLY RHEUMATOID ARTHRITIS IN UNDERWEIGHT PATIENTS IS ASSOCIATED WITH MORE PROGRESSION OF EROSIONS OVER 15 YEARS AND IN OBESE PATIENTS WITH LESS PROGRESSION OF JOINT SPACE NARROWING
   AbstractTwigg Sarah (United Kingdom)THU0075THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND DISABILITY IS MEDIATED BY PAIN AND FATIGUE IN EARLY RHEUMATOID ARTHRITIS.
   AbstractYoungstein Taryn (United Kingdom)THU0076DISEASE-MODIFYING TREATMENT REGIMENS HAVE BEEN INSUFFICIENT TO REDUCE THE INCIDENCE OF SYSTEMIC AA AMYLOIDOSIS ASSOCIATED WITH RHEUMATOID ARTHRITIS IN CONTRAST TO A SIGNIFICANT REDUCTION IN THOSE WITH JUVENILE IDIOPATHIC ARTHRITIS
   AbstractManivel Vivek Anand (Sweden)THU0077ANTI-COLLAGEN TYPE II ANTIBODIES ARE ASSOCIATED WITH AN ACUTE ONSET RHEUMATOID ARTHRITIS PHENOTYPE AND PROGNOSTICATE LOWER DEGREE OF INFLAMMATION
  
Poster Tour: Rheumatology training and disease burden
   ChairIagnocco Annamaria (Italy)  
   ChairDobrota Rucsandra (Switzerland)  
   AbstractCikes Nada (Croatia)THU0596RHEUMATOLOGY SPECIALTY TRAINING IN EUROPEAN UNION COUNTRIES
   AbstractEl Miedany Yasser (United Kingdom)THU0597FLIPPED LEARNING: CAN RHEUMATOLOGY LEAD THE SHIFT IN MEDICAL EDUCATION?
   AbstractKwok Fiona Yi Haan (United Kingdom)THU0598CAN YOU HEAR THE JOINTS CRYING? MUSCULOSKELETAL EXAMINATION IN JUNIOR DOCTORS’ MEDICAL ADMISSION CLERKINGS
   AbstractCabrera Natalia (France)THU0599BENEFIT RISK RATIO FOR BIOLOGICAL AGENTS IN JUVENILE IDIOPATHIC ARTHRITIS, A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
   AbstractDeQuattro Kimberly (United States)THU0600CUMULATIVE ADVERSE CHILDHOOD EXPERIENCES ARE ASSOCIATED WITH POOR OUTCOMES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractKjeldgaard Anette (Denmark)THU0601CARDIOVASCULAR SCREENING AMONG PATIENTS WITH INFLAMMATORY ARTHRITIS: TO WHAT EXTENT DO PATIENTS FOLLOW RECOMMENDATIONS?
   AbstractVerstappen S (United Kingdom)THU0602WORKER PRODUCTIVITY LOSS REMAINS A MAJOR ISSUE FOR PATIENTS WITH INFLAMMATORY ARTHRITIS AND OSTEOARTHRITIS: RESULTS FROM THE INTERNATIONAL EULAR-PRO WORKER PRODUCTIVITY STUDY
   AbstractNielen Johannes (Netherlands)THU0603DISEASE BURDEN OF KNEE OSTEOARTHRITIS PATIENTS UNDERGOING JOINT REPLACEMENT COMPARED TO MATCHED CONTROLS: A POPULATION-BASED ANALYSIS OF A DUTCH MEDICAL CLAIMS DATABASE.
   AbstractMahmood Sehrash (Netherlands)THU0604THE ASSESSMENT OF THE DUTCH QUALITY REGISTRY RHEUMATOID ARTHRITIS QUALITY INDICATORS IN THREE PILOT HOSPITALS
   AbstractBelhassen Manon (France)THU0605IMPACT OF NON-PERSISTENCE TO SUBCUTANEOUS TNF-ALPHA INHIBITORS ON MEDICAL RESOURCE UTILIZATION AND COSTS
  
Poster Tour: Vasculities Clinical Aspects I
   ChairCalabrese Cassandra (United States)  
   ChairHernandez-Rodriguez Jose (Spain)  
   AbstractKikuchi Hirotoshi (Japan)THU0294DIFFERENTIAL PATTERNS OF ATROPHY IN HIPPOCAMPUS AND BRAINSTEM BETWEEN CHRONIC PROGRESSIVE NEURO-BEHCET'S DISEASE AND ALZHEIMER’S DISEASE
   AbstractAlibaz-Oner Fatma (Turkey)THU0295CLINICAL FEATURES OF TAKAYASU'S ARTERITIS FROM AN INCEPTION COHORT: EARLY DISEASE IS CHARACTERIZED BY ‘SYSTEMIC INFLAMMATION’
   AbstractMonti Sara (Italy)THU0296THE ROLE OF ULTRASOUND IN THE MANAGEMENT OF GIANT CELL ARTERITIS (GCA) IN ROUTINE CLINICAL PRACTICE
   AbstractMonti Sara (Italy)THU0297A NOVEL ULTRASOUND SCORING SYSTEM FOR GIANT CELL ARTERITIS
   AbstractA Goel Ruchika (India)THU0298LONG TERM OUTCOME OF PATIENTS WITH TAKAYASU ARTERITIS- A SINGLE CENTRE STUDY
   AbstractTombetti Enrico (Italy)THU0299UNDERSTANDING THE HETEROGENEITY OF LARGE-VESSEL VASCULITIDES
   AbstractSolans-Laqué Roser (Spain)THU0300CENTRAL NERVOUS SYSTEM INVOLVEMENT IN GRANULOMATOSIS WITH POLYANGIITIS (WEGENER) IN A LARGE SERIES OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIDES (AAV).REVAS STUDY-GEAS-SEMI
   AbstractNiles John (United States)THU0301SAFETY FOLLOWING INITIATION OF RITUXIMAB IN GRANULOMATOSIS WITH POLYANGIITIS (GPA) OR MICROSCOPIC POLYANGIITIS (MPA): INTERIM ANALYSIS OF THE RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS REGISTRY (RAVER)
   AbstractPonte Cristina (Portugal)THU0302HISTOLOGY FINDINGS IN GIANT CELL ARTERITIS (GCA) AND THEIR RELATIONSHIP WITH THE ULTRASOUND RESULTS: ANALYSIS OF DATA FROM THE TABUL STUDY (TEMPORAL ARTERY BIOPSY VS ULTRASOUND IN DIAGNOSIS OF GIANT CELL ARTERITIS)
   AbstractFukui Shoichi (Japan)THU0303CLINICAL FEATURES AND PROGNOSIS OF ANCA-ASSOCIATED VASCULITIS WITH RENAL INVOLVEMENT AT DIAGNOSIS

Thursday 15.06.2017 12:00 - 13:30


 
Poster Tour - Poster Area
  
PARE Poster Tour I
   Chairde Wit Maarten (Netherlands)  
   ChairMazuras Kristijonas (Lithuania)  
   AbstractStones Simon (Switzerland)PARE0001GROWING STRONGER TOGETHER: IMPLEMENTING EULAR YOUNG PARE’S STRATEGY
   AbstractHigginbottom Adele (United Kingdom)PARE0002CELEBRATING TEN YEARS OF SUCCESSFUL PATIENT INVOLVEMENT IN RESEARCH OF INFLAMMATORY CONDITIONS
   AbstractJurisic Skevin Aleksandra (Serbia)PARE0003ASSESSMENT OF PAIN AND IMPORTANCE OF EXERCISE IN HIP OSTEOARTHRITIS
   AbstractTekkatte Roopa (United Kingdom)PARE0004PATIENT REPORTED LONG TERM EFFECTS OF SIX WEEK PROGRESSIVE RESISTANCE TRAINING PROGRAMME FOR RHEUMATOID ARTHRITIS
   AbstractEspanha Margarida (Portugal)PARE0005EDUCATIONAL PROGRAM FOR OLDER ADULTS WITH KNEE OSTEOARTHRITIS
   AbstractNeijland Yvette (Netherlands)PARE0006PATIENT INVOLVEMENT IN BASIC RESEARCH: A PILOT STUDY.
   AbstractGarrido-Cumbrera Marco (Spain)PARE0007HOPES AND FEARS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN SPAIN. THE VALUE OF PATIENT OPINION: RESULTS FROM THE SPANISH ATLAS
   AbstractViora Ugo (Italy)PARE0008TRANSITION: PARTICULARLY DIFFICULT TIME FOR YOUNG PEOPLE WITH AR
   AbstractVisser-Noordegraaf Marianne (Netherlands)PARE0009A TAXONOMY OF DISEASE EXPERIENCES OF WOMEN WITH SJÖGREN’S SYNDROME FROM THE PERSPECTIVE OF THE PATIENT
   Abstractde Souza Savia (United Kingdom)PARE0010SIGNIFICANCE OF FOOT PROBLEMS FOR PATIENTS WITH RHEUMATOID ARTHRITIS: A PATIENT-LED QUALITATIVE STUDY
   AbstractZiegler Connie (Denmark)PARE0011ASK THE USERS - ESTABLISHING A DIGITAL USER PANEL

Thursday 15.06.2017 13:30 - 15:00


 
WIN & HOT Session - Hall 6
  
WIN & HOT Session
   ChairGonzalez-Gay Miguel Angel (Spain)  
   ChairPonte Cristina (Portugal)  
   SpeakerKhamashta Munther (United Kingdom) WIN Session: Antiphospholipid Syndrome
   SpeakerLuqmani Raashid (United Kingdom)SP0053HOT Session: Vasculitis treatment

 
Clinical Science Session - Hall 8
  
Treat-to-target in axSpA: reality or utopy?
   ChairBoonen Annelies (Netherlands)  
   ChairGensler Lianne (United States)  
   SpeakerBraun Jürgen (Germany)SP0054The concept of treat-to-target
   SpeakerDougados Maxime (France)SP0055What are the challenges for applying T2T in axSpA?
   Speakervan der Heijde Désirée (Netherlands)SP0056Treat-to-target recommendations in axSpA - update of the recommendations T2T in axSpA
   AbstractMoltó Anna (France)OP0188DEFINING CLINICALLY IMPORTANT WORSENING BASED ON ASDAS-CRP FOR AXIAL SPONDYLOARTHRITIS: A DATA-BASED CONSENSUS BY THE ASSESSMENT IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS)
   AbstractCiurea Adrian (Switzerland)OP0189TUMOR NECROSIS FACTOR INHIBITOR TREATMENT REDUCES SPINAL RADIOGRAPHIC PROGRESSION IN ANKYLOSING SPONDYLITIS BY DECREASING DISEASE ACTIVITY: A LONGITUDINAL ANALYSIS IN A LARGE PROSPECTIVE COHORT

 
Challenges in Clinical Practice Session - Hall 7A
  
What choice after failure of the first anti-TNF
   ChairSmolen Josef S. (Austria)  
   ChairGabay Cem (Switzerland)  
   PresenterSharma Ena (United States) Case 1 presentation: Primary anti-TNF failure
   DiscussantFleischmann Roy (United States) Case 1 discussion: A second anti-TNF or another mode of action is the same
   PresenterFelten Renaud (France) Case 2 presentation: Secondary anti-TNF failure
   DiscussantGottenberg Jacques-Eric (France) Case 2 discussion: Another Mode of Action is better than a second anti-TNF

 
From Bench to Bedside - Hall 7B
  
Calcium crystal deposition in rheumatic diseases
   ChairLioté Frederic (France)  
   ChairSo Alexander (Switzerland)  
   SpeakerEa Hang-Korng (France) Mechanisms of CPP and HA crystal deposition in man
   SpeakerBertrand Jessica (Germany)SP0057Calcium crystals and their link to osteoarthritis
   SpeakerOmoumi Patrick (Switzerland)SP0058Review of the different imaging modalities to detect calcium deposition diseases
   AbstractDarrieutort-Laffite Christelle (France)OP0190HISTOLOGICAL CHARACTERIZATION OF ROTATOR CUFF CALCIFIC TENDINOPATHY
   AbstractCombier Alice (France)OP0191COMPARISON OF ULTRASONOGRAPHY AND RADIOGRAPHY OF THE WRIST FOR DIAGNOSIS OF CALCIUM PYROPHOSPHATE DEPOSITION.

 
Clinical Science Session - N103 / N104
  
Fifty shades of remission in RA
   ChairKay Jonathan (United States)  
   ChairTas Sander W. (Netherlands)  
   SpeakerBoers Maarten (Netherlands)SP0059Remission: More than clinical
   Speakerd'Agostino Maria-Antonietta (France) Imaging is required for remission: PRO
   SpeakerHaavardsholm Espen A. (Norway) Imaging is required for remission: CON
   SpeakerAletaha Daniel (Austria) Biomarkers are required for remission: CON
   Speakervan Vollenhoven Ronald (Netherlands)SP0060Biomarkers are required for remission: PRO
   AbstractSepriano Alexandre (Portugal)OP0192ADDING ULTRASOUND TO THE TREAT-TO-TARGET STRATEGY SHOWS NO BENEFIT IN ACHIEVEMENT OF REMISSION: RESULTS FROM THE BIODAM COHORT

 
Basic and Translational Science Session - South Auditorium
  
Innate immunity
   ChairVoll Reinhard E. (Germany)  
   ChairZhao Yi (China, People's Republic of)  
   SpeakerHidalgo Andres (Spain)SP0061Neutrophils patrol healthy tissues
   SpeakerKrönke Gerhard (Germany)SP0062Differential scavenging of apoptotic cells and bacteria
   SpeakerRovere-Querini Patrizia (Italy)SP0063The role of mucle in innate immune responses
   AbstractCiccia Francesco (Italy)OP0193INFLAMMATION OF ADVENTITIAL NERVES OCCURS IN GIANT CELL ARTERITIS PATIENTS AND IT IS CHARACTERIZED BY INFLAMMASOMES, UPR AND AUTOPHAGY ACTIVATION
   AbstractSteiner Guenter (Austria)OP0194INVOLVEMENT OF TOLL-LIKE RECEPTOR 9 IN THE PATHOGENESIS OF EROSIVE AUTOIMMUNE ARTHRITIS AND DURING OSTEOCLASTOGENESIS

 
Joint Session HPR / PARE / Paediatric - N101 / N102
  
To be and to become: transition from paediatric to adult care
   ChairAvcin Tadej (Slovenia)  
   ChairTaal Erik (Netherlands)  
   SpeakerOlsder Wendy (Netherlands)SP0064To be and to become: reflections on my transition
   SpeakerMinden Kirsten (Germany)SP0065Are we asking the right questions in transition research?
   SpeakerRaunsbaek - Knudsen Line (Denmark)SP0066Implementation of a brief transition programme for adolescents with juvenile idiopathic arthritis
   Speakervan der Net Janjaap (Netherlands) Growing into a healthy lifestyle
   AbstractPontikaki Irene (Italy)OP0195WHAT IS THE IMPACT OF JUVENILE IDIOPATHIC ARTHRITIS IN ADULTHOOD? THE MONOCENTRIC EXPERIENCE OF 240 PATIENTS FOLLOWED IN A TRANSITION TERTIARY CLINIC OF RHEUMATOLOGY

 
Paediatric Rheumatology Session - N105 / N106
  
Heterogeneity in JIA
   ChairSwart Joost F. (Netherlands)  
   Chairde Benedetti Fabrizio (Italy)  
   SpeakerYeung Rae (Canada) Biologic basis of heterogeneity in JIA
   Speakerde Jager Wilco (Netherlands)SP0067JIA cytokine profiling
   SpeakerConsolaro Alessandro (Italy)SP0068Clinical insights into JIA heterogeneity
   AbstractHorneff Gerd (Germany)OP0196CHANGING PATTERNS OF JUVENILE IDIOPATHIC ARTHRITIS PATIENTS TREATED WITH ETANERCEPT FROM 2000 TO 2016 IN THE GERMAN BIKER REGISTRY POPULATION
   AbstractMallalieu Navita L. (United States)OP0197EVALUATION OF A DOSING REGIMEN FOR TOCILIZUMAB IN PATIENTS YOUNGER THAN TWO YEARS OF AGE WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

 
Clinical Science Session - N111 / N112
  
EULAR - EMA Session
   ChairBreedveld Ferdinand C. (Netherlands)  
   ChairStrand Vibeke (United States)  
   SpeakerVesely Richard (United Kingdom)SP0069Registries in musculoskeletal diseases and their regulatory use
   SpeakerBehrens Frank (Germany) Bureaucratic hurdles in performing clinical trials
   SpeakerStrand Vibeke (United States)SP0070News from OMERACT – Imaging and more
   SpeakerChowdhury, Badrul A. (United States) The FDA's view
   Speakernot confimed yet Discussion and Q&A with the Faculty

 
PARE Session - N115 / N116
  
Barrier free employment for young people with RMDs
   ChairPhoka Andri (Cyprus)  
   ChairAlunno Alessia (Italy)  
   SpeakerKullamaa Lembe (Estonia)SP0071Young Patients: Ready, brilliant and able to work!
   SpeakerAndersen Jeanette (United Kingdom)SP0072Challenges and potential solutions about staying in work as a young person with an RMD
   SpeakerMcAllister Maureen (United Kingdom)SP0073Practical employability support for young people with RMDs
   AbstractO Leary Grainne (Ireland)OP0198-PAREFIT FOR WORK ONLINE: SUPPORTING EMPLOYEES WITH RMDS, EMPLOYERS AND HEALTHCARE PROFESSIONALS
   AbstractPutrik Polina (Netherlands)OP0199-PARESUPPORT TO STAY EMPLOYED AND SOCIAL SECURITY ARRANGEMENTS FOR WORK DISABILITY DUE TO RA – PERCEPTIONS OF PATIENTS WITH RA AND RHEUMATOLOGISTS IN 31 EUROPEAN COUNTRIES

 
EULAR Projects in Epidemiology and Health Services - N117 / N118
  
Epidemiology of rheumatic and musculoskeletal diseases - a critical appraisal
   ChairCarmona Loreto (Spain)  
   ChairMachado Pedro (United Kingdom)  
   SpeakerSymmons Deborah (United Kingdom) The impact of epidemiological research in rheumatic and musculoskeletal diseases over the past decade
   SpeakerPetersson Ingemar (Sweden) What to learn about strategies for succesfull development of epidemiological and public health research form other medical areas
   SpeakerGossec Laure (France)SP0074The future of epidemiological research in rheumatic and musculoskeletal disorders
   SpeakerDixon William G. (United Kingdom) The future of public health and health services research in rheumatic and musculoskeletal disorders
   AbstractFrisell Thomas (Sweden)OP0200CONFOUNDING BY INDICATION WILL MAKE NON-TNFI BDMARDS APPEAR MORE HARMFUL THAN TNFI BDMARDS - A NATIONWIDE STUDY OF CHANNELING IN SWEDEN 2010-2014

 
Practical Skills Session - N107 / N108
  
Crystals II
   ChairTausche Anne Kathrin (Germany)  
   ChairPascual Eliseo (Spain)  
   TutorNorkuviene Eleonora (Lithuania)  
   TutorSivera Francisca (Spain)  
   TutorPimentao José (Portugal)  
   TutorOliviero Francesca (Italy)  

 
Practical Skills Session - N109 / N110
  
Ultrasound Advanced I
   ChairFilippou Georgios (Italy)  
   ChairNaredo Esperanza (Spain)  
   SpeakerOhrndorf Sarah (Germany) How to score synovitis quantitatively - validity and feasibility + demo
   SpeakerAmmitzboll Mads (Denmark)SP0075How to use image fusion + demo
   SpeakerBong David (Spain)SP0076How and when to assess cervical facet joints + demo
   SpeakerVojinovic Jelena (Serbia)SP0077How to evaluate joints in JiA + patient cases
   TutorMidtboell Oernbjerg Lykke (Denmark)  

Thursday 15.06.2017 15:30 - 17:00


 
WIN & HOT Session - Hall 6
  
WIN & HOT Session
   ChairCarmona Loreto (Spain)  
   ChairNikiphorou Elena (United Kingdom)  
   SpeakerDixon William G. (United Kingdom) WIN Session: Disease registers and electronic patient records for bench marking in rheumatological care
   SpeakerKvien Tore K. (Norway) WIN Session: Do published guidelines and recommendations improve the quality of care in rheumatology?

 
Clinical Science Session - Hall 8
  
PsA: an integrated perspective
   ChairTam Lai-Shan (China, People's Republic of)  
   ChairCoates Laura (United Kingdom)  
   SpeakerOstergaard Mikkel (Denmark)SP0078Can imaging be a predictor of psoriatic disease?
   SpeakerLories Rik (Belgium)SP0079Pathologies across the tissues in PsA
   Speakervan den Bosch Filip (Belgium) New and old agents: how to use our new toys?
   AbstractNash Peter (Australia)OP0201A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITOR(S)
   AbstractGladman Dafna (Canada)OP0202EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: OPAL BEYOND, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL

 
Challenges in Clinical Practice Session - Hall 7A
  
Autoinflammatory diseases in children and adults
   ChairVojinovic Jelena (Serbia)  
   ChairIonescu Ruxandra (Romania)  
   PresenterBlazina Stefan (Slovenia) Case 1 presentation: Chronic nonbacterial osteomyelitis - a chlid with bone pain
   DiscussantGirschick Hermann (Germany) Case 1 discussion: Diagnosis and management of chronic nonbacterial osteomyelitis
   PresenterDeaconu Claudia (Romania)SP0080Case 2 presentation: Recurrent episodes of fever and arthiritis in adult patient
   DiscussantCantarini Luca (Italy) Case 2 discussion: Diagnosis and management of autoinflammatory diseases in adults

 
From Bench to Bedside - Hall 7B
  
Immunogenicity of biologics; Myth or reality?
   ChairWolbink Gert-Jan (Netherlands)  
   ChairMauri Claudia (United Kingdom)  
   SpeakerMaillere Bernard (France)SP0081The T-cell response against biologics
   SpeakerGils Ann (Belgium)SP0082Immunogenicity of biologics in inflammatory bowel deseases
   SpeakerBijlsma Johannes W.J. (Netherlands)SP0083As a rheumatologist, does it have any consequence in my daily practice?
   AbstractKay Jonathan (United States)OP0203IMPACT OF ADALIMUMAB SERUM CONCENTRATION ON EFFICACY AND ASSOCIATION BETWEEN ANTI-DRUG ANTIBODIES AND SERUM CONCENTRATION: 24 WEEK RESULTS FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractVencovsky Jiri (Czech Republic)OP0204IMPACT OF ANTI-DRUG ANTIBODY AND INJECTION SITE REACTION ON EFFICACY: 24-WEEK RESULTS FROM A PHASE III STUDY COMPARING SB4 (ETANERCEPT BIOSIMILAR) WITH REFERENCE ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS

 
Clinical Science Session - N103 / N104
  
Which target/outcome is more relevant in the management of SLE?
   ChairTincani Angela (Italy)  
   ChairBertsias Georges (Greece)  
   SpeakerDoria Andrea (Italy) Clinical targets
   SpeakerChizzolini Carlo (Switzerland)SP0084Biological targets
   SpeakerSchneider Matthias (Germany)SP0085Patient reported outcomes
   AbstractNakayamada Shingo (Japan)OP0205ASSOCIATION BETWEEN T FOLLICULAR HELPER CELL AND PLASMABLAST CORRELATES WITH DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractJesus Diogo (Portugal)OP0206PERFORMANCE OF SLEDAI-2K TO DETECT A CLINICALLY MEANINGFUL CHANGE IN SLE DISEASE ACTIVITY: A 36-MONTH PROSPECTIVE COHORT STUDY OF 334 PATIENTS.

 
Basic and Translational Science Session - South Auditorium
  
Joint EULAR - EFIS session: Tilting the balance: from disease to tolerance induction
   ChairToes Rene (Netherlands)  
   ChairTaams Leonie (United Kingdom)  
   SpeakerKlatzmann David (France) Low dose IL-2 and tolerance induction: the holy grail?
   SpeakerChang Hyun-Dong (Germany)SP0086Pathogenic memory cells: road blocks to tolerance induction?
   SpeakerIsaacs John D. (United Kingdom)SP0087How antigen presenting cells can be tuned into tolerogenic cells
   AbstractNumajiri Hiroko (Japan)OP0207B CELL DEPLETION INCREASES REGULATORY T CELLS AND AMELIORATES SKIN AND LUNG FIBROSIS IN A BLEOMYCIN-INDUCED SYSTEMIC SCLEROSIS MODEL MOUSE.
   AbstractKurowska-Stolarska Mariola (United Kingdom)OP0208SYNOVIAL TISSUE OF RA PATIENTS IN REMISSION CONTAINS A UNIQUE POPULATION OF REGULATORY MACROPHAGES

 
Health Professionals Session - N101 / N102
  
What to do about co-morbidity?
   ChairMoe Rikke Helene (Norway)  
   ChairHagen Kåre Birger (Norway)  
   SpeakerHäkkinen Arja Helena (Finland)SP0088New drugs, but still comorbidity
   SpeakerNeovius Martin (Sweden) Costs of comorbidity
   SpeakerDagfinrud Hanne (Norway)SP0089How to prevent and treat cardiovascular comorbidity with exercise?
   Speakerde Rooij Mariette (Netherlands)SP0090Co-morbidity-adapted exercise for patients with knee osteoarthritis
   AbstractMARTIN MARTINEZ MARIA AUXILIADORA (Spain)OP0209-HPRINCIDENCE OF FIRST CARDIOVASCULAR EVENT IN SPANISH PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: PROSPECTIVE DATA FROM THE CARMA PROJECT

 
Practical Skills Session - N111 / N112
  
Data visualisation: tables and graphs for publication and presentation I
   SpeakerBoers Maarten (Netherlands)SP0091Data visualisation: tables and graphs for publication and presentation

 
PARE Session - N115 / N116
  
Difficult to reach patient groups
   ChairBoteva Boryana (Bulgaria)  
   ChairBetteridge Neil (United Kingdom)  
   SpeakerZänker Michael (Germany)SP0092The vicious circle of educational level of rheumatoid arthritis and risk of poverty - results of a cross-sectional multicentre study in Germany
   SpeakerKumar Kanta (United Kingdom)SP0093The challenges and solutions for engaging patients from ethnic backgrounds in rheumatology care
   SpeakerDiao Tidiane (Sweden)SP0094The Swedish experience - how a patient organisation could reach out to immigrants and develop through integration
   AbstractStones Simon (United Kingdom)OP0210-PARETHE DEVELOPMENT AND EVALUATION OF AN INTERACTIVE HEALTH COMMUNICATION APPLICATION TO EDUCATE AND EMPOWER YOUNG PEOPLE LIVING WITH JUVENILE IDIOPATHIC ARTHRITIS: A PILOT STUDY
   AbstractBosworth Ailsa (United Kingdom)OP0211-PAREWHO CARES? AN INVESTIGATION OF THE HEALTH AND PERCEIVED SOCIAL CARE NEEDS OF PEOPLE WITH RHEUMATOID ARTHRITIS LIVING IN SCOTLAND.

 
EULAR Projects in Musculoskeletal Imaging - N117 / N118
  
EULAR Projects in Musculoskeletal Imaging
   ChairNaredo Esperanza (Spain)  
   ChairBaraliakos Xenophon (Germany)  
   SpeakerDejaco Christian (Austria)SP0095EULAR recommendations for the use of imaging in the diagnosis and management of large vessel vasculitis in clinical practice
   Speakerd'Agostino Maria-Antonietta (France) Development of EULAR recommendations for the reporting of musculoskeletal ultrasound studies in rheumatology
   SpeakerCollado Paz (Spain)SP0096EULAR-PReS Standardised procedures for Ultrasound Imaging in Paediatric Rheumatology
   SpeakerGandjbakhch Frédérique (France) Definition of Rheumatoid Arthritis bone erosion
   Speakerd'Agostino Maria-Antonietta (France) EULAR Recommendation/criteria for the Appropriate Use of MSK US in Rheumatology Clinical Practice
   SpeakerMöller Ingrid (Spain)SP0097EULAR Standardised procedures for Rheumatology Ultrasound Imaging

 
Practical Skills Session - N107 / N108
  
Capillaroscopy I
   ChairIngegnoli Francesca (Italy)  
   ChairSulli Alberto (Italy)  
   SpeakerSmith Vanessa (Belgium)SP0098The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease
   SpeakerSulli Alberto (Italy) Scoring the capillaroscopic images: manual versus (semi)automatic systems
   SpeakerHerrick Ariane L. (United Kingdom) How to distinguish the major capillaroscopic patterns in connective tissue diseases
   SpeakerCutolo Maurizio (Italy)SP0099Why capillaroscopy can predict disease severity and prognosis
   SpeakerHermann Walter (Germany)SP0100How to select the most appropriate capillaroscopic device: pros and cons
   Speakernot confimed yet Live Practical sessions with patients and case discussion

 
Practical Skills Session - N109 / N110
  
Ultrasound, Clinical, diagnostic and therapeutic skills I
   ChairDamjanov Nemanja (Serbia)  
   ChairRoccatello Dario (Italy)  
   SpeakerMandl Peter (Austria)SP0101Diagnostic and therapeutic ultrasound-guided procedures
   SpeakerDoherty Michael (United Kingdom)SP0102How to perform a quick and efficient physical examination
   SpeakerCaporali Roberto (Italy) How to read and interpret imaging tools: X-Ray
   SpeakerHammer Hilde Berner (Norway)SP0103How to assess US competency skills
   Speakernot confimed yet Q&A

Thursday 15.06.2017 17:30 - 19:00


 
Basic and Translational Science Session - South Auditorium
  
Macrophage M2 polarization: implications in fibrotizing diseases
   ChairDistler Oliver (Switzerland)  
   ChairMüller-Ladner Ulf (Germany)  
   SpeakerSica Antonio (Italy)SP0104Molecular and epigenetic basis of macrophage polarized activation
   SpeakerCamara Niels (Brazil)SP0105Macrophages during the fibrotic process: friend or foe
   SpeakerLafyatis Robert (United States) Alternative activation of monocyte/macrophages in pathophysiology of fibrotizing diseases
   AbstractSoldano Stefano (Italy)OP0212ENDOTHELIN-1 INDUCES A PROFIBROTIC PHENOTYPE IN CULTURED HUMAN MICROVASCULAR ENDOTHELIAL AND CIRCULATING MONOCYTE/MACROPHAGE CELLS
   AbstractKing Jamie (United Kingdom)OP0213MACROPHAGES FROM A SCLERODERMA SUBGROUP WITH HIGHER SKIN SCORES EXPRESS ACTIVATION MARKERS AND INDUCE FIBROBLASTS IN CO-CULTURE

Friday 16.06.2017 08:15 - 09:45


 
Basic and Translational Science Session - South Auditorium
  
Mucosal B cells: gatekeepers of immune function
   ChairSomers Veerle (Belgium)  
   ChairJacques Peggy (Belgium)  
   SpeakerMauri Claudia (United Kingdom) How microbiota shape regulatory B cells
   SpeakerCatrina Anca (Sweden)SP0106The lung in RA as driver of ACPA: cause or consequence
   AbstractChiba Asako (Japan)OP0214ACTIVATION STATUS OF MUCOSAL-ASSOCIATED INVARIANT T CELLS REFLECTS PATHOLOGY OF SYSTEMIC LUPUS ERYTHEMATOSUS.
   AbstractHirose Sachiko (Japan)OP0215ROLE OF INHIBITORY IGG FC RECEPTOR IIB ON B CELLS AND MONOCYTES IN YAA-RELATED MURINE LUPUS

Friday 16.06.2017 10:15 - 11:45


 
WIN & HOT Session - Hall 6
  
WIN & HOT Session
   ChairCalvo Alén Jaime (Spain)  
   ChairPisetsky David S. (United States)  
   SpeakerDenton Christopher (United Kingdom)SP0107HOT Session: Scleroderma treatment
   SpeakerGottenberg Jacques-Eric (France) WIN Session: Sjögren’s Syndrome

 
Abstract Session - Hall 8
  
Abstract Session: PsA: The options grow!
   ChairTam Lai-Shan (China, People's Republic of)  
   ChairHueber Axel (Germany)  
   AbstractMease Philip (United States)OP0216EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): A RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL
   AbstractAraujo Elizabeth (Germany)OP0217USTEKINUMAB IS SUPERIOR TO TNF INHIBITOR TREATMENT IN RESOLVING ENTHESITIS IN PSA PATIENTS WITH ACTIVE ENTHESITIS- RESULTS FROM THE ENTHESIAL CLEARANCE IN PSORIATIC ARTHRITIS (ECLIPSA) STUDY
   AbstractDeodhar Atul (United States)OP0218EFFICACY AND SAFETY RESULTS OF GUSELKUMAB, AN ANTI-IL23 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
   AbstractNash Peter (Australia)OP0219EARLY ONSET OF EFFICACY WITH APREMILAST MONOTHERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: A PHASE 3B, RANDOMIZED, CONTROLLED TRIAL
   AbstractO'Dell James (United States)OP0220RANDOMIZED, DOUBLE-BLIND, GLOBAL CLINICAL TRIAL TO EVALUATE EQUIVALENCE OF CHS-1420 TO ADALIMUMAB IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
   Abstractvan der Heijde Désirée (Netherlands)OP0221RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH IXEKIZUMAB OVER 52 WEEKS
   AbstractMcInnes Iain (United Kingdom)OP0222SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL, FUTURE 2
   AbstractMease P (United States)OP0223ABATACEPT IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: 1-YEAR RESULTS FROM A PHASE III STUDY

 
Abstract Session - Hall 7A
  
Abstract Session: From classics to new: synthetic DMARDs in RA
   ChairTaylor Peter C. (United Kingdom)  
   ChairMourão Ana Filipa (Portugal)  
   AbstractBergstra Sytske Anne (Netherlands)OP0224SIMILAR SHORT TERM CLINICAL RESPONSE TO INITIAL TREATMENT WITH HIGH VERSUS LOW DOSE METHOTREXATE IN MONO- AND COMBINATION THERAPY IN EARLY RHEUMATOID ARTHRITIS PATIENTS
   AbstractDavies Rebecca (United Kingdom)OP0225THE EFFECT OF A LOW VERSUS HIGH FIRST PRESCRIBED DOSE OF METHOTREXATE ON EULAR RESPONSE AT SIX MONTHS USING DATA FROM THE RAMS STUDY
   AbstractStouten Veerle (Belgium)OP0226SUSTAINED EFFECTIVENESS OF METHOTREXATE WITH STEP-DOWN GLUCOCORTICOID REMISSION INDUCTION (COBRA SLIM) FOR EARLY RHEUMATOID ARTHRITIS IN A TREAT-TO- TARGET SETTING: 2-YEAR RESULTS OF THE CARERA TRIAL
   AbstractBrunekreef Tammo (Netherlands)OP0227REMISSION INDUCTION WITH METHOTREXATE STEP-UP THERAPY VERSUS COMBINATION OF HYDROXYCHLOROQUINE, METHOTREXATE AND TRIAMCINOLONE: 3 YEAR RESULTS
   AbstractWesthovens René (Belgium)OP0229EFFECT OF BASELINE SERUM CRP LEVELS ON CLINICAL EFFICACY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH FILGOTINIB: POST-HOC ANALYSIS FROM TWO PHASE 2B STUDIES
   AbstractFleischmann Roy (United States)LB0003TOFACITINIB WITH AND WITHOUT METHOTREXATE VERSUS ADALIMUMAB WITH METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: RESULTS FROM ORAL STRATEGY, A PHASE 3B/4 RANDOMISED TRIAL
   AbstractWinthrop Kevin (United States)OP0230THE EFFECTIVENESS OF ZOSTER VACCINE IN RA PATIENTS SUBSEQUENTLY TREATED WITH TOFACITINIB

 
Abstract Session - Hall 7B
  
Abstract Session: New treatments in SLE, Sjögren's and APS
   ChairHiepe Falk (Germany)  
   ChairAlunno Alessia (Italy)  
   AbstractRodríguez-Pintó Ignasi (Spain)OP0231THE EFFECT OF “TRIPLE THERAPY” WITH ANTICOAGULATION PLUS CORTICOSTEROIDS PLUS PLASMA EXCHANGE AND/OR INTRAVENOUS IMMUNOGLOBULINS ON THE MORTALITY OF CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME (CAPS) PATIENTS
   AbstractWallace Daniel (United States)OP0232SUSTAINED SAFETY AND EFFICACY OVER 10 YEARS WITH BELIMUMAB (BEL) PLUS STANDARD SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) THERAPY (SOC) IN PATIENTS WITH SLE
   AbstractFasano Serena (Italy)OP0233PRIMARY PROPHYLAXIS OF CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE ANALYSIS OF 291 PATIENTS FROM TWO ITALIAN CENTERS
   AbstractCheng Laurence (United States)OP0234CLINICAL AND BIOLOGIC EFFECTS OF ICOSL BLOCKADE BY AMG 557 IN SUBJECTS WITH LUPUS ARTHRITIS
   AbstractEl-Sherbiny Yasser (United Kingdom)OP0235A NOVEL B CELL SPECIFIC IFN-I BIOMARKER IS ASSOCIATED WITH PLASMABLAST NUMBERS FOLLOWING B CELL DEPLETION THERAPY IN SLE
   AbstractYelnik Cécile (France)OP0236BENEFIT AND SAFETY OF ANTITHROMBOTIC TREATMENT IN 264 PREGNANCIES IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
   AbstractDobronravov Vladimir (Russian Federation)LB000248 WEEK COMPLETE REMISSION OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN
   AbstractShojaei Amir (United States)OP0237LIFITEGRAST OPHTHALMIC SOLUTION 5.0% FOR TREATMENT OF DRY EYE DISEASE: COMBINED EVIDENCE FROM 5 RANDOMIZED CONTROLLED TRIALS.

 
Abstract Session - N103 / N104
  
Abstract Session: Axial Spondyloarthritis from risk factor to clinical outcomes
   Chairvan Gaalen Floris A. (Netherlands)  
   Chairvan Onna Marloes (Netherlands)  
   AbstractGarrido-Castro Juan (Spain)OP0238MEASUREMENT OF SPINAL MOBILITY IN AXIAL SPONDYLOARTHRITIS USING INERTIAL SENSORS: RELIABILITY AND VALIDATION PRELIMINARY RESULTS.
   AbstractAlivernini Stefano (Italy)OP0239HISTOLOGICAL FEATURES OF JOINT AND COLONIC INFLAMMATION IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH ANTI-TNF
   AbstractBengtsson Karin (Sweden)OP0240HOW STRONG ARE THE ASSOCIATIONS OF SPONDYLOARTHRITIS-RELATED COMORBIDITIES WITH ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS AND UNDIFFERENTIATED SPONDYLOARTHRITIS? – A REGISTER-BASED STUDY FROM SWEDEN
   Abstractde Koning Anoek (Netherlands)OP0241ERAP1 IS A SUSCEPTIBILITY FACTOR FOR EARLY AXIAL SPONDYLOARTHRITIS MEETING THE ASAS CLASSIFICATION CRITERIA: RESULTS FROM THE DESIR AND SPACE COHORTS
   AbstractPuyraimond-Zemmour Deborah (France)OP0242HEALTH-RELATED QUALITY OF LIFE IMPROVED ONLY SLIGHTLY ALTHOUGH DISEASE ACTIVITY DECREASED OVER 3 YEARS IN EARLY AXIAL SPONDYLOARTHRITIS: 442 PATIENTS FROM THE DESIR COHORT.
   AbstractSieper Joachim (Germany)OP0243PREDICTORS OF REMISSION AT WEEK 12 IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING OPEN-LABEL ADALIMUMAB TREATMENT IN THE ABILITY-3 STUDY
   Abstractvan Gaalen Floris (Netherlands)OP0244FAMILY MATTERS: VALUE OF FAMILY HISTORY OF SPONDYLOARTHRITIS IN THE DIAGNOSTIC WORK-UP OF PATIENTS WITH CHRONIC BACK PAIN: RESULTS FROM THE SPACE AND DESIR COHORTS.
   AbstractWebers Casper (Netherlands)OP0245EMPLOYMENT PERSPECTIVES OF PATIENTS WITH ANKYLOSING SPONDYLITIS IN THE BIOLOGICS ERA

 
Abstract Session - South Auditorium
  
Abstract Session: RA - causes and courses
   ChairTuresson Carl (Sweden)  
   ChairVerstappen Suzanne (United Kingdom)  
   AbstractWallman Johan (Sweden)OP0246IMPACT OF DISEASE ACTIVITY MEASURES ON SICK LEAVE IN BIOLOGICS-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATIONAL DATA FROM SOUTHERN SWEDEN
   AbstractVanier Antoine (France)OP0247AN IMPROVED MATRIX TO PREDICT RAPID RADIOGRAPHIC PROGRESSION OF EARLY RHEUMATOID ARTHRITIS PATIENTS: POOLED ANALYSES FROM SEVERAL DATABASES
   AbstractWinthrop Kevin (United States)OP0248SERIOUS INFECTION AND ASSOCIATED RISK FACTORS IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB
   AbstractHagen Melanie (Germany)OP0249MULTI-BIOMARKER DISEASE ACTIVITY AND AUTOANTIBODY STATUS LEAD TO COST EFFECTIVE TAPERING ALGORITHMS IN RHEUMATOID ARTHRITIS PATIENTS IN SUSTAINED REMISSION
   AbstractFreeston Jane (United Kingdom)OP0250CAN RANKL SERUM LEVELS PREDICT FUTURE PROGRESSION TO RHEUMATOID ARTHRITIS IN ACPA NEGATIVE PATIENTS?
   AbstractDreyer Lene (Denmark)OP0251INCIDENCE OF KNEE AND HIP REPLACEMENTS IN RHEUMATOID ARTHRITIS PATIENTS FOLLOWING INTRODUCTION OF BIOLOGICAL DMARDS: AN INTERRUPTED TIME SERIES ANALYSIS USING NATIONWIDE HEALTH CARE REGISTERS
   AbstractBergstra Sytske Anne (Netherlands)OP0252RHEUMATOID ARTHRITIS PATIENTS WITH CONTINUED LOW DISEASE ACTIVITY HAVE SIMILAR OUTCOMES OVER 10 YEARS, REGARDLESS OF INITIAL THERAPY.
   AbstractSeror Raphaèle (France)OP0253PASSIVE SMOKING IN CHILDHOOD AND HISTORY OF CHRONIC DIARRHEA INCREASES THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS (RA).

 
Abstract Session - N101 / N102
  
HPR Abstract Session: Move to improve
   ChairOesch Peter (Switzerland)  
   ChairAlliot Francoise (France)  
   AbstractEllegaard Karen (Denmark)OP0254-HPRHAND EXERCISE FOR WOMEN WITH RHEUMATOID ARTHRITIS AND DECREASED ADL ABILITY: AN EXPLORATORY RANDOMISED CONTROLLED TRIAL
   AbstractBerdal G. (Norway)OP0255-HPRAN ADD-ON PROGRAMME IMPROVED THE SHORT-TERM, BUT NOT THE LONG-TERM EFFECT OF REHABILITATION IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM A PRAGMATIC MULTI-CENTRE STEPPED-WEDGE CLUSTER RANDOMIZED CONTROLLED TRIAL
   AbstractBoström Carina (Sweden)OP0256-HPRPHYSICAL ACTIVITY AND INACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractVillarreal Laura (Colombia)OP0257-HPRRELATIONSHIP BETWEEN SLEEP DISORDERS AND DISEASE ACTIVITY IN PATIENS WITH RHEUMATOID ARTHRITIS
   AbstractLange Elvira (Sweden)OP0258-HPRINTENSIVE PHYSICAL EXERCISE FOR ELDERLY PERSONS WITH RHEUMATOID ARTHRITIS IMPROVES PHYSICAL CAPACITY
   AbstractMiyamoto Samira (Brazil)OP0259-HPRSUPERVISED WALKING IMPROVES AEROBIC CAPACITY, EXERCISE TOLERANCE, FATIGUE AND PERCEIVED IMPROVEMENT IN WOMEN WITH PRIMARY SJÖGREN’S SYNDROME: A RANDOMIZED CONTROLLED TRIAL
   AbstractMannerkorpi Kaisa (Sweden)OP0260-HPRHIGHER SATISFACTION WITH ACTIVITY-RELATED SYMPTOMS AFTER 15-WEEK RESISTANCE EXERCISE IN WOMEN WITH FIBROMYALGIA
   AbstractRisum Kristine (Norway)OP0261-HPRPHYSICAL ACTIVITY LEVEL MEASURED BY ACCELEROMETER IS COMPARABLE BETWEEN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AND CONTROLS, BUT PATIENTS SPEND LESS TIME IN VIGOROUS PHYSICAL ACTIVITY

 
Abstract Session - N105 / N106
  
Abstract Session: Gout: advances in diagnosis and management
   ChairPascual Eliseo (Spain)  
   ChairDalbeth Nicola (New Zealand)  
   AbstractDehlin Mats (Sweden)OP0262TRENDS AND COSTS FOR GOUT HOSPITALIZATION IN SWEDEN
   AbstractMerriman Tony (New Zealand)OP0263TRANS-ANCESTRAL META-ANALYSIS IDENTIFIES 13 NEW LOCI ASSOCIATED WITH SERUM URATE LEVELS
   AbstractChoi Hyon (United States)OP0264CAN MODERATE ALCOHOL INTAKE LOWER THE RISK OF MYOCARDIAL INFARCTION AND MORTALITY EVEN AMONG GOUT PATIENTS?
   AbstractGaffo Angelo (United States)OP0265VALIDATION OF A DEFINITION FOR ATTACK (FLARE) IN PATIENTS WITH ESTABLISHED GOUT
   AbstractDalbeth Nicola (New Zealand)OP0266PRESENCE OF MONOSODIUM URATE CRYSTALS BY DUAL-ENERGY COMPUTED TOMOGRAPHY IN GOUT PATIENTS TREATED WITH ALLOPURINOL
   AbstractStamp Lisa (New Zealand)OP0267SERUM URATE AS A SURROGATE ENDPOINT FOR GOUT FLARES: RESULTS OF A SYSTEMATIC REVIEW AND META-REGRESSION ANALYSIS OF RANDOMIZED TRIALS
   AbstractDoherty Michael (United Kingdom)OP0268NURSE-LED CARE VERSUS GENERAL PRACTITIONER CARE OF PEOPLE WITH GOUT: A UK COMMUNITY-BASED RANDOMISED CONTROLLED TRIAL
   AbstractBredemeier Markus (Brazil)OP0269EFFECT OF XANTHINE OXIDASE INHIBITORS ON THE INCIDENCE OF CARDIOVASCULAR EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

 
Abstract Session - N111 / N112
  
Abstract Session: Low back pain and fibromyalgia
   ChairHider Samantha (United Kingdom)  
   ChairPrior James (United Kingdom)  
   AbstractNguyen Christelle (France)LB0001INTRADISCAL GLUCOCORTICOID INJECTION FOR PATIENTS WITH CHRONIC LOW BACK PAIN ASSOCIATED WITH ACTIVE DISCOPATHY: A RANDOMIZED TRIAL
   AbstractHansen Liselotte (Denmark)OP0270LONG-TERM PROGNOSIS IN CHRONIC PLANTAR FASCIITIS BASED ON DISEASE DURATION AND ULTRASONIC CHANGES
   AbstractNissen Michael (Switzerland)OP0271CORTICOSTEROID INJECTIONS FOR GREATER TROCHANTERIC PAIN SYNDROME: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
   AbstractSingh Gurkirpal (United States)OP0272CHRONIC LOW BACK PAIN AND ANXIETY: SIGNIFICANT DECREASE WITH GLUCOSAMINE-CHONDROITIN SULFATE TREATMENT IN A LARGE, COMMUNITY-BASED, PILOT, OPEN PROSPECTIVE INTERVENTIONAL STUDY
   AbstractWeitzman Dahlia (Israel)OP0273A RETROSPECTIVE DATABASE STUDY OF ONE-YEAR ADEHERNCE AND PERSISTENCE WITH PHARMACOLOGICAL THERAPY AMONG FIBROMYALGIA PATIENTS IN ISRAEL
   AbstractLaroche Françoise (France)OP0274FIBROMYALGIA IN REAL LIFE A NATIONAL FRENCH WEB-BASED SURVEY IN 4516 PATIENTS
   AbstractGhib Linda Jessica (Romania)OP0275FIBROMYALGIA PREVALENCE AND IMPACT ON DISEASE ACTIVITY SCORES IN RHEUMATOID ARTHRITIS PATIENTS WHO ARE UNRESPONSIVE TO BIOLOGICAL TREATMENT

 
Abstract Session - N115 / N116
  
PARE Abstract Session
   ChairO'Leary Gráinne (Ireland)  
   ChairCattelaens Karl (Germany)  
   SpeakerHulst Stefanie (Netherlands) Edgar Stene Prize 2017: Diagnosis from the perspective of a child
   AbstractMateus Elsa (Portugal)OP0276-PAREMORE PARTICIPATION, BETTER HEALTH – PROMOTING PUBLIC INVOLVEMENT IN HEALTH
   AbstractEkroth M. (Finland)OP0277-PAREINITIAL INFORMATION PACKAGE FOR CHILDREN DIAGNOSED WITH JIA
   AbstractGrange Laurent (France)OP0278-PARETHE FRENCH PATIENT'S ASSOCIATION (AFLAR: FRENCH LEAGUE AGAINST RHEUMATISM) HAS GENERATED THE FRENCH NATIONAL ALLIANCE AGAINST OSTEOARTHRITIS AND THE FIRST GENERAL CONVENTION OF OSTEOARTHRITIS IN FRANCE: A CAMPAIGN TO CREATE A NATIONAL LOBBYING TOOL TO IMPROVE THE MANAGEMENT OF OSTEOARTHRITIS.
   AbstractJacklin Clare (United Kingdom)OP0279-PARENRAS KNOW YOUR DAS APP SELF ASSESSMENT TOOL EMPOWERING PATIENTS
   AbstractAndersen Jeanette (United Kingdom)OP0280-PAREPATIENT PANELS ON ACCESS AND ADHERENCE TO TREATMENT FOR SLE PATIENTS
   AbstractPhoka Charalambous Androulla (Cyprus)OP0281-PAREEDUCATING PATIENT EXPERTS/PATIENT PARTNERS - A NEW WAY
   AbstractNordlund Kim (Sweden)OP0282-PARE#DOESNTSHOWDOESNTEXIST / #SYNSINTEFINNSINTE – A PHOTO CAMPAIGN BY UNGA REUMATIKER

 
Abstract Session - N117 / N118
  
Abstract Session: Imaging and treamtent response in Rheumatology
   ChairConaghan Philip (United Kingdom)  
   ChairDale James (United Kingdom)  
   AbstractStoenoiu Maria (Belgium)OP0283ULTRASONOGRAPHIC EVALUATION IN RHEUMATOID ARTHRITIS USING THE GLOBAL OMERACT/EULAR ULTRASOUND SYNOVITIS SCORE (GLOESS)
   AbstractAhmad HA (United States)OP0284EVALUATION OF THE IMPACT OF BASELINE LEVELS OF MRI-DETECTED INFLAMMATION ON TREATMENT RESPONSE IN EARLY, SEROPOSITIVE, MTX-NAÏVE RA: DATA FROM THE AVERT TRIAL
   AbstractNielsen Berit (Denmark)OP0285ATTENUATION OF FLUORINE-18-FLUORODEOXYGLUCOSE UPTAKE IN LARGE VESSEL GIANT CELL ARTERITIS AFTER SHORT-TERM HIGH-DOSE STEROID TREATMENT - A DIAGNOSTIC WINDOW OF OPPORTUNITY
   AbstractAmmitzbøll-Danielsen Mads (Denmark)OP0286THE UTILITY OF THE OMERACT ULTRASOUND TENOSYNOVITIS SCORING SYSTEM IN MULTICENTER CLINICAL TRIALS
   AbstractSeven Sengül (Denmark)OP0287ULTRASONOGRAPHY-DETECTED PERIPHERAL ENTHESITIS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS – ANATOMICAL DISTRIBUTION, MORPHOLOGY AND RESPONSE TO ANTI-TNF THERAPY
   AbstractMandl Peter (Austria)OP0288RELIABILITY OF A EULAR-OMERACT SEMIQUANTITATIVE SCORING SYSTEM FOR THE ASSESSMENT OF CARTILAGE IN RHEUMATOID ARTHRITIS
   AbstractSundlisater Nina (Norway)OP0289TREAT-TO-TARGET IN EARLY RHEUMATOID ARTHRITIS: ASSOCIATION BETWEEN SUSTAINED REMISSION AND JOINT DAMAGE
   AbstractPimenta Emanuela (Brazil)OP0290CORRELATION OF CXCL13 AND ULTRASSONOGRAPHIC FINDINGS OF JACCOUD ARTHROPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS

 
Abstract Session - N107 / N108
  
Abstract Session: From genetics through epigenetics to proteomics: understanding disease mechanisms
   ChairBarton Anne (United Kingdom)  
   ChairOspelt Caroline (Switzerland)  
   AbstractSmith Samantha (United Kingdom)OP0291IDENTIFICATION OF NOVEL SUSCEPTIBILITY LOCI IN A LARGE UK COHORT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) CASES
   AbstractAterido Adrià (Spain)OP0292GENETIC VARIATION ASSOCIATED WITH CARDIOVASCULAR RISK IN AUTOIMMUNE DISEASES
   AbstractTeitsma Xavier (Netherlands)OP0293WEIGHTED GENE CO-EXPRESSION NETWORK ANALYSIS OF DMARD-NAÏVE EARLY RA PATIENTS ACHIEVING SUSTAINED DRUG-FREE REMISSION AFTER INITIATING TOCILIZUMAB THERAPY
   AbstractFerrari Serge (Switzerland)OP0294FRACTURE PREDICTION USING A GENETIC MARKERS ALGORITHM COMPARED TO FRAX IN THREE EUROPEAN COHORTS
   AbstractAnaparti Vidyanand (Canada)OP0295UNIQUE WHOLE BLOOD MICRORNA BIOSIGNATURE FOR RHEUMATOID ARTHRITIS
   AbstractPurvis Harriet (United Kingdom)OP0296AUTOIMMUNE ASSOCIATED GENE PTPN22 NEGATIVELY REGULATES DECTIN-1 SIGNALLING IN DENDRITIC CELLS
   AbstractStiburkova Blanka (Czech Republic)OP0297FUNCTIONAL POLYMORPHISMS OF THE ABCG2 GENE IN PRIMARY GOUT
   AbstractMartin Paul (United Kingdom)OP0298CHROMATIN INTERACTIONS REVEAL NOVEL GENE TARGETS FOR DRUG REPOSITIONING IN RHEUMATIC DISEASES

 
Abstract Session - N109 / N110
  
Abstract Session: Innovative insights into mechanism of SLE, Sjögren's and APS
   ChairIsenberg David (United Kingdom)  
   ChairPeene Isabelle (Belgium)  
   AbstractTruglia Simona (Italy)OP0299SERUM AND GLOMERULAR EXPRESSION OF IL32 IN LUPUS NEPHRITIS
   AbstractPontarini Elena (United Kingdom)OP0300ENRICHMENT OF T FOLLICULAR-HELPER CELLS (TFH) AND EXCLUSION OF T FOLLICULAR-REGULATORY CELLS (TFR) FROM ECTOPIC GERMINAL CENTERS IN SALIVARY GLANDS OF SJOGREN’S SYNDROME PATIENTS.
   AbstractLiu Hao (United States)OP0301TYPE I IFN GENE SIGNATURE TEST–HIGH AND –LOW PATIENTS WITH MODERATE TO SEVERE SLE DISEASE ACTIVITY HAVE DISTINCT GENE EXPRESSION SIGNATURES OF IMMUNOLOGIC PATHWAYS AND CELL TYPES
   AbstractKraaij Tineke (Netherlands)OP0302SIGNIFICANT REDUCTIONS OF PATHOGENIC AUTOANTIBODIES BY SYNERGETIC RITUXIMAB AND BELIMUMAB TREATMENT EFFECTIVELY INHIBITS NEUTROPHIL EXTRACELLULAR TRAPS IN SEVERE, REFRACTORY SLE - THE SYNBIOSE STUDY
   AbstractBlokland Sofie (Netherlands)OP0303THE SALIVARY GLAND SECRETOME AS A POTENTIAL NEW TOOL TO IDENTIFY BIOMARKERS OF DRYNESS AND IMMUNOPATHOLOGY IN PRIMARY SJÖGREN’S SYNDROME AND NON-AUTOIMMUNE SICCA PATIENTS
   AbstractRangel-Moreno Javier (United States)OP0304SELECTIVE INHIBITORS OF NUCLEAR EXPORT PREVENT LUPUS PROGRESSION BY TARGETING GERMINAL CENTER FORMATION AND AUTOREACTIVE ANTIBODY SECRETING CELLS
   AbstractWahren Marie (Sweden)OP0305TYPE I IFN SYSTEM ACTIVATION IN NEWBORNS EXPOSED TO ANTI-RO/SSA AUTOANTIBODIES IN UTERO
   AbstractVan Den Hoogen Lucas (Netherlands)OP0306DOWNREGULATION OF MICRORNAS IN PLASMACYTOID DENDRITIC CELLS IS ASSOCIATED WITH A TYPE I INTERFERON SIGNATURE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME.

Friday 16.06.2017 11:45 - 13:30


 
Poster Tour - Poster Area
  
Poster Tour: Imaging advances in arthritis - what is new?
   ChairTerslev Lene (Denmark)  
   ChairMoeller-Bisgaard Signe (Denmark)  
   Abstractvan der Laken CJ (Netherlands)FRI0623[18F]FLUORIDE PET-CT IMAGING OF BONE FORMATION IN ANKYLOSING SPONDYLITIS BEFORE AND AFTER 12 WEEKS OF ANTI-TNF TREATMENT.
   AbstractRamirez Giuseppe A. (Italy)FRI0624STRUCTURAL MRI-BASED CONNECTOMICS IN SLE: A PILOT STUDY
   AbstractKampylafka Eleni (Germany)FRI0625IMPROVEMENT OF JOINT INFLAMMATION AS ASSESSED BY MRI AND POWER DOPPLER ULTRASOUND (PDUS) IN AN OPEN LABEL STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB (PSARTROS)
   AbstractRezaei Hamed (Sweden)FRI0626ANALYSIS OF CORRELATION AND CAUSES FOR DISCREPANCY BETWEEN QUANTITATIVE AND SEMI-QUANTITATIVE DOPPLER SCORES IN SYNOVITIS IN RHEUMATOID ARTHRITIS
   AbstractHussain Sidra (United Kingdom)FRI0627ULTRASOUND HAND EXAMINATION IS MORE SENSITIVE IN DIAGNOSING HAND OSTEOARTHRITIS THAN CONVENTIONAL RADIOGRAPHY: COMPARISON BETWEEN DIFFERENT ULTRASONOGRAPHIC SCORES
   AbstractMøller Døhn Uffe (Denmark)FRI0628ULTRASOUND SHOWS SIGNS OF INFLAMMATION IN MOST PATIENTS WITH RHEUMATOID ARTHRITIS IN LONGSTANDING CLINICAL REMISSION, IRRESPECTIVE OF CONVENTIONAL SYNTHETIC OR BIOLOGIC DMARD THERAPY
   AbstractMathew Ashish Jacob (India)FRI0629MAGNETIC RESONANCE IMAGING (MRI) INFLAMMATION OF THE FEET DEMONSTRATES SUBCLINICAL INFLAMMATORY DISEASE IN CUTANEOUS PSORIASIS PATIENTS WITHOUT CLINICAL ARTHRITIS
   AbstractFreeston Jane (United Kingdom)FRI0630CAN WHOLE BODY MRI AT BASELINE IDENTIFY DEFINITE INFLAMMATORY ARTHRITIS PATTERNS IN UNDIFFERENTIATED ARTHRITIS?
   AbstractMayordomo Lucia (Spain)FRI0631PREDICTIVE VALUE OF POWER DOPPLER ULTRASONOGRAPHY (PDUS) IN THE DIAGNOSIS OF EARLY RHEUMATOID ARTHRITIS
   AbstractCimmino Marco (Italy)FRI0632MRI-US FUSION IMAGES FOR RHEUMATOID ARTHRITIS: CAN DOPPLER SUBSTITUTE FOR GADOLINIUM?
  
Poster Tour: Indexes and predictors in systemic sclerosis and myositis
   ChairCutolo Maurizio (Italy)  
   ChairSmith Vanessa (Belgium)  
   AbstractSalazar Gloria (United States)FRI0363KL6 AND NOT CCL-18 IS A PREDICTOR OF EARLY PROGRESSION IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE
   AbstractNakamura Hiroyuki (Japan)FRI0364USEFULNESS OF SERUM HAPTOGLOBIN LEVELS AS A NOVEL MARKER FOR PULMONARY ARTERIAL HYPERTENSION COMPLICATED WITH CONNECTIVE TISSUE DISEASE
   AbstractDobrota Rucsandra (Switzerland)FRI0365NEW COLLAGEN BIOMARKERS PREDICT PROGRESSION OF FIBROSIS IN SYSTEMIC SCLEROSIS
   AbstractVan Roon Anniek (Netherlands)FRI0366A PILOT STUDY ON ISCHEMIA AND REPERFUSION INJURY DURING A RAYNAUD’S ATTACK: SEQUENTIAL ASSESSMENT OF REDOX STRESS PARAMETERS IN A UNIQUE COOLING AND REWARMING EXPERIMENT
   AbstractNotarnicola Antonella (Sweden)FRI0367NEW AUTOIMMUNE TARGETS IN IDIOPATHIC INFLAMMATORY MYOPATHIES - AN ANTIGEN BEAD ARRAY APPROACH
   AbstractGheorghiu Ana Maria (Romania)FRI0368NAILFOLD CAPILLAROSCOPY CHANGES REFLECT ENDOTHELIAL ACTIVATION AND INJURY IN PATIENTS WITH SYSTEMIC SCLEROSIS
   AbstractJaeger Veronika (Switzerland)FRI0369PROSPECTIVE EVALUATION OF THE CAPILLAROSCOPIC SKIN ULCER INDEX (CSURI) IN CLINICAL PRACTICE.
   AbstractAbignano Giuseppina (United Kingdom)FRI0370THREE-DIMENSIONAL NAILFOLD CAPILLARY IMAGING BY DYNAMIC OPTICAL COHERENCE TOMOGRAPHY IN SYSTEMIC SCLEROSIS: A VALIDATION STUDY USING NAILFOLD VIDEO-CAPILLAROSCOPY.
   AbstractHax Vanessa (Brazil)FRI0371CLINICAL ALGORITHMS FOR THE DIAGNOSIS AND PROGNOSIS OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS
   AbstractBruni Cosimo (Italy)FRI0372THE DUCAS: PROPOSAL FOR A DIGITAL ULCER ASSESSMENT SCORE IN SCLERODERMA
  
Poster Tour: New drivers in RA and SPA pathophysiology
   ChairBreban Maxime (France)  
   ChairNeumann Elena (Germany)  
   AbstractSánchez Maria Alejandra (Spain)FRI0420ASSOCIATION OF SUPRESSOR OF CYTOKINE SIGNALING -3 (SOCS-3) EXPRESSION WITH INTERLEUKIN-23 RECEPTOR (IL-23R) SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) IN ANKYLOSING SPONDYLITIS (AS).
   AbstractWade Sarah (Ireland)FRI0421DYSREGULATED MIR-125 PROMOTES JOINT ANGIOGENESIS IN PSA THROUGH ALTERED BIOENERGETICS.
   AbstractJeong Hyemin (Korea, Republic Of)FRI0422ESTROGEN ATTENUATES THE DISEASE ACTIVITY OF SPONDYLOARTHRITIS IN SKG MICE
   AbstractVinci Chiara (United Kingdom)FRI0423ANTIBODIES TO TYPE II COLLAGEN: A NOVEL TOOL FOR THE SPONDYLOARTHRITIS DIAGNOSIS?
   AbstractSendo Sho (Japan)FRI0080CD11B+GR1DIM TOLEROGENIC DENDRITIC CELL-LIKE CELLS ARE EXPANDED IN INTERSTITIAL LUNG DISEASE IN SKG MICE
   AbstractBitoun Samuel (France)FRI0081A MACAQUE MODEL OF RHEUMATOID ARTHRITIS BY IMMUNIZATION WITH CITRULLINATED PEPTIDES: LESSONS FOR THE HUMAN DISEASE
   AbstractZayoud Morad (Israel)FRI0082RAS SIGNALING INHIBITORS ATTENUATE ARTHRITIS IN ANIMAL MODELS OF RHEUMATOID ARTHRITIS BY DOWN MODULATING THE PATHOGENIC TH17 CELL RESPONSE
   AbstractBondt Albert (Netherlands)FRI0083REDUCED INCREASE OF ACPA IGG-FC GALACTOSYLATION DURING PREGNANCY IN COMPARISON TO TOTAL IGG: AN EXPLANATION WHY AUTOANTIBODY POSITIVE RA-PATIENTS IMPROVE LESS DURING PREGNANCY?
   AbstractLi Jing (China)FRI0084THE TONSIL MICROBIOME IS INVOLVED IN RHEUMATOID ARTHRITIS
  
Poster Tour: Novelty in the clinical approach to SLE, Sjögren's and APS II
   ChairTincani Angela (Italy)  
   ChairGatto Mariele (Italy)  
   AbstractBortoluzzi Alessandra (Italy)FRI0255PATTERNS OF DISEASE ACTIVITY IMPACT ON ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractJousse-Joulin Sandrine (France)FRI0256ULTRASOUND CONSENSUS DEFINITIONS ON NORMAL AND ABNORMAL FINDINGS IN SALIVARY GLANDS IN SJÖGREN’S SYNDROME: RESULTS OF AN OMERACT DELPHI PROCESS.
   AbstractMok Chi Chiu (Hong Kong)FRI0257URINARY ANGIOSTATIN, CXCL4 AND VCAM-1 AS BIOMARKERS FOR LUPUS NEPHRITIS
   AbstractWang Qian (China)FRI0258LONG-TERM PROGNOSISOFPATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: CSTAR-PAH COHORT STUDY
   AbstractMonov Simeon (Bulgaria)FRI0259LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) IN PATIENTS WITH LUPUS NEPHRITIS (LN)
   AbstractFerro Francesco (Italy)FRI0260ULTRASOUND STUDY OF PLEURAL PROFILE AND CHEST HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT): DIAGNOSTIC ROLE IN PRIMARY SJÖGREN'S SYNDROME-INDUCED LUNG INVOLVEMENT
   AbstractTaraborelli Mara (Italy)FRI0261SKIN CANCER IN A COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractPark Eun-Kyoung (Korea, Republic Of)FRI0262CLINICAL, LABORATORY AND IMMUNOLOGICAL CHARACTERISTICS OF 413 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN SOUTH KOREA: A MULTICENTER RETROSPECTIVE COHORT STUDY
   AbstractQuartuccio Luca (Italy)FRI0263SYSTEMIC DISEASE ACTIVITY PROGRESSION IN A LARGE COHORT OF PRIMARY SJÖGREN’S SYNDROME: A LONG-TERM FOLLOW-UP DATA BASED ON THE ESSDAI SCORE
   AbstractMerayo-Chalico Javier (Mexico)FRI0264EPIDEMIOLOGIC PROFILE OF ERECTILE DYSFUNCTION IN SLE: A MULTI-CENTER STUDY IN LATIN AMERICAN PATIENTS
   AbstractPettersson Susanne (Sweden)FRI0265CYTOKINES AND CORRELATIONS WITH PATIENT REPORTED OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND POPULATION CONTROLS
  
Poster Tour: Osteoporosis risk assessment and treatment: new tools and new strategies
   ChairTam Lai-Shan (China, People's Republic of)  
   ChairWong Priscilla (China, People's Republic of)  
   AbstractCheng Tsz Ho (Hong Kong)FRI0524CAROTID ATHEROSCLEROSIS IS ASSOCIATED WITH COMPROMISED VOLUMETRIC BONE MINERAL DENSITY AND MICROSTRUCTURES IN PATIENTS WITH INFLAMMATORY ARTHRITIS
   AbstractBuehring Bjoern (Germany)FRI0525ASSOCIATION OF DYSMOBILITY SYNDROME WITH FRACTURE RISK IN THE MROS COHORT
   AbstractChen Ying-Chou (Taiwan, Province of China)FRI0526ANTI-OSTEOPOROTIC THERAPY DECREASE CANCER RISK IN PATIENTS WITH OSTEOPOROTIC VERTEBRAL FRACTURES
   AbstractZaia Annamaria (Italy)FRI0527LACUNARITY OF TRABECULAR BONE MICROARCHITECTURE, TBLΒ, AS A PREDICTOR OF BONE FRAGILITY FRACTURE AND POTENTIAL INDEX OF OSTEOPOROSIS TREATMENT EFFICACY. THE LOTO STUDY.
   AbstractBuehring Bjoern (Germany)FRI0528SUCCESSFUL IMPLEMENTATION OF A PHARMACIST-LED FRACTURE LIAISON SERVICE AT A US VETERAN AFFAIRS (VA) HOSPITAL
   AbstractGifre Laia (Spain)FRI0529ANALYSIS OF THE EVOLUTION OF CORTICAL AND TRABECULAR BONE COMPARTMENTS IN THE PROXIMAL FEMUR AFTER SPINAL CORD INJURY BY 3D-DXA.
   AbstractNaranjo Antonio (Spain)FRI0530EFECTIVENESS OF AN ORTHOGERIATRIC FRACTURE LIAISON SERVICE COMPARED WITH STANDARD CARE
   AbstractSuarez-Almazor Maria (United States)FRI0531DUAL ENERGY X-RAY ABSORPTIOMETRY TESTING IN ELDERLY MEN WITH PROSTATE CANCER INITIATING ANDROGEN DEPRIVATION THERAPY REDUCES SUBSEQUENT FRACTURE RISK
   AbstractUrsani Mohammad (United States)FRI0532DUAL ENERGY X-RAY ABSORPTIOMETRY TESTING IN WOMEN WITH BREAST CANCER INITIATING THERAPY WITH AROMATASE INHIBITORS REDUCES SUBSEQUENT FRACTURE RISK
   AbstractChoi Sang Tae (Korea, Republic Of)FRI0533INCIDENCE AND RISK FACTORS OF OSTEOPOROTIC FRACTURE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A MULTICENTER COMPARATIVE STUDY OF THE FRAX CRITERIA AND WHO CRITERIA
  
Poster Tour: Outcome in AxSpA: does it matter?
   ChairRamiro Sofia (Netherlands)  
   ChairSepriano Alexandre (Portugal)  
   AbstractMoltó Anna (France)FRI0472EXTRA-RHEUMATOLOGICAL FEATURES ARE FREQUENTLY ASSOCIATED WITH PERIPHERAL RHEUMATOLOGICAL FEATURES IN AXIAL SPONDYLOARTHRITIS AND INFLUENCE THE CHOICE OF THE ANTI-TNF IN DAILY PRACTICE. AN ANALYSIS OF 519 PATIENTS.
   AbstractDesthieux Carole (France)FRI0473PATIENT-PHYSICIAN DISCORDANCE IN GLOBAL ASSESSMENT IN 401 EARLY AXIAL SPONDYLOARTHRITIS (AXSPA) PATIENTS FROM THE DESIR COHORT: WHAT IS THE EFFECT ON OUTCOMES AT 3 YEARS?
   AbstractBaraliakos Xenofon (Germany)FRI0474DOES AXIAL SPONDYLOARTHRITIS PHENOTYPE CORRELATE WITH IMAGING MORPHOTYPE?
   Abstractde Winter Janneke (Netherlands)FRI0475ANTI-CD74 ANTIBODIES AS DIAGNOSTIC BIOMARKER FOR EARLY AXIAL SPONDYLOARTHRITIS: DATA FROM THE SPONDYLOARTHRITIS CAUGHT EARLY (SPACE) COHORT STUDY
   AbstractZiade Nelly (Lebanon)FRI0476ANTI-CD74 ANTIBODIES: DIAGNOSTIC PROPERTIES IN LOW HLA-B27 EARLY AXIAL SPONDYLOARTHRITIS
   AbstractChimenti Maria Sole (Italy)FRI0477PROSPECTIVE OBSERVATIONAL STUDY ON THE EVALUATION OF QUALITY OF LIFE IN PATIENTS AFFECTED BY ENTEROPATHIC SPONDYLOARTHRITIS
   AbstractMaksymowych Walter (Canada)FRI0478SUBCHONDRAL BONE SCLEROSIS ON COMPUTED TOMOGRAPHY – DOES IT HAVE ANY VALUE IN THE DIAGNOSIS OF INFLAMMATORY SACROILIITIS OR IS IT A NON-SPECIFIC FINDING?
   AbstractCoates Laura (United Kingdom)FRI0479PREDICTORS OF LONG-TERM MODIFIED MINIMAL DISEASE ACTIVITY RESPONSE IN PERIPHERAL SPONDYLOARTHRITIS PATIENTS TREATED WITH ADALIMUMAB
   Abstractvan der Heijde Désirée (Netherlands)FRI0480SCORING SYNDESMOPHYTES ON CT SPINE IMAGES OF PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS FROM THE SENSITIVE IMAGING OF AXIAL SPONDYLOARTHRITIS (SIAS) COHORT
   AbstractMadsen Ole Rintek (Denmark)FRI0481INTERPLAY BETWEEN PATIENT GLOBAL ASSESSMENT, PAIN AND FATIGUE AND INFLUENCE OF OTHER CLINICAL DISEASE ACTIVITY MEASURES IN PATIENTS WITH ACTIVE SPONDYLOARTHRITIS
  
Poster Tour: RA all over the body
   ChairSzekanecz Zoltán (Hungary)  
   ChairSzentpetery Agnes (Sweden)  
   AbstractSuissa Samy (Canada)FRI0129COMPARATIVE SAFETY OF BIOLOGIC DMARD INITIATION IN RA: A POPULATION-BASED OBSERVATIONAL STUDY OF MALIGNANCY RISK
   AbstractStrangfeld Anja (Germany)FRI0130RATES AND RISK FACTORS OF NEW-ONSET PSORIASIS UNDER DIFFERENT BIOLOGIC AGENTS AND CONVENTIONAL SYNTHETIC DMARD TREATMENT
   AbstractBoeters Debbie (Netherlands)FRI0131THE 2010 ACR/EULAR CRITERIA ARE INSUFFICIENTLY ACCURATE IN THE EARLY IDENTIFICATION OF AUTOANTIBODY-NEGATIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE LEIDEN-EAC AND ESPOIR COHORTS
   AbstractKuriya Bindee (Canada)FRI0132HIGH DISEASE ACTIVITY IS A PREDICTOR OF DEPRESSION AND PERSISTENT DEPRESSION IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI)
   AbstractGanguly Rita (United States)FRI0133IS THERE INCREMENTAL MENTAL HEALTH BURDEN ASSOCIATED WITH RHEUMATOID ARTHRITIS?
   AbstractTanaka Ayae (Japan)FRI0134CLUSTER ANALYSIS OF PULMONARY LESIONS IN RHEUMATOID ARTHRITIS(RA); AIRWAY DISEASE IS SHARED AND CRITICAL PULMONARY ABNORMALITY IN RA
   AbstractTorikai Eiji (Japan)FRI0135TREATMENT OF JAPANESE EARLY RHEUMATOID ARTHRITIS PATIENTS WITH LOW-DOSE PREDNISOLONE FOR MAXIMUM 1 YEAR LEADS TO EARLIER IMPROVEMENT OF DISEASE ACTIVITY AND DOES NOT WORSEN BONE METABOLISM STATUS AND RATES OF NEW COMPLICATIONS
   AbstractBrouwer Jenny (Netherlands)FRI0136OVARIAN RESERVE, AS ASSESSED BY MEASURING SERUM ANTI-MÜLLERIAN HORMONE LEVELS, DECLINES MORE RAPIDLY OVER TIME IN RHEUMATOID ARTHRITIS PATIENTS COMPARED TO CONTROLS
   AbstractEmamifar Amir (Denmark)FRI0137PRESENCE OF THYROID DISEASE IN RHEUMATOID ARTHRITIS PATIENTS IS PREDICTOR OF WORSE INITIAL TREATMENT RESPONSE: AN OBSERVATIONAL, COHORT STUDY.
   AbstractDuarte Ana Catarina (Portugal)FRI0138LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS – A PORTUGUESE REALITY
  
Poster Tour: RA stromal cells - reloaded
   ChairMüller-Ladner Ulf (Germany)  
   ChairRichez Christophe (France)  
   AbstractTakahashi Soshi (Japan)FRI0022GLUTAMINE METABOLISM PLAYS A KEY ROLE IN THE CELL GROWTH OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS
   AbstractDai Lie (China)FRI0023ARTESUNATE CAN INHIBIT MIGRATION AND INVASION OF FIBROBLAST-LIKE SYNOVIOCYTES VIA SUPPRESSION OF MATRIX METALLOPROTEINASE 9 IN RHEUMATOID ARTHRITIS PATIENTS
   AbstractSaferding Victoria (Austria)FRI0024MICRORNA-146A CONTROLS LOCAL BONE DESTRUCTION BY REGULATING FIBROBLAST INDUCED OSTEOCLASTOGENESIS IN INFLAMMATORY ARTHRITIS
   AbstractWaterborg Claire (Netherlands)FRI0025THE TAM RECEPTORS AXL AND MER PLAY A PROTECTIVE ROLE IN A TEMPORAL AND SPATIAL MANNER IN INFLAMMATORY ARTHRITIS
   AbstractKurowska Weronika (Poland)FRI0026IDENTIFICATION OF MICRORNAS CANDIDATES SPECIFICALLY EXPRESSED IN MONOCYTES OF UNDIFFERENTIATED ARTHRITIS PATIENTS WHO PROGRESSED TO RHEUMATOID ARTHRITIS.
   AbstractBarbati Cristiana (Italy)FRI0027TNF EXPRESSION ON MICROPARTICLES FROM RHEUMATOID ARTHRITIS PATIENTS MEDIATES ENDOTHELIAL CELL FATE IN VITRO
   AbstractVomero Marta (Italy)FRI0028IN VITRO INHIBITORY EFFECT OF ETANERCEPT ON AUTOPHAGY: A NEW MECHANISM OF ACTION OF TNF INHIBITORS IN RHEUMATOID ARTHRITIS
   AbstractDe Wilde Katelijne (Belgium)FRI0029THE OXYGEN SENSOR PHD1 IS AN INDISPENSABLE REGULATOR OF ARTHRITIS DEVELOPMENT
   AbstractRivellese Felice (United Kingdom)FRI0030SYNOVIAL MAST CELLS IDENTIFY PATIENTS WITH A SEVERE PHENOTYPE IN A COHORT OF DMARD NAÏVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
   AbstractKawabe Akio (Japan)FRI0031DNA OXIDASE ENZYME TET3 EXACERBATES SYNOVIAL INFLAMMATION AND BONE DESTRUCTION
  
Poster Tour: Risk factors for RMDs or comorbid conditions
   ChairFinckh Axel (Switzerland)  
   ChairNikiphorou Elena (United Kingdom)  
   AbstractOvalles-Bonilla Juan (Spain)FRI0683CAUSES OF DEATH IN 350 PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES (SARD)
   AbstractWiddifield Jessica (Canada)FRI0684EARLY TREATMENT WITH METHOTREXATE IMPROVES ALL-CAUSE AND CARDIOVASCULAR SURVIVAL AMONG AN INCEPTION COHORT OF SENIORS WITH RHEUMATOID ARTHRITIS
   AbstractEun Yeong Hee (Korea, Republic Of)FRI0685THE PRESENCE OF RHEUMATOID FACTOR IS ASSOCIATED WITH LOWER BONE MASS IN KOREAN HEALTH SCREENING MALE SUBJECTS WITHOUT CLINICALLY APPARENT ARTHRITIS
   AbstractJakobsson Karin (Sweden)FRI0686NEGATIVE ASSOCIATIONS FOR FASTING BLOOD GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS WITH THE DEVELOPMENT OF GIANT CELL ARTERITIS
   AbstractJakobsson Karin (Sweden)FRI0687BODY MASS INDEX, SMOKING, SOCIOECONOMIC STATUS AND THE RISK OF GIANT CELL ARTERITIS
   AbstractMayr Michael (Austria)FRI0688PRERA (PREDICTING RHEUMATOID ARTHRITIS): PRELIMINARY FINDINGS FROM AN ON-GOING PROSPECTIVE STUDY OF SEROPOSITIVE AND SERONEGATIVE INDIVIDUALS AND THEIR RISK FOR DEVELOPING RA
   AbstractStojanovich Ljudmila (Serbia)FRI0689LIPID PEROXIDATION AS RISK FACTOR FOR ENDOTHELIAL DYSFUNCTION IN ANTIPHOSPHOLIPID SYNDROME (APS) PATIENTS
   AbstractAbdul Sultan Alyshah (United Kingdom)FRI0690RISK OF FRACTURE AMONG PATIENTS WITH GOUT: A POPULATION-BASED COHORT STUDY
   AbstractChen Hsin-Hua (Taiwan, Province of China)FRI0691ASSOCIATION BETWEEN PERIODONTITIS AND THE RISK OF PALINDROMIC RHEUMATISM: A NATIONWIDE, POPULATION-BASED, CASE-CONTROL STUDY
   AbstractSingh Jasvinder (United States)FRI0692ALLOPURINOL AND THE RISK OF VENTRICULAR ARRHYTHMIAS IN THE ELDERLY: A STUDY USING U.S. MEDICARE DATA
  
Poster Tour: Scleroderma and myositis: etiology
   ChairRiemekasten Gabriela (Germany)  
   ChairHumrich Jens (Germany)  
   AbstractDe Santis Maria (Italy)FRI0353SERUM PROTEOMICS PROFILE IN SYSTEMIC SCLEROSIS PATIENTS
   AbstractSakata Komei (Japan)FRI0354CIRCULATING MICROPARTICLE SUBSETS ARE ASSOCIATED WITH PATIENTS WITH EXTENDED FIBROTIC PHENOTYPE IN SYSTEMIC SCLEROSIS
   AbstractVettori Serena (Italy)FRI0355IL-17A UP-REGULATION IN PERIPHERAL BLOOD MONONUCLEAR CELLS CO-CULTURED WITH AUTOLOGOUS SKIN FIBROBLASTS IS ASSOCIATED WITH DOWN-REGULATION OF PRO-FIBROTIC MEDIATORS AND INCREASED FIBROBLAST APOPTOSIS
   AbstractKurreeman Fina (Netherlands)FRI0356ANTISENSE LONG NONCODING RNAS ARE DEREGULATED IN SKIN TISSUE OF SSC PATIENTS.
   AbstractManfredi Angelo (Italy)FRI0357MICROPARTICLES AS A BIOMARKER AND A REDOX-DEPENDENT REGULATOR OF NEUTROPHIL ACTIVATION AND PROTEOLYTIC ACTIVITY IN PATIENTS WITH SYSTEMIC SCLEROSIS
   AbstractGuo Li (China)FRI035899MTC-RHANNEXIN V-128 AS A NOVEL EARLY DIAGNOSTIC MARKER FOR INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS
   AbstractKarpec Diana (Lithuania)FRI0359THE IMPACT OF NARROWBAND ULTRAVIOLET A1 ON PROLIFERATION AND APOPTOSIS MARKERS IN ANIMAL MODEL OF SCLERODERMA
   AbstractPerez-Sanchez Carlos (Spain)FRI0360ANALYSIS OF ENDOCANNABINOID SYSTEM ELEMENTS AND RELATED INFLAMMATORY MOLECULES IN PERIPHERAL BLOOD LEUKOCYTES OF PATIENTS WITH SYSTEMIC SCLEROSIS
   AbstractAkiyama Mitsuhiro (Japan)FRI0361INTERLEUKIN-4 INDUCES CLASS-SWITCHING TO IGG4 AND SYNERGISTICALLY CONTRIBUTES TO PLASMABLASTS DIFFERENTIATION WITH INTERLEUKIN-21 THROUGH CD40 DEPENDENT MANNER IN IGG4-RELATED DISEASE
   AbstractManetti Mirko (Italy)FRI0362ANGIOGENIC T CELL EXPANSION CORRELATES WITH SEVERITY OF PERIPHERAL VASCULAR DAMAGE IN SYSTEMIC SCLEROSIS
  
Poster Tour: TNF inhibitors in RA = always and again
   ChairMariette Xavier (France)  
   Chairvan der Woude Diane (Netherlands)  
   AbstractClowse Megan (United States)FRI0179MINIMAL TO NO TRANSFER OF CERTOLIZUMAB PEGOL INTO BREAST MILK: RESULTS FROM CRADLE, A PROSPECTIVE, POSTMARKETING, MULTICENTER, PHARMACOKINETIC STUDY
   AbstractBitoun Samuel (France)FRI0180MULTIPLE SCLEROSIS RISK-ALLELES STUDY IN PATIENTS WITH DEMYELINATING SIDE EFFECTS ON ANTI TNF ALPHA THERAPY.
   AbstractGhang Byeongzu (Korea, Republic Of)FRI0181TAPERING OR CESSATION OF ANTIVIRAL AGENT IN HEPATITIS B VIRUS-INFECTED PATIENTS CONCOMITANTLY TREATED WITH BIOLOGIC AGENTS
   AbstractGoll Guro (Norway)FRI0182DISEASE WORSENING AND SAFETY IN PATIENTS SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN THE NOR-SWITCH STUDY: EXPLORATIVE ANALYSIS OF RA PATIENTS
   AbstractVogelzang Erik (Netherlands)FRI0183ASSESSING ADHERENCE OF RA PATIENTS TREATED WITH ETANERCEPT USING ETANERCEPT SERUM TROUGH CONCENTRATIONS AND PATIENT SELF-REPORT
   AbstractRaya E. (Spain)FRI0184THE PROFILES OF PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO THEIR BELIEFS IN THEIR BIOLOGICAL DRUGS. ARCO STUDY
   AbstractGavan Sean (United Kingdom)FRI0185A SYSTEMATIC REVIEW AND BIVARIATE META-ANALYSIS OF STUDIES THAT MEASURED ADALIMUMAB DRUG LEVELS BY ELISA TO DETECT TREATMENT RESPONSE IN RHEUMATOID ARTHRITIS
   AbstractBogas Patricia (Spain)FRI0186INFLUENCE OF IMMUNOGENICITY TO THE FIRST TNF-I THERAPY ON RESPONSE TO THE SECOND BIOLOGIC AGENT IN RA PATIENTS
   AbstractSmolen Josef S. (Austria)FRI0187RADIOGRAPHIC PROGRESSION BY DISEASE ACTIVITY STATES IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SB2 OR REFERENCE INFLIXIMAB
   AbstractPappas Dimitrios (United States)FRI0188EFFECTIVENESS OF ADALIMUMAB COMBINATION THERAPY WITH METHOTREXATE AND NON-METHOTREXATE CSDMARDS: RESULTS FROM THE CORRONA RHEUMATOID ARTHRITIS REGISTRY
   AbstractCohen Stanley (United States)FRI0189SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND HUMIRA® REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE®-RA)
   AbstractGlintborg Bente (Denmark)FRI0190CLINICAL OUTCOMES FROM A NATIONWIDE NON-MEDICAL SWITCH FROM ORIGINATOR TO BIOSIMILAR ETANERCEPT IN PATIENTS WITH INFLAMMATORY ARTHRITIS AFTER 5 MONTHS FOLLOW-UP. RESULTS FROM THE DANBIO REGISTRY
  
Poster Tour: Trends in non-TNF alpha biologicals for RA I
   ChairBijlsma Johannes W.J. (Netherlands)  
   ChairTeitsma Xavier M. (Netherlands)  
   AbstractSilvagni Ettore (Italy)FRI0212COMPARATIVE EFFECTIVENESS OF FIRST-LINE BIOLOGIC MONOTHERAPY IN RHEUMATOID ARTHRITIS
   AbstractFrisell Thomas (Sweden)FRI0213COMPARATIVE EFFECTIVENESS OF ABATACEPT, RITUXIMAB, TOCILIZUMAB AND ANTI-TNF BIOLOGICAL DMARDS IN RA: RESULTS FROM THE NATIONWIDE SWEDISH REGISTER
   AbstractTanaka Yoshiya (Japan)FRI0214LONG-TERM EFFICACY AND SAFETY OF SIRUKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TUMOR NECROSIS FACTOR THERAPY: RESULTS OF THE RANDOMIZED, PHASE 3 SIRROUND-T STUDY
   AbstractFavalli Ennio Giulio (Italy)FRI0215COMPARATIVE EFFICACY AND RETENTION RATE OF TOCILIZUMAB AND TNF INHIBITORS USED IN COMBINATION WITH METHOTREXATE AS FIRST-LINE BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS: DATA FROM A MULTICENTRE OBSERVATIONAL REGISTRY
   AbstractBurmester Gerd (Germany)FRI0216RESULTS OF A LONGITUDINAL REVIEW OF PULMONARY FUNCTION AND SAFETY DATA IN A PHASE IIB CLINICAL PROGRAMME TESTING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM–CSF) RECEPTOR ANTAGONIST MAVRILIMUMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS (RA)
   AbstractKöhm Michaela (Germany)FRI0217IMPACT OF RITUXIMAB IN COMBINATION WITH LEFLUNOMIDE AND RITUXIMAB RETREATMENT WITH TWO DIFFERENT DOSAGES ON PATIENT-REPORTED OUTCOMES: RESULTS FROM A MULTICENTER RANDOMIZED PLACEBO CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL IN ACTIVE RHEUMATOID ARTHRITIS (AMARA-STUDY)
   AbstractOryoji Kensuke (Japan)FRI0218SHARED EPITOPE POSITIVITY IS RELATED TO EFFICACY OF ABATACEPT IN RHEUMATOID ARTHRITIS.
   AbstractHuizinga TWJ (Netherlands)FRI0219ASSOCIATION BETWEEN CONVERSION TO ACPA/RF SERONEGATIVE STATUS AND CLINICAL OUTCOMES FOLLOWING TREATMENT WITH ABATACEPT IN COMBINATION WITH METHOTREXATE COMPARED WITH METHOTREXATE ALONE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS AND POOR PROGNOSTIC INDICATORS
   AbstractKafaja Suzanne (United States)FRI0220ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (MPCS): A NOVEL APPROACH TO TREATING BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS
   AbstractCourvoisier Delphine (Switzerland)FRI0221DOES SEROPOSITIVITY INFLUENCE DIFFERENTIALLY DRUG DISCONTINUATION OF BIOLOGIC ANTIRHEUMATIC AGENTS WITH NON-ANTI-TNF MODE OF ACTION?
   AbstractKremer Joel (United States)FRI0222SUSTAINED RESPONSE FOLLOWING DISCONTINUATION OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOCILIZUMAB: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL (COMP-ACT)
   AbstractYoo Dae Hyun (Korea, Republic Of)FRI0178RITUXIMAB IS EFFECTIVE IN THE TREATMENT OF RHEUMATOID ARTHRITIS REGARDLESS OF BODY MASS INDEX
  
Poster Tour: Vasculities Clinical Aspects II
   ChairMolloy Eamonn S. (Ireland)  
   ChairSoriano Alessandra (Italy)  
   AbstractAl-Soudi Aram (Netherlands)FRI0303THE IGG4:IGG RNA RATIO IS A NEW AND PROMISING DISEASE ACTIVITY MARKER IN GRANULOMATOSIS WITH POLYANGIITIS.
   AbstractWang Yiwen (China)FRI0304THE UTILITY OF 18F FDG-PET/CT IN DISTINGUISHING BENIGN FROM MALIGNANT RETROPERITONEAL FIBROSIS
   AbstractIhata Atsushi (Japan)FRI0305RELATIVE FDG ACCUMULATION OF THE AORTIC WALL LESIONS TO AORTIC BLOOD POOL IN 18F-FDG-PET AND PET/CT COULD BE A USEFUL PARAMETER FOR THE PREDICTION OF DISEASE RELAPSE AFTER SUCCESSFUL TREATMEN IN TAKAYASU ARTERITIS
   AbstractSfikakis Petros (Greece)FRI0306LONG TERM DRUG-FREE REMISSION IS FEASIBLE IN SEVERE BEHCET’S DISEASE AFTER CESSATION OF SUCCESSFUL ANTI-TNF TREATMENT: A SINGLE CENTER, RETROSPECTIVE LONGITUDINAL OUTCOME STUDY
   AbstractOzguler Yesim (Turkey)FRI0307AN OUTCOME SURVEY OF 100 PATIENTS WITH CEREBRAL VENOUS SINUS THROMBOSIS DUE TO BEHÇET'S SYNDROME FOLLOWED UP AT A SINGLE, DEDICATED CENTER
   AbstractPadoan Roberto (Italy)FRI0308PREDICTORS OF HYPOGAMMAGLOBULINAEMIA IN RITUXIMAB TREATED PATIENTS. A RETROSPECTIVE ANALYSIS ON A MONOCENTRIC COHORT.
   AbstractHouben Eline (Netherlands)FRI0309CARDIOVASCULAR EVENTS IN ANCA-ASSOCIATED VASCULITIS: A META-ANALYSIS OF OBSERVATIONAL STUDIES
   AbstractBerti Alvise (Italy)FRI0310LONG-TERM MORTALITY AND COMPLICATIONS IN YOUNG AND ELDERLY PATIENTS WITH ANCA-ASSOCIATED VASCULITIS
   AbstractJung Jae Hyun (Korea, Republic Of)FRI0311ENDOVASCULAR INTERVENTION VERSUS SURGERY IN PATIENTS WITH TAKAYASU ARTERITIS: A META-ANALYSIS
   AbstractMonti Sara (Italy)FRI0312THE FREQUENCY AND SEVERITY OF PATIENT-REPORTED SYMPTOMS IN GIANT CELL ARTERITIS
  
Poster Tour: What's new in orphan diseases
   ChairIonescu Ruxandra (Romania)  
   ChairOstojic Predrag (Serbia)  
   AbstractGabay Cem (Switzerland)FRI0582OPEN-LABEL, MULTICENTER, DOSE-ESCALATING PHASE II CLINICAL TRIAL ON THE SAFETY AND EFFICACY OF TADEKINIG ALPHA IN ADULT ONSET STILL’S DISEASE
   AbstractLomborg Niels (Denmark)FRI0583IGG4-RELATED DISEASE AMONG PATIENTS PREVIOUSLY DIAGNOSED WITH IDIOPATHIC RETROPERITONEAL FIBROSIS. A NATIONWIDE DANISH STUDY.
   AbstractMarie Kostine (France)FRI0584RHEUMATIC AND MUSCULOSKELETAL DISORDERS RELATED TO IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS: A PROSPECTIVE SINGLE-INSTITUTION STUDY.
   AbstractJaeger Veronika (Switzerland)FRI0585FREQUENT, UNUSUALLY SEVERE, LONG LASTING, LOCAL AND SYSTEMIC PNEUMOCOCCAL VACCINE REACTIONS IN PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): RESULTS OF A PROSPECTIVE REGISTRY BASED STUDY
   AbstractFabiani Claudia (Italy)FRI0586INTERLEUKIN (IL)-1 INHIBITION WITH ANAKINRA AND CANAKINUMAB IN BEHÇET’S DISEASE RELATED UVEITIS: A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY
   AbstractMizushima Ichiro (Japan)FRI0587DIFFERENT FACTORS ARE RELATED TO RECURRENCE OF EXISTING ORGAN INVOLVEMENT AND NEW DEVELOPMENT OF ORGAN INVOLVEMENT IN IGG4-RELATED DISEASE
   AbstractStone John (United States)FRI0588INTERIM RESULTS OF A PHASE 2 STUDY OF XMAB®5871, A REVERSIBLE B CELL INHIBITOR, IN IGG4-RELATED DISEASE
   AbstractVázquez-Triñanes Caritina (Spain)FRI0589CANCER IS FREQUENT IN PATIENTS WITH ANTICENTROMERE PATTERN
   AbstractAkiyama Mitsuhiro (Japan)FRI0590SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS REFLECT DISEASE ACTIVITY IN IGG4-RELATED DISEASE AND PRIMARY SJÖGREN'S SYNDROME
   AbstractSasaki Takanori (Japan)FRI0591RISK FACTORS FOR DISEASE RELAPSE IN IGG4-RELATED DISEASE FOLLOWING GLUCOCORTICOIDS TREATMENT

Friday 16.06.2017 12:00 - 13:30


 
Poster Tour - Poster Area
  
PARE Poster Tour II
   ChairWiek Dieter (Germany)  
   ChairCaeyers Nele (Belgium)  
   AbstractEgert Tsipora (Israel)PARE0012EDUCATING YOUNG CHILDREN, PARENTS AND DOCTORS THROUGH THE MEDIUM OF AN ILLUSTRATED CHILDREN’S BOOK
   AbstractJacklin Clare (United Kingdom)PARE0013BEHIND THE SMILE - RA AWARENESS VIDEOS - RAISING AWARENESS OF THE HIDDEN IMPACT OF RHEUMATOID ARTHRITIS
   AbstractOlsder Wendy (Ireland)PARE0015THE IMPORTANCE OF FACE-TO-FACE NETWORKS: FINDINGS FROM THE 2ND EULAR YOUNG PARE CONFERENCE, ‘CHANGE THE FUTURE’
   AbstractViora Ugo Giuseppe (Italy)PARE0016KEEP CALM AND TELL ME YOUR STORY!: A NARRATIVE MEDICINE PILOT PROJECT FOR ITALIAN YOUNG PEOPLE LIVING WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES
   AbstractVergés Josep (Spain)PARE0017EMPOWERING PATIENTS WITH OSTEOARTHRITIS WITH NON-PHARMACOLOGICAL MEASURES
   AbstractBankova Hristina (Bulgaria)PARE0018WE DO THE IMPOSSIBLE, BECAUSE THE POSSIBLE EVERYONE CAN DO WAD AWARENESS CAMPAIGN
   AbstractViora Ugo (Italy)PARE0019ADHERENCE TO THERAPY: A COMPARISON BETWEEN THREE PATIENTS POPULATIONS WITH AUTOIMMUNE INFLAMMATORY DISEASES
   AbstractGarrido-Castro Juan (Spain)PARE002025 YEARS OF PATIENTS’ ASSOCIATIONS OF ANKYLOSING SPONDYLITIS IN SPAIN: ACEADE
   AbstractMacdonald Christopher (United Kingdom)PARE0021PUBLIC AND PATIENT INVOLVEMENT AT ARTHRITIS RESEARCH UK: ENSURING BENEFIT FOR ALL
   AbstractVan Der Giesen Florus (Netherlands)PARE0022ORGANIZATION OF GROUP EXERCISE THERAPY (GET) FOR PATIENTS WITH AXIAL SPONDYLOARTRITIS (AXSPA) IN THE NETHERLANDS; A NATIONWIDE SURVEY

Friday 16.06.2017 13:30 - 15:00


 
WIN & HOT Session - Hall 6
  
WIN & HOT Session
   ChairBlanco Francisco J. (Spain)  
   ChairSivera Francisca (Spain)  
   SpeakerKloppenburg Margreet (Netherlands) WIN Session: Osteoarthritis
   SpeakerSo Alexander (Switzerland) HOT Session: Gout and other crystal induced arthritis treatment

 
Clinical Science Session - Hall 8
  
Co-morbidities in rheumatoid arthritis
   ChairDougados Maxime (France)  
   ChairStrangfeld Anja (Germany)  
   SpeakerCalabrese Leonard (United States)SP0108Herpes zoster: how to prevent, to diagnose and to treat
   SpeakerWells Athol (United Kingdom) Intersticial lung disease in RA and its treatment: where are we ?
   SpeakerMariette Xavier (France) Lymphomas in RA and its treatment: Where are we?
   AbstractNocturne Gaetane (France)OP0307TREATMENT OF BAFF TRANSGENIC MICE WITH ANTI-TNF: MONOCLONAL ANTI-TNF ARE ASSOCIATED WITH A HIGHER RISK OF LYMPHOMA THAN ETANERCEPT
   AbstractRaaschou Pauline (Sweden)OP0308TNF INHIBITOR TREATMENT AND RISK OF CANCER RECURRENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NATIONWIDE COHORT STUDY FROM SWEDEN

 
Challenges in Clinical Practice Session - Hall 7A
  
Life-threatening presentation of rheumatic diseases
   ChairRiemekasten Gabriela (Germany)  
   ChairAnton Jordi (Spain)  
   PresenterBirolo Carolina (Italy)SP0109Case 1 presentation: Pediatric difficult case presentation
   DiscussantWouters Carine (Belgium) Case 1 discussion: Life-threatening presentation of pediatric rheumatic diseases: an overview
   PresenterSiegert Elise (Germany) Case 2 presentation: Adult difficult case presentation
   DiscussantCid Maria C (Spain)SP0110Case 2 discussion: Life-threatening presentation of adult rheumatic diseases: an overview

 
From Bench to Bedside - Hall 7B
  
AxSpA: From bug to gut and to disease phenotype
   ChairVereecke Lars (Belgium)  
   ChairKiltz Uta (Germany)  
   SpeakerScher Jose U. (United States) How microbiota shape the inflammatory response
   SpeakerElewaut Dirk (Belgium) The gut and SpA: implication for disease phenotype
   SpeakerSchett Georg (Germany) What drives new bone formation in axSp? Progress from basic research
   SpeakerLandewé Robert B.M. (Netherlands)SP0111Inhibiting bone formation in axSpA in the clinic: are we there yet?
   AbstractCiccia Francesco (Italy)OP0309INTESTINAL SCLEROSTIN/SEROTONIN AXIS IS MODULATED BY DYSBIOSIS AND REGULATES ILC3 EXPANSION IN AS PATIENTS

 
Clinical Science Session - N103 / N104
  
Pregnancy meets Rheumatic Patients
   ChairBoumpas Dimitrios (Greece)  
   ChairTincani Angela (Italy)  
   SpeakerØstensen Monika (Norway)SP0112Which drugs in pregnant patients?
   SpeakerFischer-Betz Rebecca (Germany)SP0113Pregnancy in SLE: still challenging fetal and maternal issues
   SpeakerAndreoli Laura (Italy)SP0114Children of patients with rheumatic diseases: disease and treatment related problems
   AbstractBlomjous Birgit (Netherlands)OP0310PREGNANCY OUTCOME IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS, A MULTICENTER COHORT-STUDY
   AbstractLisney Anna (Germany)OP0311HIGH MATERNAL EXPRESSION OF SIGLEC1 ON CD14+ MONOCYTES AS A SURROGATE MARKER OF A TYPE I INTERFERON SIGNATURE IS A RISK FACTOR FOR THE DEVELOPMENT OF AUTOIMMUNE CONGENITAL HEART BLOCK

 
Basic and Translational Science Session - South Auditorium
  
Neuronal and hormonal alterations in arthritis
   ChairNeumann Elena (Germany)  
   ChairCapellino Silvia (Germany)  
   SpeakerStraub Rainer H. (Germany)SP0115Neurotransmitters and innervation in synovium
   Speakerda Silva José Antonio P. (Portugal) Neutrotransmitters and hormones as modulators in bone
   SpeakerCutolo Maurizio (Italy)SP0116How to target neuronal and hormonal alterations in arthritis
   AbstractOmdal Roald (Norway)OP0312A PROTEOMIC SIGNATURE OF FATIGUE IN PRIMARY SJÖGREN’S SYNDROME
   AbstractWelle Stefanie (Germany)OP0313P75 LOW AFFINITY RECEPTOR OF NERVE GROWTH FACTOR ON PERIPHERAL LEUKOCYTES AND CD11C-POSITIVE DENDRITIC CELLS ARE UPREGULATED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

 
Health Professionals Session - N101 / N102
  
Fighting osteoporosis fragilities
   ChairFerreira Ricardo (Portugal)  
   ChairAdams Jo (United Kingdom)  
   SpeakerKanis John (United Kingdom)SP0117Osteoporotic fractures in Europe: are we doing enough?
   SpeakerStephenson Sonya M. (United Kingdom)SP0118Establishing and implementing fracture liaison services
   SpeakerMarques Andrea (Portugal)SP0119Predicting fracture risk: accuracy and feasibility of tools
   SpeakerRose Debra J. (United States)SP0120Predicting the risk of falls and promoting balance in older adults
   AbstractNiedermann Karin (Switzerland)OP0314-HPRA HOME-BASED FALL PREVENTION PROGRAMME REDUCES FEAR OF FALLING IN SENIORS

 
Paediatric Rheumatology Session - N105 / N106
  
Biological agents in juvenile idiopathic arthritis: open issues
   Chairvan Rossum Marion (Netherlands)  
   ChairFoell Dirk (Germany)  
   SpeakerSwart Joost F. (Netherlands)SP0121Long term side effects of biological agents in JIA
   SpeakerQuartier Pierre (France)SP0122Autoimmune phenomena associated with biological agents
   SpeakerHorneff Gerd (Germany) When and How to discontinue biological agents in JIA
   AbstractMourão Ana (Portugal)OP0315REASONS FOR DISCONTINUATION OF BIOLOGICAL AGENTS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM THE PORTUGUESE REGISTER, REUMA.PT.
   AbstractAlexeeva Ekaterina (Russian Federation)OP0316DURATION OF CLINICAL REMISSION AND FLARE RATES IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS AFTER WITHDRAWAL OF BIOLOGICAL TREATMENT (PRELIMINARY DATA)

 
Practical Skills Session - N111 / N112
  
Data visualisation: tables and graphs for publication and presentation II
   SpeakerBoers Maarten (Netherlands)SP0091Data visualisation: tables and graphs for publication and presentation

 
PARE Session - N115 / N116
  
Health equity and economy – a vital relationship
   ChairPchelnikova Polina (Russian Federation)  
   ChairMateus Elsa (Portugal)  
   SpeakerBetteridge Neil (United Kingdom) Mind the gap! EULAR: campaigning for equity in Europe
   SpeakerPutrik Polina (Netherlands)SP0123Uncovering the equity gap in rheumatic and musculoskeletal diseases
   SpeakerFautrel Bruno (France)SP0124Health economics and Health equity: two complementary disciplines
   AbstractBosworth Ailsa (United Kingdom)OP0317-PAREAN INDEPENDENT REVIEW OF PEOPLE WITH RHEUMATOID ARTHRITIS (RA) AND THEIR CAREGIVER’S LOST WORK TIME
   AbstractCarreira Roca Francisco Javier (Spain)OP0318-PARECONSULTING SERVICES TO EMPLOYERS OF PEOPLE WITH RMDS.

 
EULAR Projects in Clinical Affairs - N117 / N118
  
Biomarkers in cardiovascular rheumatology – state-of-the-art 2017
   ChairMüller-Ladner Ulf (Germany)  
   ChairKurowska-Stolarska Mariola (United Kingdom)  
   SpeakerChoy Ernest (United Kingdom)SP0125Inflammation and cardiovascular disease – Relevant metabolic biomarkers
   SpeakerCeglarek Uta (Germany) Myths and facts about the lipidome and lipids in inflammatory rheumatic diseases
   SpeakerSzekanecz Zoltán (Hungary)SP0126The vessel wall in IMIDs – new emerging vascular markers
   SpeakerNurmohamed Michael (Netherlands)SP0127Tapering biologics induces a pro-thrombotic state in rheumatoid arthritis
   AbstractSacre Karim (France)OP0319HIGH SENSITIVITY CARDIAC TROPONIN T IS A BIOMARKER FOR ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOUS PATIENTS: A CROSS-SECTIONAL CONTROLLED STUDY

 
Practical Skills Session - N107 / N108
  
MRI I
   ChairOstergaard Mikkel (Denmark)  
   ChairHermann Kay-Geert (Germany)  
   SpeakerEshed Iris (Israel)SP0128MRI of enthesitis – by conventional and wholebody MRI - including patient cases
   SpeakerGlinatsi Daniel (Denmark) Are MRI findings important to the rheumatoid arthritis patient – relation to patient reported outcomes - including patient cases
   SpeakerOstergaard Mikkel (Denmark)SP0129Classification, diagnosis and differential diagnosis of axial spondyloarthritis by MRI - including patient cases
   SpeakerHermann Kay-Geert (Germany) MRI of the sacroiliac joint – lessons learnt from comparisons with CT - including patient cases

 
Practical Skills Session - N109 / N110
  
Ultrasound Basic II
   ChairKortekaas Marion (Netherlands)  
   ChairBruyn George A. W. (Netherlands)  
   SpeakerFilippou Georgios (Italy)SP0037How to assess US elementary lessons in CPPD + demo
   SpeakerMandl Peter (Austria)SP0038How to assess cartilage in RA and pitfalls + demo
   SpeakerIagnocco Annamaria (Italy)SP0039How to evaluate the subtalar joint + demo
   SpeakerMöller Ingrid (Spain) How to scan the hip - new approaches + demo
   TutorMidtboell Oernbjerg Lykke (Denmark)  

Friday 16.06.2017 15:30 - 17:00


 
WIN & HOT Session - Hall 6
  
WIN & HOT Session
   ChairGuanabens Nuria (Spain)  
   ChairBours Sandrine (Netherlands)  
   SpeakerGeusens Piet (Netherlands)SP0130WIN Session: Osteoporosis
   SpeakerJorgensen Christian (France) WIN Session: Regenerative medicine

 
Clinical Science Session - Hall 8
  
What is behind vasculitis?
   ChairFischer-Betz Rebecca (Germany)  
   ChairDougados Maxime (France)  
   SpeakerSzekanecz Zoltán (Hungary)SP0131Autoimmune atherosclerosis
   SpeakerCalabrese Leonard (United States)SP0132Viruses driving vasculitis
   SpeakerLuqmani Raashid (United Kingdom)SP0133ANCA and their environment
   AbstractCornec Divi (United States)OP0320DETERMINANTS OF RITUXIMAB PHARMACOKINETICS AND CLINICAL OUTCOMES IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS
   AbstractPugnet Grégory (France)OP0321RISK OF CORONARY ARTERY DISEASE AND ISCHEMIC STROKE IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS. A FRENCH POPULATION-BASED STUDY

 
Challenges in Clinical Practice Session - Hall 7A
  
Comorbidities in connective tissue diseases
   ChairTektonidou Maria (Greece)  
   ChairGalindo Izquierdo Maria (Spain)  
   PresenterFredi Micaela (Italy) Case 1 presentation: Infections in immunosuppressed patient
   DiscussantCostedoat Nathalie (France) Case 1 discussion: The challenge to prevent and manage simultaneously infections and autoimmunity
   PresenterSpinelli Francesca (Italy) Case 2 presentation: Depression and mood disorders
   DiscussantMosca Marta (Italy) Case 2 discussion: Improving the quality of life: how to recognize and manage the different presentations of mood disorders

 
From Bench to Bedside - Hall 7B
  
Cytokine taxonomy: reflection in the therapy of arthritides and other IMIDs
   Chairvan Vollenhoven Ronald (Netherlands)  
   ChairSzentpetery Agnes (Sweden)  
   SpeakerCrow Mary K. (United States) What are the implication of our understanding of cytokine networks for the managment of diseases such as RA and SLE?
   SpeakerMcInnes Iain (United Kingdom) The exciting cytokine network: differences between RA, SpA and other IMIDs
   SpeakerSchett Georg (Germany) Reflection of the cytokine network in differential efficacy of various biologics in IMIDs
   SpeakerHumrich Jens (Germany)SP0134Interleukin-2 therapy in SLE
   AbstractSato Kojiro (Japan)OP0322A NOVEL HIERARCHICAL RELATIONSHIP BETWEEN INTERLEUKIN-17A AND INTERFERON-ALPHA IS INDICATED BY ANALYSIS OF MULTIPLE CYTOKINES IN THE SERUM OF ADULT-ONSET STILL’S DISEASE AND BEHÇET’S DISEASE

 
Clinical Science Session - N103 / N104
  
Personalised care for back pain
   ChairBergman Stefan (Sweden)  
   ChairSepriano Alexandre (Portugal)  
   SpeakerFoster Nadine E. (United Kingdom) Beyond stratification: whats next for back pain?
   SpeakerAlbert Hanne (Denmark) New therapeutic options for back pain
   SpeakerAl-Kaisy Adnan (United Kingdom) Spinal cord stimulation for the treatment of back pain
   AbstractAHMED YAHIA Salim (France)OP0323DISCOPATHY ASSOCIATED WITH MODIC CHANGES IS NOT RELATED TO ANY INFECTIOUS PROCESS: A PROSPECTIVE MONOCENTRIC STUDY
   AbstractKarateev Andrey (Russian Federation)OP0324MANAGEMENT OF MUSCULOSKELETAL PAIN USING AN ALGORITHM FOR SELECTION OF ANALGESICS

 
Basic and Translational Science Session - South Auditorium
  
Regulatory molecules in connective tissue
   ChairGay Steffen (Switzerland)  
   ChairSenolt Ladislav (Czech Republic)  
   SpeakerPap Thomas (Germany)SP0135Myostatin, sclerostin, syndecan and more...
   SpeakerDenton Christopher (United Kingdom)SP0136Multifactorial tissue growth factors
   SpeakerHerrmann Martin (Germany)SP0137From glycosylation to inflammation
   AbstractKragstrup Tue (Denmark)OP0325TGF-ΒETA-INDUCED ED-A FIBRONECTIN PRODUCTION BY FIBROBLAST-LIKE SYNOVIAL CELLS CONTRIBUTES TO INFLAMMATION IN OSTEOARTHRITIS
   AbstractFrank Bertoncelj Mojca (Switzerland)OP0326EPIGENETICALLY-DRIVEN DISTAL EXPRESSION OF THE LNCRNA HOTTIP SHAPES INFLAMMATORY, ADHESIVE AND PROLIFERATIVE CHARACTERISTICS OF HAND SYNOVIAL FIBROBLASTS IN ARTHRITIS

 
Health Professionals Session - N101 / N102
  
Patient Engagement in Research: Best Practices, Benefits, and Challenges
   ChairSchlenk Elizabeth A. (United States)  
   ChairVliet Vlieland Thea (Netherlands)  
   Speakerde Wit Maarten (Netherlands)SP0138The challenges of patient involvement in scientific research
   SpeakerRedmond Anthony (United Kingdom)SP0139Meaningful patient and public involvement in planning research
   SpeakerPoole Janet L. (United States)SP0140Patient engagement in research: A PCORI exemplar
   AbstractCresswell Katharine (United Kingdom)OP0327-PAREYOUR RHEUM – GIVING YOUNG PEOPLE A VOICE IN RHEUMATOLOGY RESEARCH

 
The Young Rheumatologist - N111 / N112
  
RA treatment in patients wanting to become pregnant - interactive session
   ChairSchreiber Karen (United Kingdom)  
   ChairAlunno Alessia (Italy)  
   PresenterWillemze Annemiek (Netherlands)SP0141Case 1 presentation: New RA, but what about a new baby?
   DiscussantDolhain Radboud (Netherlands) Case 1: interactive discussion
   PresenterNero Patrícia (Portugal)SP0142Case 2 presentation: Foreplay and finale: factors affecting fertility, birth and lactation in RA patients
   DiscussantØstensen Monika (Norway) Case 2: interactive discussion

 
PARE Session - N115 / N116
  
Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of biosimilars in RMDs
   ChairWiek Dieter (Germany)  
   ChairStones Simon (United Kingdom)  
   SpeakerCoates Laura (United Kingdom)SP0143A new day for people with Psoriatic Arthritis: a heterogeneous disease that can be treated well?
   not confimed yet Q&A
   AbstractThomsen Lene Mandrup (Denmark)OP0328-PAREPATIENT SAFETY IN RELATION TO BIOSIMILARS – HOW CAN WE ACT AS A PATIENT ORGANIZATION?
   Speakerden Broeder Alfons (Netherlands)SP0144Biosimilars in rheumatic diseases: society chances versus patient concerns
   Speakernot confimed yet Q&A

 
EULAR Projects in Investigative Rheumatology - N117 / N118
  
From pre-RA to established RA
   ChairMariette Xavier (France)  
   ChairFinckh Axel (Switzerland)  
   SpeakerToes Rene (Netherlands)SP0145Pathophysiologic processes leading to the development of autoimmunity
   Speakervan der Woude Diane (Netherlands)SP0146Can we predict who is going to develop rheumatoid arthritis?
   SpeakerDeane Kevin (United States)SP0147Can we prevent the onset of rheumatoid arthritis in high risk individuals?
   SpeakerLauwerys Bernard (Belgium)SP0148Pathophysiology of established RA synovitis

 
Practical Skills Session - N107 / N108
  
Laboratory course – from the clinic to the lab and back I
   ChairBurmester Gerd Rüdiger (Germany)  
   ChairDörner Thomas (Germany)  
   SpeakerDörner Thomas (Germany) ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder
   SpeakerMiossec Pierre (France) Vasculitis, systemic autoimmunity
   SpeakerFeist Eugen (Germany)SP0149New trends in biomarkers in inflammatory joint diseases

 
Practical Skills Session - N109 / N110
  
Ultrasound Advanced II
   ChairNaredo Esperanza (Spain)  
   ChairFilippou Georgios (Italy)  
   SpeakerOhrndorf Sarah (Germany) How to score synovitis quantitatively - validity and feasibility + demo
   SpeakerAmmitzboll Mads (Denmark) How to use image fusion + demo
   SpeakerBong David (Spain)SP0076How and when to assess cervical facet joints + demo
   SpeakerVojinovic Jelena (Serbia)SP0077How to evaluate joints in JiA + patient cases
   TutorMidtboell Oernbjerg Lykke (Denmark)  

Friday 16.06.2017 17:30 - 19:00


 
Basic and Translational Science Session - South Auditorium
  
Switching ´T on and off: how T cells drive and regulate chronic inflammation
   ChairMalmström Vivianne (Sweden)  
   ChairTaams Leonie (United Kingdom)  
   SpeakerKuchroo Vijay (United States)SP0150How T cells drive and regulate chronic inflammation: a story of mice and men
   SpeakerWraith David C. (United Kingdom)SP0151Learning from other fields: developing peptide immunotherapy for human autoimmune disease
   SpeakerKlareskog Lars (Sweden) Becoming more tolerant: can we induce T cell tolerance in RA?
   AbstractAbdollahi-Roodsaz Shahla (Netherlands)OP0329INVOLVEMENT OF T HELPER 17 CELLS IN INFLAMMATORY ARTHRITIS DEPENDS ON THE HOST INTESTINAL MICROBIOTA
   AbstractRenoux Florian (Switzerland)OP0330FRA2 OVEREXPRESSION LEADS TO SYSTEMIC AUTOIMMUNITY BY DECREASING IL-2 RESPONSIVENESS AND THYMIC TREG DEVELOPMENT.

Saturday 17.06.2017 08:30 - 10:00


 
WIN & HOT Session - Hall 6
  
WIN & HOT Session: The Lancet session - Pathogenesis and treatment of rheumatoid arthritis
   ChairGomez-Reino Carnota Juan Jesus (Spain)  
   ChairCrow Mary K. (United States)  
   ChairSargent Jennifer (United States)  
   SpeakerMcInnes Iain (United Kingdom) WIN Session: Dissecting the pathogenesis of rheumatoid arthritis – what have therapeutics taught us
   SpeakerBurmester Gerd Rüdiger (Germany) WIN Session: Don´t delay – new treatment concepts in rheumatoid arthritis

 
Clinical Science Session - Hall 8
  
Reverse translation - learning from clinical trials in SLE, Sjögren's and APS
   ChairKalden Joachim R. (Germany)  
   Chairde Vita Salvatore (Italy)  
   SpeakerIsenberg David (United Kingdom)SP0152The learnings from SLE trials
   SpeakerSeror Raphaele (France) The learnings from Sjögren trials
   SpeakerRovin Brad (United States) Lesson from Lupus Nephritis
   SpeakerKhamashta Munther (United Kingdom)SP0153Lessons from APS trials
   AbstractChen Bo (United States)OP0331A NOVEL HUMANIZED EFFECTOR-DEFICIENT FCYRIIA ANTIBODY INHIBITS IMMUNE COMPLEX MEDIATED PROINFLAMMATORY RESPONSES

 
Challenges in Clinical Practice Session - Hall 7A
  
Myositis
   ChairDoria Andrea (Italy)  
   ChairVencovsky Jiri (Czech Republic)  
   PresenterSchneider Udo (Germany) Case 1 presentation: Severe autoimmune myositis
   DiscussantCooper Robert (United Kingdom) Case 1 discussion: Management of autoimmune myositis in 2017
   PresenterGatto Mariele (Italy) Case 2 presentation: Severe dermatomyositis with cardiac manifestations
   DiscussantDiederichsen Louise (Denmark) Case 2 discussion: Imaging on cardiac involvement in myositis

 
From Bench to Bedside - Hall 7B
  
Genomic imprinting and post-translational modifiations
   ChairHerrmann Martin (Germany)  
   ChairRadbruch Andreas (Germany)  
   SpeakerChang Hyun-Dong (Germany)SP0154Rationale to target immune memory residing in inflamed tissues
   SpeakerToes Rene (Netherlands)SP0155The role of post-translational modification and autoreactivity
   SpeakerLipsky Peter (United States)SP0156How big data help us to understand new and old therapy targets
   AbstractBertsias George (Greece)OP0332THE GENOMIC ARCHITECTURE OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) BY RNA-SEQ: DISTINCT DISEASE SUSCEPTIBILITY, ACTIVITY AND SEVERITY SIGNATURES AND EXTENSIVE GENETIC EFFECTS ON WHOLE BLOOD GENE EXPRESSION
   AbstractSchulz-Knappe Peter (Germany)OP0333DISCOVERY AND VALIDATION OF NOVEL AUTOANTIGENS IN SJÖGREN’S SYNDROME WITH POTENTIAL FOR SUBGROUPING OF DISEASE

 
Clinical Science Session - N103 / N104
  
Optimizing treatment for osteoarthritis. Take the phenotype in account "one size does not fit all"
   ChairAbishek Abishek (United Kingdom)  
   ChairKroon Féline (Netherlands)  
   SpeakerBerenbaum Francis (France)SP0157Metabolic phenotype: the two faces of obesity in OA
   SpeakerVincent Tonia (United Kingdom) Post-traumatic phenotype: resulting in new insight's in OA pathogenesis
   SpeakerAbishek Abishek (United Kingdom)SP0158Pain phenotype: can we take advantage of the placebo effect
   AbstractPan Feng (Australia)OP0334PREDICTORS AND MRI-DETECTED STRUCTURAL PATHOLOGY WITH TRAJECTORIES OF KNEE PAIN SEVERITY: A 10.7-YEAR PROSPECTIVE STUDY
   AbstractMinten Michiel (Netherlands)OP0335EXPLORING ASSOCIATIONS BETWEEN HISTOLOGICALLY ASSESSED INFLAMMATION AND PAIN AND FATIGUE IN KNEE OSTEOARTHRITIS

 
Basic and Translational Science Session - South Auditorium
  
Targeting adipose tissue inflammation
   ChairIoan-Facsinay Andreea (Netherlands)  
   ChairBokarewa Maria (Sweden)  
   SpeakerBokarewa Maria (Sweden)SP0159Adipose tissue – bystander or therapeutical target?
   SpeakerSchäffler Andreas (Germany)SP0160Is diabetes type 2 an inflammatory disease and should it be treated like that ?
   SpeakerIoan-Facsinay Andreea (Netherlands)SP0161Role of adipose tissue in osteoarthritis
   SpeakerGualillo Oreste (Spain)SP0162Adipokines in the pathophysiology of cartilage
   AbstractArias de la Rosa Ivan (Spain)OP0336ROLE OF SYSTEMIC INFLAMMATION ASSOCIATED WITH RHEUMATOID ARTHRITIS IN THE GLUCOSE AND LIPID METABOLISM: HUMANS, CIA MOUSE MODEL AND IN VITRO STUDIES.

 
Health Professionals Session - N101 / N102
  
Trials and Tribulations of Medication Adherence
   ChairPrior Yeliz (United Kingdom)  
   ChairSverker Annette (Sweden)  
   SpeakerAdams Jo (United Kingdom) Health literacy and its impact on accessing, understanding and using medication information
   SpeakerVriezekolk Joke (Netherlands)SP0163Interventions to improve medication adherence in patients with inflammatory arthritis
   SpeakerKoutsogianni Katerina (Greece)SP0164Barriers and facilitators to adherence to medication in patients with inflammatory arthritis
   SpeakerKumar Kanta (United Kingdom)SP0165Can Musculoskeletal Ultrasound inform health beliefs and play a role for medication adherence?
   AbstractAhluwalia Vandana (Canada)OP0337-HPRPREDICTORS OF PATIENT REPORTED DECISION TO DISCONTINUE ANTI-RHEUMATIC MEDICATION IN RHEUMATOID ARTHRITIS PATIENTS: DATA FROM A RHEUMATOID ARTHRITIS COHORT

 
Paediatric Rheumatology Session - N105 / N106
  
Outcome in juvenile idiopathic arthirtis
   ChairZulian Francesco (Italy)  
   ChairQuartier Pierre (France)  
   Speakervan Rossum Marion (Netherlands) Early predictors of juvenile Idiopathic arthritis outcome
   SpeakerFoell Dirk (Germany) Markers of remission in JIA
   SpeakerFlato Berit (Norway)SP0166Long-term outcome of JIA into adulthood
   AbstractMinden Kirsten (Germany)OP0338FREQUENCY OF COMORBIDITIES IN JIA PATIENTS – RESULTS OF AN OBSERVATIONAL COHORT STUDY

 
Educational Session - N111 / N112
  
Getting financial support to research in RMDs through Horizon 2020: Opportunities, good practices, and successful experiences
   ChairBetteridge Neil (United Kingdom)  
   ChairLories Rik (Belgium)  
   SpeakerHaar Soeren (Belgium) EULAR’s service to the research community
   SpeakerRiese Juan E. (Spain)SP0167Horizon 2020: Characteristics and opportunities for medical research and innovation
   SpeakerJorgensen Christian (France) Successful experiences in applying for Horizon 2020 calls in the RMD scientific community: Dos and Don’ts
   SpeakerMcInnes Iain (United Kingdom) RheuMap: A roadmap for research and innovation in RMDs for the next decade
   Speakernot confimed yet Q&A

 
EULAR Projects in Education and Training - N117 / N118
  
EULAR Projects - Challenging Projects in Education and Training
   ChairIagnocco Annamaria (Italy)  
   ChairDamjanov Nemanja (Serbia)  
   SpeakerBoers Maarten (Netherlands)SP0168Theory of poster design and presentation
   SpeakerBijlsma Johannes W.J. (Netherlands)SP0169The EULAR School of Rheumatology. A challenging Educational EULAR Project. Where are we now?
   SpeakerHaines Catherine (United Kingdom)SP0170Assessing rheumatology skills

 
Practical Skills Session - N107 / N108
  
MRI II
   ChairHermann Kay-Geert (Germany)  
   ChairOstergaard Mikkel (Denmark)  
   SpeakerEshed Iris (Israel)SP0128MRI of enthesitis – by conventional and wholebody MRI - including patient cases
   SpeakerGlinatsi Daniel (Denmark) Are MRI findings important to the rheumatoid arthritis patient – relation to patient reported outcomes - including patient cases
   SpeakerOstergaard Mikkel (Denmark) Classification, diagnosis and differential diagnosis of axial spondyloarthritis by MRI - including patient cases
   SpeakerHermann Kay-Geert (Germany) MRI of the sacroiliac joint – lessons learnt from comparisons with CT - including patient cases

 
Practical Skills Session - N109 / N110
  
Capillaroscopy II
   ChairSmith Vanessa (Belgium)  
   ChairHerrick Ariane L. (United Kingdom)  
   SpeakerSmith Vanessa (Belgium)SP0098The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease
   SpeakerSulli Alberto (Italy) Scoring the capillaroscopic images: manual versus (semi)automatic systems¨
   SpeakerHerrick Ariane L. (United Kingdom) How to distinguish the major capillaroscopic patterns in connective tissue diseases
   SpeakerCutolo Maurizio (Italy)SP0099Why capillaroscopy can predict disease severity and prognosis
   SpeakerIngegnoli Francesca (Italy)SP0171How to select the most appropriate capillaroscopic device: pros and cons
   Speakernot confimed yet Live practical sessions with patients and case discussion

Saturday 17.06.2017 10:15 - 11:45


 
PARE Session - N115 / N116
  
Workshop: Strengthening your organisation – How to manage volunteers
   SpeakerJacklin Clare (United Kingdom)SP0172How to manage volunteers – setting the scene
   SpeakerKosanovic Marija (Serbia)SP0173The challenges of a small organisation
   SpeakerSsymank Silke (Germany)SP0174Ways of supporting volunteers
   Speakernot confimed yet Group discussion and Q&A
   SpeakerJacklin Clare (United Kingdom) Resume of the group discussions

 
Poster Tour - Poster Area
  
HPR Poster Tour: Nursing and daily practice
   Chairde Thurah Annette (Denmark)  
   Chairde la Torre-Aboki Jenny (Spain)  
   AbstractZbinden Astrid (Switzerland)SAT0717-HPRPREGNANCY AND DELIVERY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS
   AbstractFerreira Ricardo (Portugal)SAT0718-HPRINFLUENCE OF PATIENT GLOBAL ASSESSMENT ON THE DISEASE ACTIVITY ASSESSMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A METEOR CROSS-SECTIONAL STUDY
   AbstractMosor Erika (Austria)SAT0719-HPR‘AND SUDDENLY YOU ARE A PERSON AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS!’ DIFFERENT PERSPECTIVES OF INDIVIDUALS ON PREDICTIVE TESTING – RESULTS OF AN INTERNATIONAL QUALITATIVE INTERVIEW STUDY
   AbstractShi Qiang (China)SAT0720-HPRLONGITUDINAL ANALYSIS OF RESPONSE, COSTS AND RESOURCE USE OF PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (BDMARDS) IN TAIWAN USING THE NATIONAL HEALTH INSURANCE RESEARCH DATABASE
   AbstractAlfredsson Lars (Sweden)SAT0721-HPREXPOSURE TO PASSIVE SMOKING AND RA RISK; RESULTS FROM THE SWEDISH EIRA STUDY
   AbstractToo Chun Lai (Malaysia)SAT0722-HPRFAMILIAL RISKS OF RHEUMATOID ARTHRITIS: EVIDENCE FROM THE MALAYSIAN EPIDEMIOLOGICAL INVESTIGATION OF RHEUMATOID ARTHRITIS CASE-CONTROL STUDY
   AbstractEsbensen Bente (Denmark)SAT0723-HPRGENDER DIFFERENCES IN COPING STRATEGIES AND ILLNESS ACCEPTANCE IN PATIENTS WITH INFLAMMATORY ARTHRITIS – A NATIONWIDE CROSS-SECTIONAL STUDY
   AbstractBergsten Ulrika (Sweden)SAT0724-HPRGOTHENBURG NURSE LED TIGHT CONTROL STUDY – GOTNET. PATIENTS’ EXPERIENCES OF NURSE-LED CARE AND TIGHT CONTROL. A QUALITATIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS.
   AbstractBergsten Ulrika (Sweden)SAT0725-HPRGOTHENBURG NURSE LED TIGHT CONTROL STUDY - GOTNET. A STUDY COMPARING "CARE AS USUAL" WITH NURSE LED CLINIC, TIGHT CONTROL AND PERSON CENTRED CARE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND WITH MODERATE/HIGH DISEASE ACTIVITY.
  
Poster Tour: A walk through PsA progress
   ChairMcInnes Iain (United Kingdom)  
   ChairFragoulis George E. (United Kingdom)  
   AbstractRuwaard Jill (Netherlands)SAT0433ANTI-TNF TREATMENT IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS IS ASSOCIATED WITH A STRONG INCREASE OF PALMOPLANTAR PUSTULOSIS BUT NOT OF PSORIASIS VULGARIS.
   AbstractTsoi Man Fung (Hong Kong)SAT0434NETWORK META-ANALYSIS ON THE EFFICACY OF NOVEL THERAPEUTIC AGENTS IN PATIENTS WITH PSORIATIC ARTHRITIS
   AbstractPinto-Tasende Jose (Spain)SAT0435IL17 CORRELATES POSITIVELY WITH TGF-BETA 1 AND DKK1 AND INVERSELY WITH BMP2 AND 4 IN SYNOVIAL MEMBRANE OF PATIENTS WITH PSORIATIC ARTHRITIS.
   AbstractKavanaugh Arthur (United States)SAT0436DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL
   AbstractKristensen L (Denmark)SAT0437IXEKIZUMAB IMPROVES NAIL AND SKIN LESIONS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR TNF INADEQUATE RESPONSE
   AbstractBahadur Sardar (United Kingdom)SAT0438PSORIATIC ARTHRITIS AND NODAL OSTEOARTHRITIS CAN BE DIFFERENTIATED USING HAND RADIOGRAPHS: A NOVEL METHOD
   AbstractBurmester Gerd (Germany)SAT0439INTEGRATED SAFETY SUMMARY OF TOFACITINIB IN PSORIATIC ARTHRITIS CLINICAL STUDIES
   AbstractMichelsen Brigitte (Norway)SAT0440DO DEPRESSION AND ANXIETY INFLUENCE THE CHANCE OF REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS? REAL LIFE DATA FROM THE NOR-DMARD STUDY
   AbstractCoates Laura (United Kingdom)SAT0441COMPARISON OF DIFFERENT REMISSION TARGETS IN PATIENTS WITH PSORIATIC ARTHRITIS AND EVALUATION OF THEIR PROGNOSTIC VALUE
  
Poster Tour: Comorbidities and outcomes in RMDs
   ChairFinckh Axel (Switzerland)  
   ChairHetland Merete (Denmark)  
   AbstractChatzidionysiou Katerina (Sweden)SAT0669HOW DO WE USE BIOLOGICS IN PATIENTS WITH A HISTORY OF MALIGNANCY? AN ASSESSMENT OF TREATMENT PATTERNS USING SCANDINAVIAN REGISTERS
   AbstractFernandes Gwen (United Kingdom)SAT0670THE PREVALENCE OF NEUROPATHIC PAIN-LIKE SYMPTOMS AND ASSOCIATED RISK FACTORS IN THE NOTTINGHAM COMMUNITY: A CROSS-SECTIONAL STUDY
   AbstractNikiphorou Elena (United Kingdom)SAT0671THE IMPACT OF OBESITY ON TREAT TO TARGET GOALS AND FUNCTIONAL ABILITY IN THE ERAS/ERAN UK PROSPECTIVE COHORTS
   AbstractWhittle Rebecca (United Kingdom)SAT0672RISK OF FRAGILITY FRACTURE AMONG PATIENTS WITH PSORIASIS: A POPULATION BASED MATCHED COHORT STUDY FROM THE UNITED KINGDOM
   AbstractWibetoe Grunde (Norway)SAT0673RISK AGE AND RELATIVE RISK OF CVD IN INFLAMMATORY JOINT DISEASES
   AbstractStrangfeld Anja (Germany)SAT0674EARLY TREATMENT RESPONSE TO CONVENTIONAL DMARD THERAPY IN RHEUMATOID ARTHRITIS IS A BETTER PREDICTOR OF LOW DISEASE ACTIVITY OR TREATMENT ESCALATION AT 12 AND 24 MONTHS THAN AUTOANTIBODIES OR EROSIONS
   AbstractBrinkmann Gina (Norway)SAT0675THE ROLE OF EROSIONS TYPICAL OF RHEUMATOID ARTHRITIS IN THE 2010 ACR/EULAR RHEUMATOID CLASSIFICATION CRITERIA: RESULTS FROM A VERY EARLY ARTHRITIS COHORT
   AbstractYates Mark (United Kingdom)SAT0676(SERONEGATIVE) MALES SHOW BETTER EULAR TREATMENT RESPONSE THAN FEMALES IN NEWLY DIAGNOSED RHEUMATOID ARTHRITIS (RA)
   AbstractSkorpen Anna Carina (Norway)SAT0677THE IMPACT OF DISEASE ACTIVITY DURING PREGNANCY IN WOMEN WITH SLE ON THE OCCURRENCE OF PREECLAMPSIA AND PREMATURE BIRTH
   AbstractMurphy Dan (United Kingdom)SAT0678SIGNIFICANTLY INCREASED SEROPOSITIVITY, RHEUMATOID FACTOR TITRES AND RHEUMATOID NODULES IN CORNISH KAOLIN WORKERS.
  
Poster Tour: From the heart of rheumatology
   ChairSzekanecz Zoltán (Hungary)  
   ChairMadruga Dias Joao (Portugal)  
   AbstractTejera Segura Beatriz (Spain)SAT0088HDL CHOLESTEROL EFFLUX CAPACITY IN RHEUMATOID ARTHRITIS PATIENTS: CONTRIBUTING FACTORS AND RELATIONSHIP WITH SUBCLINICAL ATHEROSCLEROSIS
   AbstractKang Eun Ha (Korea, Republic Of)SAT0089COMPARATIVE CARDIOVASCULAR SAFETY OF ABATACEPT AND TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS WITH AND WITHOUT TYPE 2 DIABETES: A POPULATION-BASED COHORT STUDY
   AbstractRollefstad Silvia (Norway)SAT0090SUCCESS RATE OF BLOOD PRESSURE GOAL ACHIEVEMENT IN INFLAMMATORY JOINT DISEASES
   AbstractTen Brinck Robin (Netherlands)SAT0091IS CLINICAL ARTHRITIS ALWAYS PRECEDED BY SUBCLINICAL INFLAMMATION? A LONGITUDINAL STUDY AT JOINT LEVEL IN PATIENTS WITH ARTHRALGIA THAT DEVELOPED ARTHRITIS
   AbstractSkeoch Sarah (United Kingdom)SAT0092PROGRESSION OF ATHEROSCLEROSIS OVER 5 YEARS IN A COHORT OF EARLY INFLAMMATORY ARTHRITIS PATIENTS: RESULTS FROM THE NORFOLK ARTHRITIS REGISTER
   AbstractRodríguez-Carrio Javier (Spain)SAT0093HIGH TRIGLYCERIDES AND LOW HDL LIPID PROFILE AS A SURROGATE MARKER OF HDL DYSFUNCTION IN RA: POTENTIAL LINKS WITH INFLAMMATION AND OXIDATIVE STATUS
   AbstractRempenault Claire (France)SAT0094METABOLIC AND CARDIO-VASCULAR BENEFITS OF HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
   AbstractSegura Beatriz (Spain)SAT0095INCRETINS-INSULIN AXIS IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractKoivuniemi Riitta (Finland)SAT0096MYOCARDIAL FUNCTION IMPROVES IN RHEUMATOID ARTHRITIS PATIENTS TREATED ACTIVELY A MAGNETIC RESONANCE FOLLOW-UP STUDY
   AbstractGiollo Alessandro (Italy)SAT0097FACTORS ASSOCIATED WITH ATHEROSCLEROSIS PROGRESSION IN PATIENTS WITH LOW-ACTIVE RHEUMATOID ARTHRITIS.
  
Poster Tour: How B and T cells contribute to rheumatic disease
   ChairTaams Leonie (United Kingdom)  
   ChairScherer Hans-Ulrich (Netherlands)  
   AbstractChen Wei (United States)SAT0027IMMUNOMODULATORY EFFECTS OF MGD010, A DART® MOLECULE TARGETING HUMAN B-CELL CD32B AND CD79B
   AbstractRingheim Garth (United States)SAT0028AIOLOS OVEREXPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS B-CELL SUBTYPES AND BAFF INDUCED MEMORY B-CELL DIFFERENTIATION ARE REDUCED BY CC-220 MODULATION OF CEREBLON ACTIVITY
   AbstractNéel Antoine (France)SAT0029B CELL DEPLETION AFFECTS CD8 T CELLS IN ANCA-ASSOCIATED VASCULITIS
   AbstractDekkers Jacqueline (Netherlands)SAT0030BREACH OF AUTOREACTIVE B-CELL TOLERANCE BY POST-TRANSLATIONALLY MODIFIED FOREIGN PROTEINS
   AbstractGjertsson Inger (Sweden)SAT0031DETECTION AND ISOLATION OF ANTIGEN SPECIFIC B CELLS IN PATIENTS WITH RHEUMATOID ARTHRITIS
   AbstractGerstner Christina (Sweden)SAT0033EX VIVO ANALYSIS OF AUTOANTIGEN-SPECIFIC T CELL RESPONSES USING A MULTI HLA-CLASS II TETRAMER APPROACH
   AbstractWasén Caroline (Sweden)SAT0032SMOKING CONTRIBUTES TO EXHAUSTED STATE OF CD4+ T CELLS IN RHEUMATOID ARTHRITIS
   AbstractDulic Sonja (Hungary)SAT0034ANALYSIS OF THE T-CELL SUBSET COMPOSITION IN ANKYLOSING SPONDYLITIS PATIENTS WITH LONG-STANDING ANTI-TNF THERAPY
   AbstractHur Eun Mi (United States)SAT0035INHIBITION OF PROTEIN KINASE C THETA BY THE SELECTIVE INHIBITOR CC-90005 INDUCES T CELL ANERGY
   AbstractSteel Kathryn (United Kingdom)SAT0036IL-17+CD8+ T CELLS ENRICHED IN THE SYNOVIAL FLUID OF PSA/SPA PATIENTS EXHIBIT A PRO-INFLAMMATORY CYTOKINE PHENOTYPE
  
Poster Tour: Imaging advances in vasculitis, crystal and connective tissue disease
   ChairTerslev Lene (Denmark)  
   ChairDalsgaard Nielsen Berit (Denmark)  
   AbstractDe Miguel Eugenio (Spain)SAT0609GIANT CELL ARTERITIS: ATHEROSCLEROSIS AS PITFALL IN THE HALO SIGN
   AbstractEstrada Paula (Spain)SAT0610TEMPORAL ARTERY ULTRASOUND IN THE DIAGNOSIS OF GIANT CELL ARTERITIS IN A COHORT WITH ELEVATED CLINICAL IMPRESSION
   AbstractMilchert Marcin (Poland)SAT0611INTIMA-MEDIA THICKNESS REFERENCE RANGES DEPICTING HALO SIGN FOR THE DIAGNOSING OF LARGE VESSEL GIANT CELL ARTERITIS BY ULTRASOUND
   AbstractBlockmans Daniel (Belgium)SAT0612THE USE OF 18F-FDG-PET IN THE DIAGNOSIS OF POLYMYALGIA RHEUMATICA (PMR) – A PROSPECTIVE STUDY OF 99 PATIENTS SUSPECTED OF PMR
   AbstractBertolazzi Chiara (Mexico)SAT0613HIGH PREVALENCE OF SUBCLINICAL ATHEROSCLEROSIS IN GOUT AND ASYMPTOMATIC HYPERURICEMIA: A STUDY BASED ON CAROTID ULTRASOUND.
   AbstractBhadu Danveer (India)SAT0614ULTRASOUND AND URATE CRYSTAL DEPOSITION: HOW MANY JOINTS TO SCREEN?
   AbstractPerricone Carlo (Italy)SAT0615THE RS11803505 IL-23R POLYMORPHISM IS A RISK FACTOR FOR THE DEVELOPMENT OF MSUS-DETECTED EROSIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractBudde Petra (Germany)SAT0616DIAGNOSTIC MODELING OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON NEW AND TRADITIONAL AUTOANTIBODIES- DEMONSTRATION OF FEASIBILITY
   AbstractDelli Konstantina (Netherlands)SAT0617SALIVARY GLAND ULTRASOUND CAN DIFFERENTIATE PRIMARY SJÖGREN’S SYNDROME FROM SYSTEMIC DISEASES WITH SALIVARY GLAND INVOLVEMENT
   AbstractLüders Susanne (Germany)SAT0618DISTURBANCES OF THE ACRAL PERFUSION DETECTED BY FLUORESCENCE OPTICAL IMAGING ARE ASSOCIATED WITH THE DEVELOPMENT OF ISCHEMIC COMPLICATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS
  
Poster Tour: Infection Related Rheumatic Disease: clinical and epidemiologic aspects
   ChairCalabrese Leonard (United States)  
   ChairThomas Konstantinos (Greece)  
   AbstractMd Yusof Md Yuzaiful (United Kingdom)SAT0556RISK FACTORS FOR SEVERE INFECTION AND RATIONALE FOR IMMUNOGLOBULIN MONITORING DURING RITUXIMAB TREATMENT IN AUTOIMMUNE RHEUMATIC DISEASES
   AbstractMarques Claudia (Brazil)SAT0557CHIKUNGUNYA OUTBREAK IN BRAZIL: DEMOGRAPHIC AND CLINICAL CHARACTERIZATION OF 732 PATIENTS – CHIKBRASIL COHORT
   AbstractMarques Claudia (Brazil)SAT0558CONCORDANCE BETWEEN CLINICAL-EPIDEMIOLOGICAL CRITERIA AND CHIKUNGUNYA FEVER SEROLOGY
   AbstractVivekanantham Arani (United Kingdom)SAT0559SEPTIC ARTHRITIS IN COVENTRY IN THE UK: 5 YEAR DATA
   AbstractGarcia-Mira Yaiza (Spain)SAT0560COEXISTENCE OF SEPTIC AND CRYSTAL-INDUCED ARTHRITIS: A DIAGNOSTIC CHALLENGE.
   AbstractSaraux Alain (France)SAT0561USEFULNESS OF POLYMERASE CHAIN REACTION FOR DIAGNOSING WHIPPLE’S DISEASE IN RHEUMATOLOGY
   AbstractDantas Andrea (Brazil)SAT0562CHIKUNGUNYA FEVER IN PATIENTS WITH PRIOR RHEUMATIC DISEASES: IS IT MORE SEVERE?
   AbstractBhama Manoj (India)SAT0563EVALUATION OF ROLE OF SLEEP DISTURBANCE, DEPRESSION, OBESITY, AND PHYSICAL INACTIVITY IN FATIGUE IN CHIKUNGUNYA ARTHRITIS
   AbstractLLANO HERNÁNDEZ KEILA (Spain)SAT0564SUBLINGUAL VACCINE: NEW CHALLENGE IN THE PREVENTION OF RECURRENT INFECTIONS IN AUTOIMMUNE DISEASES
   AbstractPetersen Soeren Kjaer (Denmark)SAT0565THE FREQUENCY OF SEPTIC ARTHRITIS AFTER ARTHROCENTESIS AND INTRA ARTICULAR GLUCOCORTICOID INJECTION IS LOW
  
Poster Tour: Innate mediators and autoantibodies in Rhematic disease
   ChairHerrmann Martin (Germany)  
   ChairCanavan Mary (Ireland)  
   AbstractKusche Yvonne (Germany)SAT0010THE DAMP PROTEIN S100A8/A9 IS CRUCIALLY INVOLVED IN MYELOID-DERIVED SUPPRESSOR CELL (MDSC) DIFFERENTIATION AND FUNCTION IN COLLAGEN-INDUCED ARTHRITIS
   AbstractSommerlatte Sabine (Germany)SAT0011THE ACTIVATION OF MUSCARINIC ACETYLCHOLINE RECEPTORS INFLUENCES THE ONTOGENY OF NEUTROPHILS
   AbstractCremers Niels (Netherlands)SAT0012S100A8/A9 INCREASES THE MOBILIZATION OF LY6C HIGH MONOCYTES TO THE SYNOVIUM DURING EXPERIMENTAL OSTEOARTHRITIS
   AbstractCanavan Mary (Ireland)SAT0013THE PATHOGENIC ROLE OF MYELOID CD141+ DENDRITIC CELLS IN INFLAMMATORY ARTHRITIS
   AbstractSkriner Karl (Germany)SAT0014THE MUTATED RNA SPLICING PROTEIN HNRNP-A3 IS A NOVEL AUTOANTIGEN IN SYSTEMIC RHEUMATIC DISEASES A LINK TO WARBURG EFFECT IN RA
   AbstractVan Dam L. (Netherlands)SAT0015ANCA-ASSOCIATED VASCULITIS- AND SYSTEMIC LUPUS ERYTHEMATOSUS-INDUCED NEUTROPHIL EXTRACELLULAR TRAPS HAVE INTRINSICALLY DIFFERENT FEATURES
   AbstractCruz González Daniela (Mexico)SAT0016A NEW SUBSET OF NK CELLS, WITH ENHANCED CYTOTOXIC FUNCTION, IS INCREASED IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS.
   AbstractBaker Matthew (United States)SAT0017INVESTIGATING NOVEL AUTOANTIBODIES IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS
   AbstractPala Ozlem (United States)SAT0018EFFECTS OF ANTI-TNF ALPHA THERAPY ON B CELLS IN RHEUMATOID ARTHRITIS (RA) PATIENTS
   AbstractEngdahl Cecilia (Sweden)SAT0019ESTROGEN INFLUENCES THE SIALYLATION PROFILE AND INFLAMMATORY PROPERTIES OF ANTIBODIES- A POTENTIAL EXPLANATION FOR THE SEX DIFFERENCES AND INCREASED RISK FOR RA IN POSTMENOPAUSAL WOMEN
  
Poster Tour: Last news on systemic sclerosis and myositis
   ChairCutolo Maurizio (Italy)  
   ChairSulli Alberto (Italy)  
   AbstractMilo Jay (United States)SAT0372CLINICAL AND SEROLOGICAL ASSOCIATIONS OF AUTOANTIBODIES TO BICD2 AS A NOVEL MARKER FOR SYSTEMIC SCLEROSIS
   AbstractKhanna Dinesh (United States)SAT0373EVALUATION OF AMERICAN COLLEGE OF RHEUMATOLOGY PROVISIONAL COMPOSITE RESPONSE (CRISS) INDEX IN THE FASSCINATE TRIAL
   AbstractCooper Robert G. (United Kingdom)SAT0374THE EUROMYOSITIS REGISTRY: AN INTERNATIONAL DESCRIPTION OF MYOSITIS
   AbstractAhmed Sakir (India)SAT0375METABOLOMICS OF SERA REVEALS POTENTIAL BIOMARKERS OF SKIN FIBROSIS IN SYSTEMIC SCLEROSIS THAT CORRELATE WITH PRO-FIBROTIC GENE EXPRESSION IN SKIN BIOPSIES.
   AbstractYeker Richard (United States)SAT0376ANTI-NT5C1A AUTOANTIBODIES ARE FREQUENT IN JUVENILE MYOSITIS AND ASSOCIATED WITH INCREASED ILLNESS SEVERITY
   AbstractTrombetta Amela Chiara (Italy)SAT0377RELIABILITY OF A NEW AUTOMATED SYSTEM FOR ABSOLUTE CAPILLARY NUMBER COUNTING (AUTOCAPI) ON SYSTEMIC SCLEROSIS NAILFOLD VIDEOCAPILLAROSCOPIC IMAGES
   AbstractStamenkovic Bojana (Serbia)SAT0378BONE MARROW OEDEMA AND SYNOVITIS ON MRI OF THE HAND ARE ASSOCIATE WITH DIGITAL ULCERS, ACTIVE DISEASE AND IMPAIRED FUNCTIONAL CAPACITY IN SYSTEMIC SCLEROSIS
   AbstractMillan Arciniegas Ana (Spain)SAT0379NAILFOLD CAPILLAROSCOPY FINDINGS IN PATIENTS WITH INFLAMMATORY MYOPATHY AND/OR SPECIFIC OR ASSOCIATED ANTIBODIES.
   AbstractBlagojevic Jelena (Italy)SAT0380CLASSIFICATION, CATEGORISATION AND ESSENTIAL ITEMS FOR DIGITAL ULCER (DU) EVALUATION IN SYSTEMIC SCLEROSIS (SSC): A DESSCIPHER/EUSTAR SURVEY
   AbstractRuaro Barbara (Italy)SAT0381CORRELATION BETWEEN THREE DIFFERENT METHODS TO ASSESS DERMAL THICKNESS IN SYSTEMIC SCLEROSIS PATIENTS WITH DIFFERENT PATTERNS OF NAILFOLD MICROANGIOPATHY
  
Poster Tour: New treatment options in SLE, Sjögren's and APS
   ChairAringer Martin (Germany)  
   ChairBootsma Hendrika (Netherlands)  
   AbstractMerrill Joan (United States)SAT0219EFFICACY AND SAFETY OF ATACICEPT IN PATIENTS WITH HIGH DISEASE ACTIVITY IN A 24-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE IIB STUDY (ADDRESS II)
   AbstractWhite Wendy (United States)SAT0220EFFECTS OF TYPE I INTERFERON INHIBITION ON BLOOD LEUKOCYTE SUBSETS IN PATIENTS TREATED IN A PHASE IIB CLINICAL STUDY OF ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
   AbstractCascino Matthew (United States)SAT0221SIX-MONTH PROTEINURIA MEASUREMENT PREDICTS RENAL RESPONSE AT 18 MONTHS IN LUPUS NEPHRITIS: ANALYSIS OF TWO PHASE III RANDOMIZED CLINICAL TRIALS
   AbstractFurie Richard (United States)SAT0222BIIB059, A MONOCLONAL ANTIBODY TARGETING BDCA2, SHOWS EVIDENCE OF BIOLOGICAL ACTIVITY AND EARLY CLINICAL PROOF OF CONCEPT IN SUBJECTS WITH ACTIVE CUTANEOUS LE
   AbstractRamachandran Sulabha (United States)SAT0223INDIRECT COMPARATIVE CLINICAL EFFECTIVENESS OF INTRAVENOUS AND SUBCUTANEOUS FORMULATIONS OF BELIMUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH ACTIVE, AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS WITH HIGH DISEASE ACTIVITY
   AbstractWang Qian (China)SAT0224THE ROLE OF INTENSIVE IMMUNOSUPPRESSIVE THERAPY IN THE MANAGEMENT OF SLE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION:A SINGLE-CENTER COHORT STUDY
   AbstractGaudy Allison (United States)SAT0225CEREBLON MODULATOR CC-220 DECREASES NAÏVE AND MEMORY B CELLS AND PLASMACYTOID DENDRITIC CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS: EXPOSURE-RESPONSE RESULTS FROM A PHASE 2A PROOF OF CONCEPT STUDY
   AbstractCatlett Ian (United States)SAT0226A FIRST-IN-HUMAN, STUDY OF BMS-986165, A SELECTIVE, POTENT, ALLOSTERIC SMALL MOLECULE INHIBITOR OF TYROSINE KINASE 2
   AbstractHammond Edward (United States)SAT0227HEALTH CARE UTILIZATION AND COSTS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE UNITED STATES: SYSTEMATIC REVIEW
   AbstractSpinelli Francesca Romana (Italy)SAT0228APOPTOTIC EFFECT OF BLYS ON ENDOTHELIAL CELLS AND ENDOTHELIAL PROGENITOR CELLS IS MEDIATED BY BLYS RECEPTROS AND IS REVERTED BY BELIMUMAB
   AbstractSaavedra Miguel (Mexico)SAT0229THE USE OF ANTIMALARIAL DRUGS DURING PREGNANCY CAN PREVENT THE DEVELOPMENT OF PREECLAMPSIA IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
   AbstractSatybaldyeva Maria (Russian Federation)SAT0230NEW ORAL ANICOAGULANTS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
  
Poster Tour: RA - risk factors and consequences
   ChairPetersson Ingemar (Sweden)  
   ChairVerstappen Suzanne (United Kingdom)  
   AbstractGerlag Daniëlle (United Kingdom)SAT0037THE EFFECTS OF B CELL DIRECTED THERAPY ON DISEASE RELEVANT BIOMARKERS IN SUBJECTS AT RISK OF RHEUMATOID ARTHRITIS
   AbstractBaraka Eman (Egypt)SAT0038SERUM B LYMPHOCYTE CHEMOATTRACTANT PROTEIN 13 (CXCL 13) AND MUSCULOSKELETAL ULTRASONOGRAPHIC FINDINGS IN EARLY RHEUMATOID ARTHRITIS
   AbstractLim Siok Hoon Lily (Canada)SAT0039LARGE TENDER JOINTS HAVE THE GREATEST IMPACT ON LONGITUDINAL TRAJECTORIES OF FUNCTION IN EARLY RHEUMATOID ARTHRITIS
   AbstractCarpenter Lewis (United Kingdom)SAT0040ASSESSING 5-YEAR RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS WITH MODERATE DISEASE: FINDINGS FROM A UK MULTI-CENTRE PROSPECTIVE OBSERVATIONAL STUDY
   AbstractFleischmann R (United States)SAT0041EFFICACY OF ABATACEPT VERSUS ADALIMUMAB IN PATIENTS WITH SEROPOSITIVE, EROSIVE EARLY RA: ANALYSIS OF A RANDOMIZED CONTROLLED CLINICAL TRIAL (AMPLE)
   AbstractEun Jung Su (Korea, Republic Of)SAT0042SEVERITY OF RADIOGRAPHIC DESTRUCTION ON PERIPHERAL JOINTS IS A STRONG INDEPENDENT RISK FACTOR FOR CAROTID ATHEROSCLEROSIS
   AbstractFevang Bjorg-Tilde (Norway)SAT0043FACTORS AFFECTING THE NEED FOR ORTHOPAEDIC SURGERY IN PATIENTS WITH RHEUMATOID ARTHRITIS. RESULTS FROM 1010 PATIENTS DIAGNOSED WITH RA FROM 1972-2009.
   AbstractPaalanen Kirsi (Finland)SAT0044A 10-YEAR FOLLOW UP STUDY OF EARLY SERONEGATIVE ARTHRITIS DIAGNOSED AT AN ADULT AGE
   AbstractHetland Merete Lund (Denmark)SAT004511 YEARS’ FOLLOW-UP OF A DANISH 2-YEAR TREAT-TO-TARGET RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: BASELINE PREDICTORS OF FUNCTIONAL AND RADIOGRAPHIC OUTCOMES
   AbstractCavaco Marco (Portugal)SAT0046TNF ANTAGONIST DRUG SAFETY ASSESSMENT BY PHARMACOVIGILANCE SIGNALING AND POST-MARKETING ADVERSE EVENT REPORTS
  
Poster Tour: SSc, myositis and rare diseases: etiology
   ChairRiemekasten Gabriela (Germany)  
   ChairHumrich Jens (Germany)  
   AbstractKozlova Anastasiia (Switzerland)SAT0312MICRORNA-125B AS A POTENTIAL FIBROTIC AND APOPTOTIC REGULATOR IN SYSTEMIC SCLEROSIS
   AbstractDi Benedetto Paola (Italy)SAT0313ROLE OF CD248 MOLECULE AS POTENTIAL REGULATOR OF TRANS-DIFFERENTIATION TOWARD MYOFIBROBLASTS OF PERIVASCULAR STROMAL CELLS IN SYSTEMIC SCLEROSIS PATIENTS.
   AbstractEkström Gunilla (Sweden)SAT0314A NOVEL HIGHLY SELECTIVE 5-HYDROXYTRYPTAMINE 2B (5-HT2B) RECEPTOR ANTAGONIST AMELIORATING FIBROSIS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS
   AbstractCodullo Veronica (Italy)SAT0315IMATINIB-LOADED TARGETED GOLD NANOPARTICLES AMELIORATE EXPERIMENTAL LUNG FIBROSIS INDUCED BY BLEOMYCIN
   AbstractGonzález-Tajuelo Rafael (Spain)SAT0316ANGII INVOLVEMENT IN LUNG ENDOTHELIAL DYSFUNCTION AND PAH DEVELOPMENT IN PSGL-1 DEFICIENT FEMALE MICE
   AbstractJuhl Pernille (Denmark)SAT0317TYPE VI COLLAGEN FORMATION: A NEW OBJECTIVE BLOOD-BASED MARKER REFLECTING FIBROSIS OF THE SKIN IN SYSTEMIC SCLEROSIS
   AbstractBergmann Christina (Germany)SAT0318EPIGENETIC REGULATION OF FRA2 BY JMJD3 REGULATES FIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS
   AbstractBudde Petra (Germany)SAT0319MULTIPARAMETRIC DETECTION OF AUTOANTIBODIES TO INVESTIGATE RELATIONSHIPS BETWEEN SEROLOGICAL AND CLINICAL SUBSETS OF SYSTEMIC SCLEROSIS PATIENTS
   AbstractRiemekasten Gabriela (Germany)SAT0320SSC- IGG EFFECTS ARE MEDIATED THROUGH DISTINCT PATHWAYS IN THP-1 CELLS
   AbstractScotece Morena (Finland)SAT0321MKP-1 AS A PROTECTIVE FACTOR AND NOVEL DRUG TARGET IN SCLERODERMA: MKP-1 DEFICIENT MICE DEVELOP MORE SEVERE DERMAL FIBROSIS IN A WIDELY USED EXPERIMENTAL MODEL OF SCLERODERMA.
  
Poster Tour: Steps forward in osteoarthritis research
   ChairKloppenburg Margreet (Netherlands)  
   ChairSellam Jeremie (France)  
   AbstractHayward Richard (United Kingdom)SAT0483OSTEOARTHRITIS(OA) AND SOCIO-ECONOMIC STATUS(SES) PREDICTS THE ONSET OF COMORBIDITIES LINKED TO FREQUENT HEALTHCARE CONSULTATION
   AbstractShmagel Anna (United States)SAT0484LOW MAGNESIUM INTAKE IS ASSOCIATED WITH INCREASED PAIN IN SUBJECTS WITH RADIOGRAPHIC KNEE OSTEOARTHRITIS: DATA FROM THE OSTEOARTHRITIS INITIATIVE.
   AbstractIlas Dragos (United Kingdom)SAT0485INCREASED EXPRESSION OF OSTEOPROTEGERIN IN CD271+ MULTIPOTENTIAL STROMAL CELLS FROM FEMORAL HEADS OF PATIENTS WITH HIP OSTEOARTHRITIS
   AbstractVerhoeven Frank (France)SAT0486CATASTROPHIZING IN OSTEOARTHRITIS OF THE KNEE: DOES THE LEQUESNE SCORE TAKE IT IN COUNT? A PROSPECTIVE STUDY
   AbstractWright Anthony (Australia)SAT0487A RANDOMIZED, BLINDED, COMPARATOR-CONTROLLED TRIAL INVESTIGATING A 4-WEEK COURSE OF LYRICA IN SUBJECTS WITH KNEE OSTEOARTHRITIS WHO EXHIBIT NEUROPATHIC PAIN, COMPARED WITH A 4-WEEK COURSE OF PARACETAMOL
   AbstractKessler Christian (Germany)SAT0488COMPARATIVE EFFECTIVENESS OF AYURVEDA AND CONVENTIONAL CARE IN KNEE OSTEOARTHRITIS - A RANDOMIZED CONTROLLED TRIAL
   AbstractMeng Tao (Australia)SAT0489ASSOCIATION OF CHILDHOOD OVERWEIGHT MEASURES WITH ADULTHOOD KNEE CARTILAGE DEFECTS AND BONE MARROW LESIONS: A 25-YEAR COHORT STUDY
   AbstractJeffries Matlock (United States)SAT0490GENOME-WIDE DNA METHYLATION PROFILING OF OSTEOARTRHITIS PERIPHERAL BLOOD MONONUCLEAR CELLS REVEALS SLOWED EPIGENETIC AGING AMONG RAPID RADIOGRAPHIC PROGRESSORS: DATA FROM THE OSTEOARTHRITIS INITATIVE (OAI)
   AbstractShirinsky Ivan (Russian Federation)SAT0491USE OF HISTAMINE H1-RECEPTOR ANTAGONISTS IS ASSOCIATED WITH DECREASED PREVALENCE OF RADIOGRAPHIC KNEE OSTEOARTHRITIS: A CROSS-SECTIONAL ANALYSIS OF OSTEOARTHRITIS INITIATIVE DATA
   AbstractBierma-Zeinstra Sita (Netherlands)SAT0492INTRAMUSCULAR CORTICOSTEROID INJECTION VERSUS PLACEBO INJECTION IN HIP OSTEOARTHRITIS: A 12- WEEK BLINDED RANDOMIZED CONTROLLED TRIAL
   AbstractZheng Shuang (Australia)SAT0493MAINTAINING SUFFICIENT SERUM VITAMIN D LEVELS OVER TWO YEARS IS ASSOCIATED WITH IMPROVED KNEE STRUCTURAL AND SYMPTOMATIC OUTCOMES IN PEOPLE WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS OF THE VIDEO TRIAL
   AbstractGoicoechea Carlos (Spain)SAT0494EARLY TOLL-LIKE RECEPTOR 4 BLOCKADE IMPEDES THE BEHAVIOURAL AND HISTOLOGICAL CHARACTERISTICS OBSERVED IN A MIA-INDUCED ANIMAL MODEL OF OSTEOARTHRITIC PAIN.
  
Poster Tour: Trends in non-TNF alpha biologicals for RA II
   ChairBijlsma Johannes W.J. (Netherlands)  
   Chairvan Spil W. Erwin (Netherlands)  
   AbstractThomas Konstantinos (Greece)SAT0176PATTERNS OF BIOLOGIC DMARD MONOTHERAPY IN A LARGE NATIONWIDE RHEUMATOID ARTHRITIS COHORT: DATA FROM 1036 PATIENTS
   AbstractSoule B (United States)SAT0177SAFETY EVENTS ARE SIMILAR WITH ABATACEPT VS PLACEBO TREATMENT IN RA: RESULTS FROM INTEGRATED DATA ANALYSIS FROM NINE CLINICAL TRIALS
   AbstractGuerrero Edurne (Spain)SAT0178PULMONARY INVOLVEMENT IN RHEUMATOID ARTHRITIS TREATED WITH BIOLOGIC
   AbstractPaulding Charles (United States)SAT0179THE ASP358ALA VARIANT IN THE IL6R GENE IS SIGNIFICANTLY ASSOCIATED WITH DIFFERENCES IN SOLUBLE IL-6R PROTEIN LEVELS BUT NOT WITH DIFFERENCES IN SARILUMAB RESPONSE IN RHEUMATOID ARTHRITIS (RA) PATIENTS
   AbstractGenovese Mark (United States)SAT0180EFFICACY AND SAFETY OF SARILUMAB 200 MG Q2W ADMINISTERED AS COMBINATION THERAPY OR MONOTHERAPY IN DIFFERENT PATIENT POPULATIONS WITH ACTIVE RA
   AbstractSheng-Xiao Zhang (China)SAT0181LOW DOSE INTERLEUKIN-2 COMBINED WITH TOCILIZUMAB SELECTIVELY INCREASES REGULATORY T CELLS HELPING REFRACTORY RHEUMATOID ARTHRITIS PATIENTS ACHIEVE REMISSION MORE RAPIDLY
   AbstractMcQuarrie Kelly (United States)SAT0182SIRUKUMAB LEADS TO SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE THAT MEET OR EXCEED NORMATIVE VALUES IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TNF INHIBITORS IN POST HOC ANALYSES OF A PHASE 3 TRIAL
   AbstractSanmarti Raimon (Spain)SAT0183CLINICAL REMISSION IN SUBJECTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE OR OTHER SYNTHETIC DMARDS: A REAL-WORLD CLINICAL TRIAL (TOSPACE).
   AbstractRuiz-Esquide Virginia (Spain)SAT0184THERAPEUTIC DRUG MONITORING ON RHEUMATOID ARTHRITIS PATIENTS WITH REDUCED DOSES OF INTRAVENOUS TOCILIZUMAB.
   AbstractTorikai Eiji (Japan)SAT0185BIO-HOLIDAY THERAPY WITH A TIGHT CONTROL STRATEGY IN RHEUMATOID ARTHRITIS PATIENTS WITH CLINICAL DISEASE ACTIVITY INDEX REMISSION ENABLES MAINTENANCE OF BONE METABOLISM STATUS.
   AbstractTakeuchi Tsutomu (Japan)SAT0186EFFECTS OF DENOSUMAB, A SUBCUTANEOUS RANKL INHIBITOR, ON THE PROGRESSION OF STRUCTURAL DAMAGE IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CSDMARDS: RESULTS FROM THE 12-MONTH DOUBLE BLIND PHASE 3, DESIRABLE STUDY
   AbstractTanaka Yoshiya (Japan)SAT0187SAFETY, PHARMACOKINETICS AND EFFICACY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN A FIRST-IN-PATIENT PHASE 1/2 STUDY IN RHEUMATOID ARTHRITIS; ADDTIONAL DATA OF 400 MG COHORT

Saturday 17.06.2017 12:00 - 13:30


 
WIN & HOT Session - Hall 6
  
WIN & HOT Session
   ChairSanmarti Raimon (Spain)  
   ChairJani Meghna (United Kingdom)  
   SpeakerSmolen Josef S. (Austria) WIN Session: Rheumatoid arthritis treatment
   SpeakerWulffraat Nico (Netherlands)SP0175WIN Session: Juvenile idiopathic arthritis

 
Clinical Science Session - Hall 8
  
Systemic sclerosis
   ChairVonk Madelon (Netherlands)  
   ChairSiegert Elise (Germany)  
   SpeakerCutolo Maurizio (Italy)SP0176Targeting vasculopathy from the beginning
   SpeakerDenton Christopher (United Kingdom)SP0177New approaches by targeting soluble mediators
   Speakervan Laar Jacob M. (Netherlands) Andvances in immunosuppressive therapeutical approaches
   SpeakerDistler Oliver (Switzerland) Addressing most promising antifibrotc and epigenetic targets
   AbstractAgueusop Inoncent (Germany)OP0339IDENTIFICATION OF A TRANSCRIPTOMIC SIGNATURE CORRELATED WITH MODIFIED RODNAN SKIN SCORE (MRSS) IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

 
Challenges in Clinical Practice Session - Hall 7A
  
The challenges of MRI in axSpA
   ChairNavarro-Compán Victoria (Spain)  
   ChairPimentel dos Santos Fernando (Portugal)  
   PresenterMoltó Anna (France) Case 1 presentation: A post-partum sacral fissure mimicking sacroiliitis
   DiscussantHermann Kay-Geert (Germany) Case 1 discussion: A positive MRI is not always axSpA
   PresenterBaraliakos Xenophon (Germany) Case 2 presentation: When MRI makes the difference
   DiscussantRudwaleit Martin (Germany) Case 2 discussion: The value of a positive MRI in axSpA

 
From Bench to Bedside - Hall 7B
  
How diet influences musculoskeletal diseases
   ChairSo Alexander (Switzerland)  
   ChairRichette Pascal (France)  
   SpeakerChoi Hyon (United States) Fructose, obesity and health
   SpeakerChoi Hyon (United States) Dietary influences on hyperuricemia - what do we know
   SpeakerRichette Pascal (France) Drastic weight loss and its effects on health
   AbstractNielsen Sabrina (Denmark)OP0340WEIGHT LOSS FOR OVERWEIGHT AND OBESE INDIVIDUALS WITH GOUT: A SYSTEMATIC REVIEW OF LONGITUDINAL OBSERVATIONAL STUDIES

 
Clinical Science Session - N103 / N104
  
Can targeting disease activity in hand osteoarthritis improve our treatment in the 21st century?
   ChairBijlsma Johannes W.J. (Netherlands)  
   Chairvan Spil W. Erwin (Netherlands)  
   SpeakerWittoek Ruth (Belgium)SP0179What is disease activity in finger OA?
   SpeakerChevalier Xavier (France)SP0180Biologics and other inflammatory therapies in finger OA. What have we learned?
   SpeakerKloppenburg Margreet (Netherlands) Thumb base OA requires a different approach than finger OA, but why and how?
   AbstractTan Ai Lyn (United Kingdom)OP0341CAN PAIN IN HAND OSTEOARTHRITIS BE ASSOCIATED WITH MRI COLLATERAL LIGAMENT ABNORMALITIES?
   Abstractvan Beest Sjoerd (Netherlands)OP0342ASSESSMENT OF STRUCTURAL DAMAGE OF THE THUMB BASE IN PATIENTS WITH HAND OSTEOARTHRITIS: COMPARING THE NEWLY DEVELOPED OMERACT MAGNETIC RESONANCE IMAGING SCORING SYSTEM WITH STANDARD RADIOGRAPHY

 
Basic and Translational Science Session - South Auditorium
  
Why we do develop autoimmunity?
   ChairHuizinga Tom (Netherlands)  
   ChairScherer Hans-Ulrich (Netherlands)  
   SpeakerRiemekasten Gabriela (Germany)SP0181Failure of natural regulatory autoantibody network as cause of autoimmunity
   SpeakerScherer Hans-Ulrich (Netherlands)SP0182Alterations in the antibody repertoire and sugar modulation as cause for autoimmunity
   SpeakerHumrich Jens (Germany)SP0183Failure of Treg control to understand autoimmunity
   SpeakerLamprecht Peter (Germany)SP0184Role of microenvironment and endogenous pathways to break tolerance
   AbstractNatalello Gerlando (Italy)OP0343THE INTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS IS CHARACTERIZED BY A PECULIAR GUT MICROBIOTA

 
Health Professionals Session - N101 / N102
  
Closing the gap between objective measures and self-report in Fibromyalgia
   ChairGeenen Rinie (Netherlands)  
   ChairGobbo Montoya Milena (Spain)  
   SpeakerHenriksen Marius (Denmark)SP0185Divergences between objective and self-reported physical function in fibromyalgia
   SpeakerWalitt Brian (United States)SP0186Cognitive fog: subjective and objective understandings of the symptom of dyscognition
   SpeakerEstévez-López Fernando (Spain)SP0187Pain catastrophizing and self-efficacy in women with fibromyalgia: the al-Ándalus project
   SpeakerStones Simon (United Kingdom) Self management of fibromyalgia from a patient perspective
   AbstractVervoort Vera (Netherlands)OP0344-HPRDEVELOPMENT OF RESPONDER CRITERIA FOR MULTICOMPONENT NON-PHARMACOLOGICAL TREATMENT IN FIBROMYALGIA.

 
The Young Rheumatologist - N111 / N112
  
Interactive cases from the HOT and WIN Sessions
   ChairRomao Vasco C (Portugal)  
   ChairIagnocco Annamaria (Italy)  
   SpeakerKloppenburg Margreet (Netherlands) WIN Session: Interactive clinical aspects and cases on osteoarthritis
   SpeakerMachado Pedro (United Kingdom) WIN Session: Interactive clinical aspects and cases on axial and peripheral spondyloarthritis
   SpeakerLuqmani Raashid (United Kingdom)SP0189HOT Session: Interactive clinical aspects and cases on vasculitis treatment
   SpeakerMcInnes Iain (United Kingdom) WIN Session: Interactive clinical aspects and cases on : rheumatoid arthritis – what have therapeutics taught us

 
Joint Session PARE / HPR - N115 / N116
  
Suffering in silence. Optimizing the management of psychological well-being for people with RMDs
   ChairMakri Souzi (Belgium)  
   ChairZangi Heidi A. (Norway)  
   SpeakerDures Emma (United Kingdom)SP0190Facts and figures: How mental health care addresses the psychological burden of RMD’s in Europe
   SpeakerMarchal Anja (Belgium) A personal account of learning to disclose: How psychological support can help to break the vicious circle of hiding and ignoring
   SpeakerChristodoulou Vasiliki (Cyprus) Mindfulness and acceptance – How to use your body and mind to manage your life with a rheumatic disease
   AbstractCattelaens Karl (Germany)OP0345-PAREGROWING UP WITH ARTHRITIS – YES WE CAN! A PROJECT OF DEUTSCHE RHEUMA-LIGA IN CO-OPERATION WITH THE GERMAN ARTHRITIS RESEARCH CENTER. WITH FINANCIAL SUPPORT BY THE GERMAN FEDERAL MINISTRY OF HEALTH.
   AbstractMingolla Serena (Italy)OP0346-PARE“LISTENING TO PAIN - UN DOLORE DA ASCOLTARE” MULTIDISCIPLINARY SUPPORT FOR WOMEN WITH FIBROMYALGIA

 
EULAR Projects in Health Professionals - N117 / N118
  
Showcasing the EULAR Online Course for Health Professionals
   Chairvan den Ende Els (Netherlands)  
   ChairNiedermann Karin (Switzerland)  
   SpeakerOesch Peter (Switzerland)SP0191Principles of non-pharmacological management of regional musculoskeletal disorders
   SpeakerVliet Vlieland Thea (Netherlands)SP0192Principles of non-pharmacological management of rheumatic diseases
   SpeakerVriezekolk Joke (Netherlands)SP0193Principles of non-pharmacological management of fibromyalgia
   SpeakerHilfiker Roger (Switzerland)SP0194Principles of assessment in clinical practice
   AbstractNisar Muhammad (United Kingdom)OP0347-HPRTRAINING RHEUMATOLOGY NURSE SPECIALISTS: WHAT DOES THE FUTURE HOLD?

 
Practical Skills Session - N107 / N108
  
Ultrasound, Clinical, diagnostic and therapeutic skills II
   ChairRoccatello Dario (Italy)  
   ChairDamjanov Nemanja (Serbia)  
   SpeakerMandl Peter (Austria)SP0101Diagnostic and therapeutic ultrasound-guided procedures
   SpeakerDoherty Michael (United Kingdom)SP0102How to perform a quick and efficient physical examination
   SpeakerCaporali Roberto (Italy) How to read and interpret imaging tools: X-Ray
   SpeakerHammer Hilde Berner (Norway)SP0103How to assess US competency skills
   Speakernot confimed yet Q&A

 
Practical Skills Session - N109 / N110
  
Laboratory course – from the clinic to the lab and back II
   ChairDörner Thomas (Germany)  
   ChairBurmester Gerd Rüdiger (Germany)  
   SpeakerDörner Thomas (Germany) ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder
   SpeakerMiossec Pierre (France) Vasculitis, systemic autoimmunity
   SpeakerFeist Eugen (Germany)SP0149New trends in biomarkers in inflammatory joint diseases

Saturday 17.06.2017 13:45 - 14:45


 
Highlight Session - Hall 8
  
Clinical Basic Translational Highlight Session
   ChairFonseca Joao Eurico (Portugal)  
   ChairLandewé Robert B.M. (Netherlands)  
   SpeakerDörner Thomas (Germany) Basic and Translational Highlights
   SpeakerCarmona Loreto (Spain) Clinical Highlights

 
Highlight Session - N101 / N102
  
HPR Highlight Session
   ChairBarbosa Lurdes (Portugal)  
   ChairPrior Yeliz (United Kingdom)  
   SpeakerFerreira Ricardo (Portugal)SP0195Highlights from the Health Professional sessions
   SpeakerSamaranayaka Muditha (United Kingdom) Highlights from the Scientific programme
   SpeakerRhodes Carol (United Kingdom) Highlights from the PARE programme

 
Highlight Session - N115 / N116
  
PARE Highlight Session
   ChairCaeyers Nele (Belgium)  
   ChairKouloumas Marios (Cyprus)  
   SpeakerPrimdahl Jette (Denmark) Highlights from the Health Professionals programme
   SpeakerAletaha Daniel (Austria) Highlights from the Scientific Programme
Logged in as Anonymous